<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth - McGoldrick, E - 2020 | Cochrane Library</title> <meta content="Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth - McGoldrick, E - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004454.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth - McGoldrick, E - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004454.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004454.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth" name="citation_title"/> <meta content="Emma McGoldrick&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Liverpool Women's NHS Foundation Trust" name="citation_author_institution"/> <meta content="emcgoldrick@nhs.net" name="citation_author_email"/> <meta content="Fiona Stewart&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="The University of Liverpool" name="citation_author_institution"/> <meta content="Roses Parker" name="citation_author"/> <meta content="Oxford University Hospitals NHS Foundation Trust Second Floor, OUH Cowley Unipart House Business Centre" name="citation_author_institution"/> <meta content="Stuart R Dalziel" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD004454.pub4" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/12/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004454.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004454.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004454.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [*administration &amp; dosage]; Betamethasone [administration &amp; dosage]; Bias; Cerebral Intraventricular Hemorrhage [prevention &amp; control]; Developmental Disabilities [epidemiology]; Dexamethasone [administration &amp; dosage]; Fetal Organ Maturity [*drug effects]; Hydrocortisone [administration &amp; dosage]; Lung [drug effects, *embryology]; Maternal Death; Perinatal Death; *Premature Birth; Prenatal Care [*methods]; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome, Newborn [*prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004454.pub4&amp;doi=10.1002/14651858.CD004454.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004454\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004454\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","pt","ko","ms","hr","fr","zh_HANS","zh_HANT","th","ja","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004454.pub4",title:"Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth",firstPublishedDate:"Dec 25, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004454.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004454.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004454.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004454.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004454.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004454.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004454.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004454.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004454.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004454.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>57428 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004454.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-sec-0277"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-sec-0271"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/appendices#CD004454-sec-0282"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/supinfo/CD004454StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/supinfo/CD004454StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/information#CD004454-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Emma McGoldrick</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/information#CD004454-cr-0005">Fiona Stewart</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/information#CD004454-cr-0006">Roses Parker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004454.pub4/information#CD004454-cr-0007">Stuart R Dalziel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/information/en#CD004454-sec-0320">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 December 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004454.pub4">https://doi.org/10.1002/14651858.CD004454.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004454-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004454-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004454-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004454-abs-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004454-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004454-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004454-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD004454-abs-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004454-abs-0015">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004454-abs-0001" lang="en"> <section id="CD004454-sec-0001"> <h3 class="title" id="CD004454-sec-0001">Background</h3> <p>Respiratory morbidity including respiratory distress syndrome (RDS) is a serious complication of preterm birth and the primary cause of early neonatal mortality and disability. Despite early evidence indicating a beneficial effect of antenatal corticosteroids on fetal lung maturation and widespread recommendations to use this treatment in women at risk of preterm delivery, some uncertainty remains about their effectiveness particularly with regard to their use in lower‐resource settings, different gestational ages and high‐risk obstetric groups such as women with hypertension or multiple pregnancies. </p> <p>This updated review (which supersedes an earlier review Crowley 1996) was first published in 2006 and subsequently updated in 2017. </p> </section> <section id="CD004454-sec-0002"> <h3 class="title" id="CD004454-sec-0002">Objectives</h3> <p>To assess the effects of administering a course of corticosteroids to women prior to anticipated preterm birth (before 37 weeks of pregnancy) on fetal and neonatal morbidity and mortality, maternal mortality and morbidity, and on the child in later life. </p> </section> <section id="CD004454-sec-0003"> <h3 class="title" id="CD004454-sec-0003">Search methods</h3> <p>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (3 September 2020), <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, the databases that contribute to the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) (3 September 2020), and reference lists of the retrieved studies. </p> </section> <section id="CD004454-sec-0004"> <h3 class="title" id="CD004454-sec-0004">Selection criteria</h3> <p>We considered all randomised controlled comparisons of antenatal corticosteroid administration with placebo, or with no treatment, given to women with a singleton or multiple pregnancy, prior to anticipated preterm delivery (elective, or following rupture of membranes or spontaneous labour), regardless of other co‐morbidity, for inclusion in this review. </p> </section> <section id="CD004454-sec-0005"> <h3 class="title" id="CD004454-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane Pregnancy and Childbirth methods for data collection and analysis. Two review authors independently assessed trials for inclusion, assessed risk of bias, evaluated trustworthiness based on predefined criteria developed by Cochrane Pregnancy and Childbirth, extracted data and checked them for accuracy, and assessed the certainty of the evidence using the GRADE approach. Primary outcomes included perinatal death, neonatal death, RDS, intraventricular haemorrhage (IVH), birthweight, developmental delay in childhood and maternal death. </p> </section> <section id="CD004454-sec-0006"> <h3 class="title" id="CD004454-sec-0006">Main results</h3> <p>We included 27 studies (11,272 randomised women and 11,925 neonates) from 20 countries. Ten trials (4422 randomised women) took place in lower‐ or middle‐resource settings. </p> <p>We removed six trials from the analysis that were included in the previous version of the review; this review only includes trials that meet our pre‐defined trustworthiness criteria. In 19 trials the women received a single course of steroids. In the remaining eight trials repeated courses may have been prescribed. </p> <p>Fifteen trials were judged to be at low risk of bias, two had a high risk of bias in two or more domains and ten trials had a high risk of bias due to lack of blinding (placebo was not used in the control arm. </p> <p>Overall, the certainty of evidence was moderate to high, but it was downgraded for IVH due to indirectness; for developmental delay due to risk of bias and for maternal adverse outcomes (death, chorioamnionitis and endometritis) due to imprecision. </p> <p><b>Neonatal/child outcomes</b> </p> <p>Antenatal corticosteroids reduce the risk of:</p> <p>‐ <b>perinatal death</b> (risk ratio (RR) 0.85, 95% confidence interval (CI) 0.77 to 0.93; 9833 infants; 14 studies; high‐certainty evidence; 2.3% fewer, 95% CI 1.1% to 3.6% fewer), </p> <p>‐ <b>neonatal death</b> (RR 0.78, 95% CI 0.70 to 0.87; 10,609 infants; 22 studies; high‐certainty evidence; 2.6% fewer, 95% CI 1.5% to 3.6% fewer), </p> <p>‐ <b>respiratory distress syndrome</b> (RR 0.71, 95% CI 0.65 to 0.78; 11,183 infants; studies = 26; high‐certainty evidence; 4.3% fewer, 95% CI 3.2% to 5.2% fewer). </p> <p>Antenatal corticosteroids probably reduce the risk of IVH (RR 0.58, 95% CI 0.45 to 0.75; 8475 infants; 12 studies; moderate‐certainty evidence; 1.4% fewer, 95% CI 0.8% to1.8% fewer), and probably have little to no effect on birthweight (mean difference (MD) ‐14.02 g, 95% CI ‐33.79 to 5.76; 9551 infants; 19 studies; high‐certainty evidence). </p> <p>Antenatal corticosteroids probably lead to a reduction in developmental delay in childhood (RR 0.51, 95% CI 0.27 to 0.97; 600 children; 3 studies; moderate‐certainty evidence; 3.8% fewer, 95% CI 0.2% to 5.7% fewer). </p> <p><b>Maternal outcomes</b> </p> <p>Antenatal corticosteroids probably result in little to no difference in <b>maternal death</b> (RR 1.19, 95% CI 0.36 to 3.89; 6244 women; 6 studies; moderate‐certainty evidence; 0.0% fewer, 95% CI 0.1% fewer to 0.5% more), <b>chorioamnionitis</b>  (RR 0.86, 95% CI 0.69 to 1.08; 8374 women; 15 studies; moderate‐certainty evidence; 0.5% fewer, 95% CI 1.1% fewer to 0.3% more), and <b>endometritis</b> (RR 1.14, 95% CI 0.82 to 1.58; 6764 women; 10 studies; moderate‐certainty; 0.3% more, 95% CI 0.3% fewer to 1.1% more) </p> <p>The wide 95% CIs in all of these outcomes include possible benefit and possible harm.</p> </section> <section id="CD004454-sec-0007"> <h3 class="title" id="CD004454-sec-0007">Authors' conclusions</h3> <p>Evidence from this updated review supports the continued use of a single course of antenatal corticosteroids to accelerate fetal lung maturation in women at risk of preterm birth. Treatment with antenatal corticosteroids reduces the risk of perinatal death, neonatal death and RDS and probably reduces the risk of IVH. This evidence is robust, regardless of resource setting (high, middle or low). </p> <p>Further research should focus on variations in the treatment regimen, effectiveness of the intervention in specific understudied subgroups such as multiple pregnancies and other high‐risk obstetric groups, and the risks and benefits in the very early or very late preterm periods. Additionally, outcomes from existing trials with follow‐up into childhood and adulthood are needed in order to investigate any longer‐term effects of antenatal corticosteroids. </p> <p>We encourage authors of previous studies to provide further information which may answer any remaining questions about the use of antenatal corticosteroids without the need for further randomised controlled trials. Individual patient data meta‐analyses from published trials are likely to provide answers for most of the remaining clinical uncertainties. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004454-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004454-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD004454-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD004454-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004454-abs-0022">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004454-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004454-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD004454-abs-0020">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004454-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004454-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD004454-abs-0023">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004454-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004454-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD004454-abs-0019">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004454-abs-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004454-abs-0017">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004454-abs-0002" lang="en"> <h3>What are the benefits and risks of giving corticosteroids to pregnant women at risk of premature birth? </h3> <p><b>Why is this question important?</b> </p> <p>Babies born prematurely (before 37 weeks of pregnancy) can have trouble breathing if their lungs are not sufficiently developed. Up to half of babies born before 28 weeks, and a third of babies born before 32 weeks, have problems breathing and many babies do not survive. Others may become disabled due to the lack of oxygen they suffer because of the breathing difficulties experienced at birth.    </p> <p>Women who may be at risk of giving birth prematurely can be given corticosteroids to prevent their babies from having trouble breathing once they are born. Corticosteroids are anti‐inflammation medicines that help the baby’s lungs mature before being born. They are usually given to women at risk of early labour, typically as two injections, though they can also be given before planned preterm birth and in some cases a repeat course can be given.  </p> <p>To find out about the benefits and risks of giving corticosteroids to women at risk of giving birth early, we reviewed the evidence from research studies. </p> <p><b>How did we identify and evaluate the evidence?</b> </p> <p>We searched the medical literature for studies that compared the effects of corticosteroids against: </p> <p>‐ a placebo (dummy) treatment; or</p> <p>‐ no treatment.</p> <p>We compared the results and summarised the evidence from all the studies. We rated our confidence in the evidence, based on factors such as study methods and sizes, and the consistency of findings across studies. </p> <p><b>What did we find?</b> </p> <p>We found 27 studies that involved 11,272 women and 11,925 infants. The studies were set in 21 different countries, which included high‐, middle‐ and low‐income countries.  </p> <p><i>Infant health</i> </p> <p>Robust evidence shows that corticosteroids:</p> <p>‐ reduce perinatal deaths (numbers of stillbirths and babies dying in the first 28 days of life); </p> <p>‐ reduce neonatal deaths (numbers of babies dying in the first 28 days of life);</p> <p>‐ reduce serious breathing problems in the first hours of life;</p> <p>‐ have little to no effect on babies’ birth weight.</p> <p>Corticosteroids probably reduce the risk of:</p> <p>‐ bleeding inside the brain;</p> <p>‐ developmental delay in later childhood.</p> <p>We are only moderately confident about these two findings, either because:</p> <p>‐ the infants in the studies may not have been representative of all babies born prematurely; or </p> <p>‐ studies may have been conducted in ways that introduced errors into their results. </p> <p><i>Maternal health</i> </p> <p>The evidence indicates that corticosteroids probably do not affect the risk of:</p> <p>‐ mothers dying after giving birth;</p> <p>‐ developing chorioamnionitis (inflammation or infection of the tissues that surround the baby in pregnancy); </p> <p>‐ developing endometritis (inflammation of the lining of the uterus).</p> <p>We are only moderately confident about these three findings because they are based on few events. Until we have more evidence from more women, we cannot be certain that there is no difference in risk. </p> <p>We found little evidence about:</p> <p>‐ women who were pregnant with multiple babies; women with high blood pressure; or women whose membranes surrounding the baby broke early; </p> <p>‐ the effects of corticosteroids in babies born prematurely versus very prematurely;</p> <p>‐ different doses of corticosteroids.</p> <p>This means that we cannot be certain that the findings in this review apply to all women and babies at risk of premature birth. Nor can we determine which dose of corticosteroids is best. </p> <p><b>What does this mean?</b> </p> <p>Corticosteroids given to women at risk of premature birth improve the chances that, once they are born, their babies will be able to breathe and survive. </p> <p>The evidence available suggests that corticosteroids are probably not associated with risks for the baby or mother. Further evidence is needed about: </p> <p>‐ whether corticosteroids work differently for women who expect multiple babies or who have high blood pressure; </p> <p>‐ whether the benefits and risks of corticosteroids are the same when babies are born very prematurely, or less prematurely; </p> <p>‐ which dose of corticosteroids works best.</p> <p><b>How‐up‐to date is this review?</b> </p> <p>The evidence in this Cochrane Review is current to September 2020.</p> <p>A visual summary of some of the results from this review can be found <a href="https://pregnancy.cochrane.org/sites/pregnancy.cochrane.org/files/public/uploads/steroids_visual_summary_0.pdf" target="_blank">here</a>. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004454-sec-0277" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004454-sec-0277"></div> <h3 class="title" id="CD004454-sec-0278">Implications for practice</h3> <section id="CD004454-sec-0278"> <p>The evidence from this review update supports the use of antenatal corticosteroids in women at risk of preterm birth in low‐, medium‐ and high‐resource settings. Treatment with antenatal corticosteroids reduces the risk of perinatal death, neonatal death, and respiratory distress syndrome (RDS) even in the current era of advanced neonatal care. Antenatal corticosteroids probably also reduce the risk of intraventricular haemorrhage (IVH). and are likely to have little or no effect on birthweight. For women at high risk of preterm birth, antenatal corticosteroids probably have little or no effect on the risk of maternal death, chorioamnionitis or endometritis. </p> <p>Antenatal corticosteroids can continue to be used in women at high risk of preterm birth. Further information is required regarding the optimal dose‐to‐delivery interval, the optimal corticosteroid, the effects in multiple pregnancy and long‐term effects into adulthood. In situations where there are significant concerns about maternal health, the timing of delivery needs to be considered in terms of the expected risks and benefits to both the mother and infant. </p> </section> <h3 class="title" id="CD004454-sec-0279">Implications for research</h3> <section id="CD004454-sec-0279"> <p>There is little need for further trials of a single course of antenatal corticosteroids versus placebo in singleton pregnancies in low‐ medium‐ and high‐resource settings. There are few data regarding risks and benefits of antenatal corticosteroids in multiple pregnancies and other high‐risk obstetric groups (e.g. women with diabetes). We encourage authors of previous studies to provide further information, which may answer any remaining questions about the use of antenatal corticosteroids in such pregnancies without the need for further randomised controlled trials. Individual patient data meta‐analysis from published trials is likely to answer some of the evidence gaps. Follow‐up studies into childhood and adulthood, particularly in the late‐preterm‐gestation and repeat‐courses groups are needed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004454-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004454-sec-0008"></div> <div class="table" id="CD004454-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Neonatal and child outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Neonatal and child outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants born of women at risk of preterm birth<br/><b>Setting:</b> hospitals settings in low‐, middle‐ and high‐resource countries<br/><b>Intervention:</b> corticosteroids<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Without Corticosteroids</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With Corticosteroids</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perinatal death (composite of fetal death (<i>in utero</i> death) and neonatal death)<br/>№ of participants: 9833<br/>(14 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.77 to 0.93) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids reduce perinatal death compared with placebo or no treatment.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3%<br/>(12 to 14.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3% fewer<br/>(3.6 fewer to 1.1 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neonatal death (infants born with signs of life who die within the first 28 days)<br/>№ of participants: 10,609<br/>(22 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/>(0.70 to 0.87) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids reduce neonatal death compared with placebo or no treatment.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3%<br/>(8.3 to 10.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6% fewer<br/>(3.6 fewer to 1.5 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Respiratory distress syndrome<br/>№ of participants: 11,183<br/>(26 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/>(0.65 to 0.78) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids reduce respiratory distress syndrome compared with placebo or no treatment.</p> <p>We did not downgrade for risk of bias (two trials) at high risk of bias due to lack of placebo in control) because sensitivity analysis removing those trials made very little difference to the effect estimate. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5%<br/>(9.6 to 11.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3% fewer<br/>(5.2 fewer to 3.2 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intraventricular haemorrhage (IVH)<br/>№ of participants: 8475<br/>(12 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.58<br/>(0.45 to 0.75) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably reduce intraventricular haemorrhage compared with placebo or no treatment. </p> <p>We did not downgrade for risk of bias (four trials infants) at high risk of bias due to lack of placebo in control groups) because sensitivity analysis removing those trials made very little difference to the effect estimate. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9%<br/>(1.5 to 2.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4% fewer<br/>(1.8 fewer to 0.8 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean birthweight (g)<br/>№ of participants: 9551<br/>(19 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean birthweight in the control group ranged from 941 g to 2654 g</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 14.02 lower<br/>(33.79 lower to 5.76 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids result in little to no difference in mean birthweight compared with placebo or no treatment. </p> <p>We did not downgrade for risk of bias (two trials at high risk of bias due to incomplete outcome data) because sensitivity analysis removing those trials made very little difference to the effect estimate. </p> <p>We did not downgrade for imprecision because the confidence interval showed a difference at most on average of 33 g in weight, which is less than 10% of the lightest mean weight in any trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developmental delay in childhood<br/>№ of participants: 600 (3 RCTs). </p> <p>Age at follow‐up: 2 to 12 years.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>RR 0.51 (0.27 to 0.97)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.0%</p> <p>(2.1 to 7.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8% fewer</p> <p>(5.7 fewer to 0.2 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corticosteroids probably lead to a slight reduction in developmental delay in childhood compared with placebo or no treatment. </p> <p>Additionally, in three studies (778 children) it was uncertain if corticosteroids had any effect on intellectual impairment (RR 0.86, 95% CI 0.44 to 1.69). In two studies (166 children) it was uncertain if corticosteroids had any effect on the risk of visual impairment (RR 0.55, 95% CI 0.24 to 1.23) and in one study (82 children) it was uncertain if corticosteroids have any effect on hearing impairment (RR 0.64, 95% CI 0.04 to 9.87). Another study reported no children with hearing impairment in either group (84 children). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for indirectness: in some trials only a subset of infants were screened for IVH; some trials diagnosed IVH at postmortem only. </p> <p><sup>2</sup> Downgraded one level for risk of bias: unclear randomisation, allocation concealment, incomplete outcome data and selective reporting </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004454-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Maternal outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Maternal outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women at risk of preterm birth<br/><b>Setting:</b> hospitals settings in low‐, middle‐ and high‐resource countries<br/><b>Intervention:</b> corticosteroids<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Without Corticosteroids</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With Corticosteroids</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maternal death<br/>follow up: 90 days<br/>№ of participants: 6244<br/>(6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.19<br/>(0.36 to 3.89) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably result in little to no difference in maternal death, but the wide 95% CI includes possible benefit and possible harm, compared to placebo or no treatment. </p> <p>Four studies (3174 women) reported zero deaths in either arm.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2%<br/>(0.1 to 0.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer (0.1 fewer to 0.5 more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chorioamnionitis<br/>№ of participants: 8374<br/>(15 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.69 to 1.08) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably make little to no difference to the risk of chorioamnionitis but the wide 95% CI includes possible benefit and possible harm, compared to placebo/no treatment. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0%<br/>(2.4 to 3.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% fewer<br/>(1.1 fewer to 0.3 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometritis<br/>№ of participants: 6764<br/>(10 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(0.82 to 1.58) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably make little to no difference to the risk of endometritis but the wide 95% CI includes possible benefit and possible harm, compared to placebo/no treatment. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1%<br/>(1.5 to 2.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3% more<br/>(0.3 fewer to 1.1 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio, </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for imprecision: few events and wide 95% CI that includes possible benefit and possible harm </p> <p><sup>2</sup> Downgraded one level for imprecision: wide 95% CI that includes possible benefit and possible harm </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004454-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004454-sec-0009"></div> <p>This updated review, which supersedes an earlier review <a href="./references#CD004454-bbs2-0115" title="CrowleyP . Prophylactic corticosteroids for preterm birth. Cochrane Database of Systematic Reviews1996, Issue 1. Art. No: CD000065. [DOI: 10.1002/14651858.CD000065]">Crowley 1996</a>, was first published in 2006 and subsequently updated in 2017. </p> <section id="CD004454-sec-0010"> <h3 class="title" id="CD004454-sec-0010">Description of the condition</h3> <p>Respiratory distress syndrome (RDS) is a serious complication of preterm birth and the primary cause of early neonatal death and disability (<a href="./references#CD004454-bbs2-0101" title="RodriguezRJ , MartinRJ , FanaroffAA . Respiratory distress syndrome and its management. In: FanaroffAA , MartinRJ , editors(s). Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant. St. Louis: Mosby, 2002:1001-10.">Rodriguez 2002</a>). It affects up to half of babies born before 28 weeks and a third of babies born before 32 weeks. Approximately 42% of extremely low birthweight babies have RDS (<a href="./references#CD004454-bbs2-0090" title="HintzSR , Van MeursKP , PerrittR , PooleWK , DasA , StevensonDK , et al. Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized controlled trial of inhaled nitric oxide. Journal of Pediatrics2007;151:e1-3.">Hintz 2007</a>). </p> <p>Respiratory failure in these infants occurs as a result of surfactant deficiency, poor lung anatomical development and immaturity in other organs. Neonatal survival after preterm birth improves with gestation (<a href="./references#CD004454-bbs2-0085" title="DoyleLW . Victorian Infant Collaborative Study Group. Outcome at 5 years of age of children 23 to 27 weeks' gestation: refining the prognosis. Pediatrics2001;108(1):134-41.">Doyle 2001a</a>), reflecting improved maturity of organ systems. However, those who survive early neonatal care are at increased risk of long‐term neurological disability (<a href="./references#CD004454-bbs2-0086" title="DoyleLW , CasalazD . Victorian Infant Collaborative Study Group. Outcome at 14 years of extremely low birthweight infants: a regional study. Archives of Diseases in Childhood: Fetal and Neonatal Edition2001;85(3):F159-F164.">Doyle 2001b</a>). </p> <p>Some understanding of fetal lung development may be useful in understanding why RDS occurs and why corticosteroids work. Fetal lung development can be divided into five stages: embryonic, pseudoglandular, canalicular, terminal sac and alveolar. From 28 to 35 weeks' gestation, the alveoli can be counted and with increasing age they become more mature. Lung volume increases four‐fold between 29 weeks and term. Alveolar number shows a curvilinear increase with age but a linear relationship with bodyweight. At birth there are an average of 150 million alveoli (half the expected adult number). The alveoli produce surfactant. The alveolar stage continues for one to two years after birth. In the preterm infant, low alveolar numbers probably contribute to respiratory dysfunction. </p> <p>The fetal lung also matures biochemically with increasing gestation. Lamellar bodies, which store surfactant, appear at 22 to 24 weeks. Surfactant is a complex mixture of lipids and apoproteins, the main constituents of which are dipalmitoylphosphatidyl choline, phosphatidylglycerol and apoproteins A, B, C and D. Surfactant is needed to maintain stability when breathing out, to prevent collapse of the alveoli. Premature infants have a qualitative and quantitative deficiency of surfactant, which predisposes them to RDS. At the low lung volume associated with expiration, surface tension becomes very high, leading to atelectasis with subsequent intrapulmonary shunting, ventilation perfusion inequalities, and ultimately respiratory failure. Capillary leakage allows inhibitors from plasma to reach alveoli and inactivate any surfactant that may be present. Hypoxia, acidosis and hypothermia (common problems in the very preterm infant) can reduce surfactant synthesis required to replenish surfactant lost from the system. The pulmonary antioxidant system develops in parallel to the surfactant system and deficiency in this also puts the preterm infant at risk of chronic lung disease. </p> </section> <section id="CD004454-sec-0011"> <h3 class="title" id="CD004454-sec-0011">Description of the intervention</h3> <p>While researching the effects of the steroid dexamethasone on premature parturition in fetal sheep in 1969, Liggins found that there was some inflation of the lungs of lambs born at gestations at which the lungs would be expected to be airless (<a href="./references#CD004454-bbs2-0094" title="LigginsGC . Premature delivery of foetal lambs infused with corticosteroids. Journal of Endocrinology1969;45:515-23.">Liggins 1969</a>). Liggins and Howie performed the first randomised controlled trial in humans of betamethasone for the prevention of RDS in 1972 (<a href="./references#CD004454-bbs2-0095" title="LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50(4):515-25.">Liggins 1972a</a>). </p> <p>Subsequent to the original Liggins study a large number of clinical trials have been performed on the effects of corticosteroids before preterm birth. The first structured review on corticosteroids in preterm birth was published in 1990 (<a href="./references#CD004454-bbs2-0078" title="CrowleyP , ChalmersI , KeirseMJ . The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. British Journal of Obstetrics and Gynaecology1990;97:11-25.">Crowley 1990</a>). This review showed that corticosteroids given prior to preterm birth (as a result of either preterm labour or planned preterm delivery) are effective in preventing RDS and neonatal mortality. Corticosteroid treatment was also associated with a significant reduction in the risk of intraventricular haemorrhage (IVH; bleeding into the brain). Corticosteroids appear to exert major vasoconstrictive effects on fetal cerebral blood flow, protecting the fetus against IVH at rest and when challenged by conditions causing vasodilatation such as hypercapnia (<a href="./references#CD004454-bbs2-0104" title="SchwabM , RoedelM , AnwarMA , MulerT , SchubertH , BuchwalderLF , et al. Effects of betamethasone administration to the fetal sheep in late gestation on fetal cerebral blood flow. Journal of Physiology2000;528(3):619-32.">Schwab 2000</a>). Crowley found no effect on necrotising enterocolitis or chronic lung disease from antenatal corticosteroid administration. The influence of the results of the original trial and Crowley's review was the subject of a Wellcome Witness Seminar (<a href="./references#CD004454-bbs2-0113" title="ReynoldsLA , TanseyEM . Prenatal corticosteroids for reducing morbidity and mortality after preterm birth. The transcript of a Witness Seminar; The Wellcome Trust Centre for History of Medicine at UCL, London2005;25.">Wellcome 2005</a>) held in 2004. </p> <p>Corticosteroids have become the mainstay of prophylactic treatment in preterm birth, as a result of these findings and subsequent work. However, there have remained a number of outstanding issues regarding the use of antenatal corticosteroids. The original trial by Liggins suggested an increased rate of stillbirth in women with hypertension syndromes (<a href="./references#CD004454-bbs2-0096" title="LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, Report of the Seventieth Ross Conference on Pediatric Research, Columbus, Ohio. 1976:97-103.">Liggins 1976</a>). There is concern about using corticosteroids in women with premature rupture of membranes due to the possible increased risk of neonatal and maternal infection (<a href="./references#CD004454-bbs2-0092" title="ImseisHM , IamsJD . Glucocorticoid use in patients with preterm premature rupture of fetal membranes. Seminars in Perinatology1996;20(5):439-50.">Imseis 1996</a>; <a href="./references#CD004454-bbs2-0097" title="National Institutes of Health (NIH) Consensus Development Conference Statement. Effect of corticosteroids for fetal maturation on perinatal outcomes. American Journal of Obstetrics and Gynecology1994;173:246-52.">NIH 1994</a>). The efficacy of this treatment in multiple births has only been addressed retrospectively (<a href="./references#CD004454-bbs2-0110" title="TurrentineMA , WilsonPD , WilkinsIA . A retrospective analysis of the effect of antenatal steroid on the incidence of respiratory distress syndrome in preterm twin pregnancies. American Journal of Perinatology1996;13(6):351-4.">Turrentine 1996</a>). From the time of the original Liggins paper, debate has continued around whether the treatment is effective at lower gestations and at differing treatment‐to‐delivery intervals. Debate has also centred around whether treatment is effective at latter gestations, up to and including term delivery (<a href="./references#CD004454-bbs2-0107" title="SotiriadisA , MakrydimasG , PapatheodorouS , IoannidisJP , McGoldrickE . Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD006614. [DOI: 10.1002/14651858.CD006614.pub3]">Sotiriadis 2018</a>). These issues will be addressed in this review in subgroup analyses. The effectiveness and safety of repeat doses of corticosteroids for women who remain undelivered, but at increased risk of preterm birth after an initial course of treatment, is addressed in a separate Cochrane Review (<a href="./references#CD004454-bbs2-0079" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD003935. [DOI: 10.1002/14651858.CD003935.pub4]">Crowther 2015</a>). </p> <p>Epidemiological evidence and animal work suggests that there may be adverse long‐term consequences of antenatal exposure to corticosteroids (<a href="./references#CD004454-bbs2-0105" title="SecklJR , CleasbyM , NyirendaMJ . Glucocorticoids, 11beta-hydroxysteroid dehydrogenase, and fetal programming. Kidney International2000;57(4):1412-7.">Seckl 2000</a>). Exposure to excess corticosteroids before birth is hypothesised to be a key mechanism underlying the fetal origins of adult disease hypothesis (<a href="./references#CD004454-bbs2-0072" title="BarkerDJP . Mothers, Babies and Health in Later Life. 2nd edition. London: Churchill Livingstone, 1998.">Barker 1998</a>; <a href="./references#CD004454-bbs2-0073" title="BenediktssonR , LindsayRS , NobleJ , SecklJR , EdwardsCR . Glucocorticoid exposure in utero: new model for adult hypertension. Lancet1993;341(8841):339-41.">Benediktsson 1993</a>). This hypothesis postulates a link between impaired fetal growth, and cardiovascular disease and type 2 diabetes in later life along with their risk factors of impaired glucose tolerance, dyslipidaemia, and hypertension (<a href="./references#CD004454-bbs2-0072" title="BarkerDJP . Mothers, Babies and Health in Later Life. 2nd edition. London: Churchill Livingstone, 1998.">Barker 1998</a>). A large body of animal experimental work has documented impaired glucose tolerance and increased blood pressure in adult animals after antenatal exposure to corticosteroids (<a href="./references#CD004454-bbs2-0077" title="ClarkPM . Programming of the hypothalamo-pituitary-adrenal axis and the fetal origins of adult disease hypothesis. European Journal of Pediatrics1998;157(1 Suppl):S7-S10.">Clark 1998</a>; <a href="./references#CD004454-bbs2-0084" title="DodicM , WintourEM , WhitworthJA , CoghlanJP . Effect of steroid hormones on blood pressure. Clinical &amp; Experimental Pharmacology &amp; Physiology1999;26(7):550-2.">Dodic 1999</a>; <a href="./references#CD004454-bbs2-0087" title="EdwardsLJ , CoulterCL , SymondsME , McMillenIC . Prenatal undernutrition, glucocorticoids and the programming of adult hypertension. Clinical &amp; Experimental Pharmacology &amp; Physiology2001;28(11):938-41.">Edwards 2001</a>). Thus, this review has considered blood pressure, glucose intolerance, dyslipidaemia, and hypothalamo‐pituitary‐adrenal axis function in childhood and adulthood. </p> <p>Experimental animal studies have also shown decreased brain growth in preterm and term infants exposed to single courses of corticosteroid (<a href="./references#CD004454-bbs2-0091" title="HuangWL , BeazleyLD , QuinlivanJA , EvansSF , NenhamJP , DunlopSA . Effect of corticosteroids on brain growth in fetal sheep. Obstetrics &amp; Gynecology1999;94(2):213-8.">Huang 1999</a>; <a href="./references#CD004454-bbs2-0093" title="JobeAH , WadaN , BerryLM , IkegamiM , ErvinMG . Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep. American Journal of Obstetrics and Gynecology1998;178(5):880-5.">Jobe 1998</a>). This review has therefore also addressed long‐term neurodevelopment and other childhood and adult outcomes after antenatal corticosteroid exposure. </p> </section> <section id="CD004454-sec-0012"> <h3 class="title" id="CD004454-sec-0012">How the intervention might work</h3> <p>Liggins (<a href="./references#CD004454-bbs2-0095" title="LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50(4):515-25.">Liggins 1972a</a>) theorised that dexamethasone might have accelerated the appearance of pulmonary surfactant. The hypothesis is that corticosteroids act to trigger the synthesis of ribonucleic acid that codes for particular proteins involved in the biosynthesis of phospholipids or in the breakdown of glycogen. Subsequent work has suggested that, in animal models, corticosteroids mature a number of organ systems (<a href="./references#CD004454-bbs2-0098" title="PadburyJF , ErvinMG , PolkDH . Extrapulmonary effects of antenatally administered steroids. Journal of Pediatrics1996;128(2):167-72.">Padbury 1996</a>; <a href="./references#CD004454-bbs2-0112" title="VyasJ , KotechaS . Effects of antenatal and postnatal corticosteroids on the preterm lung. Archives of Disease in Childhood: Fetal and Neonatal Edition1997;77(2):F147-F150.">Vyas 1997</a>). </p> </section> <section id="CD004454-sec-0013"> <h3 class="title" id="CD004454-sec-0013">Why it is important to do this review</h3> <p>Since the first version of the review was published there is a need for an updated systematic review of the effects of prophylactic corticosteroids for preterm birth, as a result of current interest and due to further published trials. In <a href="./references#CD004454-bbs2-0118" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. Art. No: CD004454. [DOI: 10.1002/14651858.CD004454.pub2]">Roberts 2006</a> we were able to re‐analyse the Auckland Steroid Study by intention‐to‐treat. In <a href="./references#CD004454-bbs2-0119" title="RobertsD , BrownJ , MedleyN , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2017, Issue 3. Art. No: CD004454. [DOI: 10.1002/14651858.CD004454.pub3]">Roberts 2017</a> we updated the review as the methodology for Cochrane Reviews had changed and we attempted to standardise the review with the Cochrane Review on '<i>Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes</i>' (<a href="./references#CD004454-bbs2-0079" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD003935. [DOI: 10.1002/14651858.CD003935.pub4]">Crowther 2015</a>). This current (2020) update has been stimulated by the publication of substantial data from new trials in low‐resource settings becoming available and the need to incorporate this new evidence into the review to provide a more definitive answer to the question of the effectiveness of antenatal corticosteroids. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004454-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004454-sec-0014"></div> <p>To assess the effects of administering a course of corticosteroids to the mother prior to anticipated preterm birth on fetal and neonatal morbidity and mortality, maternal mortality and morbidity, and on the child in later life. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004454-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004454-sec-0015"></div> <section id="CD004454-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004454-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (RCTs) for inclusion in this review, regardless of whether or not they were published in full. Cluster‐randomised as well as individually‐randomised trials were eligible. Quasi‐randomised (e.g. allocation by date of birth or record number) and cross‐over trials were not eligible for inclusion. We excluded trials where non‐randomised cohorts were amalgamated with randomised participants if the results of the randomised participants could not be separated out. </p> </section> <section id="CD004454-sec-0018"> <h4 class="title">Types of participants</h4> <p>Women, with a singleton or multiple pregnancy, expected to deliver before 37 weeks of pregnancy as a result of either spontaneous preterm labour, preterm prelabour rupture of the membranes or planned preterm delivery, regardless of other co‐morbidity. </p> </section> <section id="CD004454-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Trials investigating a corticosteroid capable of crossing the placenta (betamethasone, dexamethasone, hydrocortisone, methylprednisolone) compared with placebo or with no treatment. </p> <p>We excluded trials that tested the effect of corticosteroids along with other co‐interventions. We also excluded trials where all participants received corticosteroids before beginning their allocated treatment of corticosteroids or placebo/no treatment. </p> </section> <section id="CD004454-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We did not use the reporting of particular outcomes as a criterion for eligibility for review. We did not exclude studies from review solely on the grounds of an outcome of interest not being reported. Primary outcomes chosen were those which were thought to be the most clinically valuable in assessing effectiveness and safety of the treatment for the woman and her offspring. Secondary outcomes included possible complications and other measures of effectiveness. </p> <section id="CD004454-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>For the fetus/neonate.</p> <p> <ol id="CD004454-list-0001"> <li> <p>Perinatal death (composite of fetal death (<i>in utero</i> death) and neonatal death). </p> </li> <li> <p>Neonatal death (before 28 completed days of life).</p> </li> <li> <p>Fetal death (<i>in utero death</i>). </p> </li> <li> <p>Respiratory distress syndrome (RDS).</p> </li> <li> <p>Moderate/severe RDS.</p> </li> <li> <p>Chronic lung disease (need for continuous supplemental oxygen at 28 days postnatal age or 36 weeks' postmenstrual age, whichever was later). </p> </li> <li> <p>Intraventricular haemorrhage (IVH).</p> </li> <li> <p>Mean birthweight (g).</p> </li> </ol> </p> <p>For the woman.</p> <p> <ol id="CD004454-list-0002"> <li> <p>Maternal death (up to 90 days after giving birth).</p> </li> <li> <p>Chorioamnionitis (however defined by study authors).</p> </li> <li> <p>Endometritis (however defined by study authors and including infections).</p> </li> </ol> </p> <p>For the child.</p> <p> <ol id="CD004454-list-0003"> <li> <p>Death.</p> </li> <li> <p>Neurodevelopmental disability at follow‐up (visual impairment, hearing impairment, intellectual impairment defined as intelligence quotient less than ‐2 standard deviation below population mean, moderate/severe cerebral palsy (however defined by study authors), or developmental delay (defined as developmental quotient less than ‐2 standard deviation below population mean)). </p> </li> </ol> </p> <p>For the child as adult.</p> <p> <ol id="CD004454-list-0004"> <li> <p>Death.</p> </li> <li> <p>Neurodevelopmental disability at follow‐up (visual impairment, hearing impairment, intellectual impairment defined as intelligence quotient less than ‐2 standard deviation below population mean, moderate/severe cerebral palsy (however defined by study authors), or developmental delay (defined as developmental quotient less than ‐2 standard deviation below population mean)). </p> </li> </ol> </p> </section> <section id="CD004454-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>For the woman.</p> <p> <ol id="CD004454-list-0005"> <li> <p>Fever after trial entry requiring the use of antibiotics.</p> </li> <li> <p>Intrapartum fever requiring the use of antibiotics.</p> </li> <li> <p>Postnatal fever.</p> </li> <li> <p>Admission to intensive care unit.</p> </li> <li> <p>Side effects of therapy.</p> </li> <li> <p>Glucose intolerance (however defined by study authors).</p> </li> <li> <p>Hypertension (however defined by study authors).</p> </li> </ol> </p> <p>For the fetus/neonate.</p> <p> <ol id="CD004454-list-0006"> <li> <p>Apgar score less than seven at five minutes.</p> </li> <li> <p>Interval between trial entry and birth.</p> </li> <li> <p>Mean length at birth (height).</p> </li> <li> <p>Mean head circumference at birth.</p> </li> <li> <p>Mean skin fold thickness at birth.</p> </li> <li> <p>Small‐for‐gestational age (however defined by study authors).</p> </li> <li> <p>Mean placental weight.</p> </li> <li> <p>Neonatal blood pressure.</p> </li> <li> <p>Admission to neonatal intensive care unit (NICU).</p> </li> <li> <p>Need for inotropic support.</p> </li> <li> <p>Mean duration of inotropic support (days).</p> </li> <li> <p>Need for mechanical ventilation/continuous positive airways pressure.</p> </li> <li> <p>Mean duration of mechanical ventilation/continuous positive airways pressure (days).</p> </li> <li> <p>Air leak syndrome.</p> </li> <li> <p>Duration of oxygen supplementation (days).</p> </li> <li> <p>Surfactant use.</p> </li> <li> <p>Systemic infection in first 48 hours of life.</p> </li> <li> <p>Proven infection while in the NICU.</p> </li> <li> <p>Necrotising enterocolitis.</p> </li> <li> <p>Hypothalamo‐pituitary‐adrenal (HPA) axis function (however defined by study authors).</p> </li> </ol> </p> <p>For the child.</p> <p> <ol id="CD004454-list-0007"> <li> <p>Mean weight.</p> </li> <li> <p>Mean head circumference.</p> </li> <li> <p>Mean height.</p> </li> <li> <p>Mean skin fold thickness.</p> </li> <li> <p>Abnormal lung function (however defined by study authors).</p> </li> <li> <p>Mean blood pressure.</p> </li> <li> <p>Glucose intolerance (however defined by study authors).</p> </li> <li> <p>HPA axis function (however defined by study authors).</p> </li> <li> <p>Dyslipidaemia (however defined by study authors).</p> </li> <li> <p>Cerebral palsy (however defined by study authors).</p> </li> <li> <p>Behavioural/learning difficulties (however defined by study authors).</p> </li> </ol> </p> <p>For the child as adult.</p> <p> <ol id="CD004454-list-0008"> <li> <p>Mean weight.</p> </li> <li> <p>Mean head circumference.</p> </li> <li> <p>Mean height.</p> </li> <li> <p>Mean skin fold thickness.</p> </li> <li> <p>Abnormal lung function (however defined by study authors).</p> </li> <li> <p>Mean blood pressure.</p> </li> <li> <p>Glucose intolerance (however defined by study authors).</p> </li> <li> <p>HPA axis function (however defined by study authors).</p> </li> <li> <p>Dyslipidaemia (however defined by study authors).</p> </li> <li> <p>Mean age at puberty.</p> </li> <li> <p>Bone density (however defined by study authors).</p> </li> <li> <p>Educational achievement (completion of high school, or however defined by study authors).</p> </li> </ol> </p> <p>For health services.</p> <p> <ol id="CD004454-list-0009"> <li> <p>Mean length of antenatal hospitalisation for women (days).</p> </li> <li> <p>Mean length of postnatal hospitalisation for women (days).</p> </li> <li> <p>Mean length of neonatal hospitalisation (days).</p> </li> <li> <p>Cost of maternal care (in 10s of 1000s of USD).</p> </li> <li> <p>Cost of neonatal care (in 10s of 1000s of USD).</p> </li> </ol> </p> </section> </section> </section> <section id="CD004454-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD004454-sec-0024"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register by contacting their Information Specialist (3 September 2020). </p> <p>The Register is a database containing over 26,000 reports of controlled trials in the field of pregnancy and childbirth. It represents over 30 years of searching. For full current search methods used to populate Pregnancy and Childbirth’s Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this <a href="https://pregnancy.cochrane.org/pregnancy-and-childbirth-groups-trials-register" target="_blank">link</a> </p> <p>Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is maintained by their Information Specialist and contains trials identified from: </p> <p> <ol id="CD004454-list-0010"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set that has been fully accounted for in the relevant review sections (<a href="./references#CD004454-bbs1-0001" title="">Included studies</a>; <a href="./references#CD004454-bbs1-0002" title="">Excluded studies</a>; <a href="./references#CD004454-bbs1-0003" title="">Studies awaiting classification</a>; <a href="./references#CD004454-bbs1-0004" title="">Ongoing studies</a>). </p> <p>In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, and the databases that contribute to the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) (3 September 2020) for unpublished, planned and ongoing trial reports (see <a href="./appendices#CD004454-sec-0283">Appendix 1</a> for search terms we used). </p> </section> <section id="CD004454-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of retrieved studies.</p> <p>We did not apply any language or date restrictions.</p> </section> </section> <section id="CD004454-sec-0026"> <h3 class="title" id="CD004454-sec-0026">Data collection and analysis</h3> <p>For methods used in previous versions of this review, see <a href="./references#CD004454-bbs2-0118" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. Art. No: CD004454. [DOI: 10.1002/14651858.CD004454.pub2]">Roberts 2006</a>; <a href="./references#CD004454-bbs2-0119" title="RobertsD , BrownJ , MedleyN , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2017, Issue 3. Art. No: CD004454. [DOI: 10.1002/14651858.CD004454.pub3]">Roberts 2017</a>. </p> <p>For this update, we used the following methods to assess the new reports that were identified as a result of the updated search. </p> <p>The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD004454-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors assessed the trials for eligibility and trustworthiness. Trials were not assessed blind, as we knew the author's name, institution and the source of publication. We resolved any disagreement by discussion until we reached consensus. </p> <section id="CD004454-sec-0028"> <h5 class="title">Screening eligible studies for trustworthiness</h5> <p>All studies meeting our inclusion criteria were evaluated by at least two review authors against predefined criteria to select studies that, based on available information, are deemed to be sufficiently trustworthy to be included in the analysis. The trustworthiness screening tool was developed by Cochrane Pregnancy and Childbirth and contains the following criteria: reasons for rejecting a trial include the following. </p> <p><b>Research governance</b> </p> <p> <ul id="CD004454-list-0011"> <li> <p>Was the study prospectively registered (for those studies published after 2010) If not, was there a plausible reason? </p> </li> <li> <p>When requested, did the trial authors provide/share the protocol and/or ethics approval letter? </p> </li> <li> <p>Did the trial authors engage in communication with the Cochrane Review authors within the agreed timelines? </p> </li> <li> <p>Did the trial authors provide IPD data upon request? If not, was there a plausible reason?. </p> </li> </ul> </p> <p><b>Baseline characteristics</b> </p> <p> <ul id="CD004454-list-0012"> <li> <p>Is the study free from characteristics of the study participants that appear too similar (e.g. distribution of the mean (SD) excessively narrow or excessively wide, as noted by <a href="./references#CD004454-bbs2-0075" title="CarlisleJB . Data fabrication and other reasons for non-random sampling in 5087 randomised, controlled trial in anaesthetic and general medical journals. Anaesthesia2017;72:944-52.">Carlisle 2017</a>)? </p> </li> </ul> </p> <p><b>Feasibility</b> </p> <p> <ul id="CD004454-list-0013"> <li> <p>Is the study free from characteristics could be implausible? (e.g. large numbers of women with a rare condition (such as severe cholestasis in pregnancy) recruited within 12 months); </p> </li> <li> <p>In cases with (close to) zero losses to follow‐up, is there a plausible explanation?</p> </li> </ul> </p> <p><b>Results</b> </p> <p> <ul id="CD004454-list-0014"> <li> <p>Is the study free from results that could be implausible? (e.g. massive risk reduction for main outcomes with small sample size)? </p> </li> <li> <p>Do the numbers randomised to each group suggest that adequate randomisation methods were used (e.g. is the study free from issues such as unexpectedly even numbers of women ‘randomised’ including a mismatch between the numbers and the methods, if the authors say ‘no blocking was used’ but still end up with equal numbers, or if the authors say they used ‘blocks of 4’ but the final numbers differ by 6)? </p> </li> </ul> </p> <p>Studies assessed as being potentially ‘high risk’ were not included in the review. Where a study was classified as ‘high risk’ we attempted to contact the study authors to address any possible lack of information/concerns. In cases where we could not obtain contact details for the study authors, or where adequate information remained unavailable, the study remained in ‘awaiting classification’ and the reasons and communications with the author (or lack of) were described in detail. </p> <p><b>Abstracts</b> </p> <p>Data from abstracts will only be included if, in addition to the trustworthiness assessment, the study authors have confirmed in writing that the data to be included in the review have come from the final analysis and will not change. If such information is not available/provided, the study will remain in ‘awaiting classification’ (as above). </p> <p>See <a href="#CD004454-fig-0001">Figure 1</a> for details of how we applied the trustworthiness screening criteria. </p> <div class="figure" id="CD004454-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Applying the trustworthiness screening tool criteria" data-id="CD004454-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Applying the trustworthiness screening tool criteria</p> </div> </div> </div> </section> </section> <section id="CD004454-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted the data, checked them for discrepancies and processed them as described in <a href="./references#CD004454-bbs2-0089" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019.">Higgins 2019</a>. We contacted authors of each included trial for further information, if we thought this to be necessary. </p> </section> <section id="CD004454-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD004454-bbs2-0088" title="HigginsJPT , AltmanDG , Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We resolved any disagreement by discussion. </p> <section id="CD004454-sec-0031"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We described for each included study the methods used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the methods as:</p> <p> <ul id="CD004454-list-0015"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random‐number generator; tossing a coin, minimisation); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number; quasi‐randomised studies were excluded from the review); </p> </li> <li> <p>unclear risk of bias (unclear description or no description of randomisation sequence generation).  </p> </li> </ul> </p> </section> <section id="CD004454-sec-0032"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We described for each included study the method used to conceal the allocation sequence in sufficient detail and determine whether intervention allocation could have been foreseen in advance of, or during, recruitment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD004454-list-0016"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004454-sec-0033"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We described for each included study all the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We also provided any information relating to whether the intended blinding was effective. Where blinding was not possible, we assessed whether the lack of blinding was likely to have introduced bias. </p> <p>We assessed the methods as:</p> <p> <ul id="CD004454-list-0017"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel;</p> </li> <li> <p>low, high or unclear risk of bias for outcome assessors</p> </li> </ul> </p> <p>where low risk of bias was when there was blinding or where we assessed that the outcome or the outcome measurement was not likely to have been influenced by lack of blinding. </p> </section> <section id="CD004454-sec-0034"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We have assessed methods used to blind outcome assessment as:</p> <p> <ul id="CD004454-list-0018"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004454-sec-0035"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations) </h5> <p>We described for each included study the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported, the numbers included in the analyses at each stage (compared with the total randomised participants), reasons for attrition/exclusion where reported, and any re‐inclusions in analyses undertaken. </p> <p>We assessed the methods as:</p> <p> <ul id="CD004454-list-0019"> <li> <p>low risk of bias (e.g. where there were no missing data or where reasons for missing data were balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. where missing data were likely to be related to outcomes or were not balanced across groups); </p> </li> <li> <p>unclear risk of bias (e.g. where there was insufficient reporting of attrition or exclusions to permit a judgement to be made). </p> </li> </ul> </p> </section> <section id="CD004454-sec-0036"> <h5 class="title">(5) Selective reporting bias</h5> <p>We described for each included study how we examined the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as:</p> <p> <ul id="CD004454-list-0020"> <li> <p>low risk of bias (where it was clear that all of the study's pre‐specified outcomes and all expected outcomes of interest to the review were reported); </p> </li> <li> <p>high risk of bias (where not all the study's pre‐specified outcomes were reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest were reported incompletely and so could not be used; study failed to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004454-sec-0037"> <h5 class="title">(6) Other sources of bias</h5> <p>We described for each included study any important concerns we had about other possible sources of bias. For example, was there a potential source of bias related to the specific study design? Was the trial stopped early due to some data‐dependent process? Was there extreme baseline imbalance? Had the study been claimed to be fraudulent? </p> <p>We assessed whether each study was free of other problems that could put it at risk of bias: </p> <p> <ul id="CD004454-list-0021"> <li> <p>low risk of bias;</p> </li> <li> <p>high risk of bias;</p> </li> <li> <p>unclear.</p> </li> </ul> </p> </section> </section> <section id="CD004454-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <section id="CD004454-sec-0039"> <h5 class="title">Dichotomous data</h5> <p>We calculated risk ratios (RRs) and 95% confidence intervals (CIs) for dichotomous data. </p> </section> <section id="CD004454-sec-0040"> <h5 class="title">Continuous data</h5> <p>For continuous data, we used the mean difference (MD) with 95% CI where outcomes were measured using the same instrument. Where different instruments were used we planned to use the standardised mean difference (SMD) with 95% CI with the following interpretations. </p> <p> <ul id="CD004454-list-0022"> <li> <p>SMD 0.8 or greater = large effect</p> </li> <li> <p>SMD greater than 0.49 and less than 0.8 = medium effect</p> </li> <li> <p>SMD greater than 0.19 and less than 0.5 = small effect</p> </li> <li> <p>SMD less than 0.2 = trivial or no effect</p> </li> </ul> </p> </section> </section> <section id="CD004454-sec-0041"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation was per woman. For maternal outcomes the unit of analysis was per woman. Where possible for multiple pregnancies, the number of babies was used as the denominator for fetal and neonatal outcomes. </p> <p>In trials with one control arm and more than two intervention arms, we added the intervention arms together for binary outcomes. To avoid double‐counting continuous outcomes we divided the denominator in the control arm by the number of different intervention arms. </p> <section id="CD004454-sec-0042"> <h5 class="title">Cluster‐randomised trials</h5> <p>We did not identify any cluster‐RCTs. In future updates, if there are cluster‐RCTs that meet our inclusion criteria we will combine them with individually‐randomised trials in accordance with the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004454-bbs2-0089" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019.">Higgins 2019</a>). We will adjust their standard errors (SEs) using an estimate of the intracluster correlation coefficient (ICC) derived from the trial (if possible) or from a similar trial. If we use ICCs from other sources, we will report this, and conduct sensitivity analyses to investigate the effect of variation in the ICC. We will also acknowledge heterogeneity in the randomisation unit, and perform a subgroup analysis to investigate the effects of the randomisation unit. </p> </section> </section> <section id="CD004454-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>In cases where trial data were missing, we first sought information from the original trial investigators. Details of trial authors contacted and the questions asked of them are contained in <a href="./references#CD004454-sec-0327" title="">Characteristics of included studies</a>.  </p> <p>We recognise that some study outcomes may be applicable only to a subset of participants, for instance morbidity outcomes can only occur after live birth. However, if the denominator is not based on the intention‐to‐treat (ITT) principle,i.e. omitting those who died before birth, this could potentially bias the analysis, as the comparison is then not between the randomised groups. Since we cannot be certain that pre‐delivery fetal deaths are unrelated to the intervention, we judged that the more appropriate method would be to use numbers randomised as the denominator for all our outcomes related to the fetus/neonate. </p> <p>In the absence of appropriate statistical methods in the individual trials to account for missing data, in the following situations we deemed it appropriate to use the denominator reported by the trial rather than the number randomised in order to avoid making  potentially misleading assumptions about the outcomes for those women and fetuses with missing data: </p> <p> <ul id="CD004454-list-0023"> <li> <p>where no explanation was given for women who were lost to follow‐up before giving birth and were not included in the analysis of the individual trials; </p> </li> <li> <p>where women were not included in trial analysis because they were randomised in error, e.g. multiple pregnancy in a singleton pregnancy‐only trial. </p> </li> </ul> </p> <p>Where standard deviations (SDs) were missing from continuous outcome data, we estimated SDs by using the largest SD from the other trials in the same meta‐analysis. </p> </section> <section id="CD004454-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the I² and Chi² statistics and visual inspection of forest plots. We used the following guidance from <i>The Cochrane Handbook of Systematic Reviews</i> <i>of Interventions</i> to interpret the I² statistic (<a href="./references#CD004454-bbs2-0089" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019.">Higgins 2019</a>): </p> <p> <ul id="CD004454-list-0024"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>Where we found substantial heterogeneity we used a random‐effects model to conduct the analysis and attempted to explain possible sources of heterogeneity (<a href="./references#CD004454-bbs2-0081" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Deeks 2011</a>). </p> </section> <section id="CD004454-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>If there were 10 or more studies in the meta‐analysis we investigated reporting biases (such as publication bias) using funnel plots (<a href="./references#CD004454-bbs2-0108" title="SterneJA , EggerM , Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Sterne 2011</a>). We assessed funnel plot asymmetry visually. If asymmetry was suggested by a visual assessment, we performed exploratory analyses to investigate it. </p> </section> <section id="CD004454-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using the RevMan 5.4 software (<a href="./references#CD004454-bbs2-0100" title="Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2014.">RevMan 2020</a>). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: that is, where trials were examining the same intervention, and the trials’ populations and methods were judged sufficiently similar. </p> <p>If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random‐effects meta‐analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. The random‐effects summary was treated as the average of the range of possible treatment effects and we have discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we planned not to combine trials. </p> </section> <section id="CD004454-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed analysis of clinical groups for primary outcomes only (where data were available). </p> <p>We analysed the following clinical groups:</p> <p> <ol id="CD004454-list-0025"> <li> <p>singleton versus multiple pregnancy;</p> </li> <li> <p>intact membranes versus ruptured membranes at first dose;</p> </li> <li> <p>pregnancy‐induced hypertension syndromes;</p> </li> <li> <p>type of glucocorticoid (betamethasone, dexamethasone, hydrocortisone);</p> </li> <li> <p>decade of trial (post‐hoc, i.e. not pre‐specified in the protocol);</p> </li> <li> <p>protocol with weekly repeats (post hoc, i.e. not pre‐specified in the protocol);</p> </li> <li> <p>gestational age at trial entry (post hoc, i.e. not pre‐specified in the protocol).</p> </li> </ol> </p> <p>All covariates were proposed after deliberation with clinical experts. We planned to explore potential differences in the effect of corticosteroids in distinct clinical populations, such as pregnant women with ruptured membranes or multiple pregnancy, and in different types of trials. </p> <p>For the main analysis we did not adjust data for multiple pregnancies to take account of non‐independence of outcomes for babies from the same pregnancy. For some outcomes there will be a higher correlation between babies from the same pregnancy than between babies from different pregnancies. The degree of non‐independence of outcomes for babies from multiple pregnancies will vary considerably depending on the outcome and the type of multiple pregnancy. For some outcomes the risk of an adverse event will be highly correlated in babies from the same pregnancy (e.g. preterm birth); while for others the degree of correlation will be lower (e.g. fetal death) but still higher than for babies from different pregnancies. In view of this non‐independence, subgroup analysis examining fetal and neonatal outcomes in singleton versus multiple pregnancies must be interpreted with particular caution. </p> <p>We found that some trials included in this review had a protocol of weekly repeat doses of corticosteroid if the mother remained undelivered. None of the trials that allowed weekly repeat doses reported outcomes separately for those exposed to repeat doses. We performed a <i>post hoc</i> analysis for primary outcomes of trials where a single course was used versus those where weekly repeat doses were allowed in the protocol to determine if the inclusion of such trials biased our results. Single versus multiple doses of corticosteroids is the subject of another Cochrane Review (<a href="./references#CD004454-bbs2-0079" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD003935. [DOI: 10.1002/14651858.CD003935.pub4]">Crowther 2015</a>). The analysis in this update will differ from that of the single versus multiple doses review, because the latter review includes only those studies where the women were randomised to either single or multiple doses. </p> <p>Because the case‐fatality rate for RDS has decreased with improvements in neonatal care, we postulated that the effect of corticosteroids may not be as apparent in more recent trials. This hypothesis was tested in a post‐hoc subgroup analysis with trials grouped by the main decade of recruitment or publication of results. </p> <p>Many trials did not report outcome data split according to the listed clinical characteristics (covariates). Due to this missing information, the total number of events/participants in subgroup analysis for some outcomes does not match the overall analysis. Wherever possible we have indicated in footnotes on the forest plots where the data are discrepant between the main analysis and the clinical subgroups. </p> <p>All analyses by the covariates listed above should be considered hypothesis‐generating.</p> <p>Finally, it should be noted that we did not conduct subgroup analysis where there were too few trials reporting data to conduct meaningful analyses. </p> </section> <section id="CD004454-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analysis for the primary outcomes based on risk of bias, where we removed studies from the analysis which were judged high risk for random sequence generation, allocation concealment or attrition bias. </p> <p>We also conducted three post‐hoc sensitivity analyses:</p> <p> <ul id="CD004454-list-0026"> <li> <p>intention‐to‐treat analysis versus available‐case analysis for neonatal/fetus primary outcomes; </p> </li> <li> <p>intraventricular haemorrhage (IVH): we removed studies from the analysis whose diagnosis of IVH was by postmortem only; </p> </li> <li> <p>subgroup analyses for different gestational ages at trial entry: we removed studies from the analysis that did not fit into either of the gestational age categories. </p> </li> </ul> </p> </section> <section id="CD004454-sec-0049"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed the certainty of evidence using the GRADE approach, as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE Handbook</a>, for the following outcomes. </p> <p><b>For the fetus/neonate</b> </p> <p> <ol id="CD004454-list-0027"> <li> <p>Perinatal death (composite of fetal death (in utero death) and early neonatal death (before seven completed days of life)). </p> </li> <li> <p>Neonatal death (before 28 completed days of life).</p> </li> <li> <p>Respiratory distress syndrome (RDS).</p> </li> <li> <p>Intraventricular haemorrhage (IVH).</p> </li> <li> <p>Mean birthweight (g).</p> </li> </ol> </p> <p><b>For the child</b> </p> <p> <ol id="CD004454-list-0028"> <li> <p>Neurodevelopmental disability at follow‐up (visual impairment, hearing impairment, intellectual impairment defined as intelligence quotient less than ‐2 standard deviations below population mean, moderate/severe cerebral palsy (however defined by study authors), or developmental delay (defined as developmental quotient less than ‐2 standard deviation below population mean)). </p> </li> </ol> </p> <p><b>For the woman</b> </p> <p> <ol id="CD004454-list-0029"> <li> <p>Maternal death (up to 90 days after giving birth.</p> </li> <li> <p>Chorioamnionitis (however defined by study authors).</p> </li> <li> <p>Endometritis (however defined by study authors and including infections).</p> </li> </ol> </p> <p>We used the <a href="http://www.gradepro.org/" target="_blank">GRADEpro</a> Guideline Development Tool to import data from Review Manager 5 (<a href="./references#CD004454-bbs2-0100" title="Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2014.">RevMan 2020</a>) in order to create 'Summary of findings' tables. A summary of the intervention effect and a measure of certainty for each of the above outcomes was produced using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high certainty' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004454-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004454-sec-0050"></div> <section id="CD004454-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD004454-sec-0052"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD004454-fig-0002">Figure 2</a> for a full description of the study identification process. </p> <div class="figure" id="CD004454-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004454-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>From our assessment of the 27 trial reports that were identified from the search update we found the following: </p> <p> <ul id="CD004454-list-0030"> <li> <p>five ongoing studies;</p> </li> <li> <p>five studies (eight reports) that did not meet our inclusion criteria;</p> </li> <li> <p>10 secondary reports of studies already included in the previous version of this review;</p> </li> <li> <p>four new, completed studies that meet our inclusion criteria.</p> </li> </ul> </p> <p>We also reassessed studies that were excluded from the previous version and included two (<a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>), which had been excluded because they had a large amount of missing data. However, in line with current Cochrane standards we have now included them. </p> <section id="CD004454-sec-0053"> <h5 class="title">Screening eligible studies for trustworthiness</h5> <p>From the 30 studies included in the previous version of the review and the three eligible studies identified from the update search we judged that nine studies did not meet our criteria for trustworthiness for the following reasons. </p> <p> <ul id="CD004454-list-0031"> <li> <p>Four studies were published only as abstracts and we have not been able to confirm with the trial authors that the data were from the final analyses (<a href="./references#CD004454-bbs2-0057" title="BotetF , CararachV , SentisJ . Premature rupture of membranes in early pregnancy. Neonatal prognosis. Journal of Perinatal Medicine1994;22:45-52. CararachV , BotetF , SentisJ , CarmonaF . A multicenter, prospective randomized study in premature rupture of membranes (PROM). Maternal and perinatal complications. International Journal of Gynecology and Obstetrics1991;36 Suppl:267. CararachV , SentisJ , BotetF , De Los RiosL . A multicenter, prospective randomized study in premature rupture of membranes (PROM). Respiratory and infectious complications in the newborn. In: Proceedings of the 12th European Congress of Perinatal Medicine; 1990; Lyon, France. 1990:216. ">Cararach 1991</a>; <a href="./references#CD004454-bbs2-0058" title="CarlanSJ , ParsonsM , O'BrienWF , KrammerJ . Pharmacologic pulmonary maturation in preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology1991;164:371. ">Carlan 1991</a>; <a href="./references#CD004454-bbs2-0061" title="GoodnerDM . Antenatal steroids in the treatment of respiratory distress syndrome. In: 9th World Congress of Gynecology and Obstetrics; 1979 October 26-31; Tokyo, Japan. 1979:362. ">Goodner 1979</a>; <a href="./references#CD004454-bbs2-0064" title="ParsonsMT , SobelD , CummiskeyK , ConstantineL , RoitmanJ . Steroid, antibiotic and tocolytic vs no steroid, antibiotic and tocolytic management in patients with preterm PROM at 25-32 weeks. In: Proceedings of the 8th Annual Meeting of the Society of Perinatal Obstetricians; 1988 Feb 3-6; Las Vegas, Nevada. 1988:44. SobelD , ParsonsM , RoitmanJ , McAlpineL , CumminskyK . Antenatal antibiotics in PROM prevents congenital bacterial infection. Pediatric Research1988;23:476A. ">Parsons 1988</a>). </p> </li> <li> <p>Two studies had concerns about randomisation processes where there was no explanation for substantial imbalances between the numbers allocated to each group (<a href="./references#CD004454-bbs2-0060" title="DoranTA , SwyerP , MacMurrayB , MahonW , EnhorningG , BernsteinA , et al. Results of a double blind controlled study on the use of betamethasone in the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1980;136:313-20. ">Doran 1980</a>; <a href="./references#CD004454-bbs2-0065" title="Taeusch HW Jr, FrigolettoF , KitzmillerJ , AveryME , HehreA , FrommB , et al. Risk of respiratory distress syndrome after prenatal dexamethasone treatment. Pediatrics1979;63:64-72. ">Taeusch 1979</a>). </p> </li> <li> <p>Three studies published since 2010 demonstrated no evidence of prospective registration (<a href="./references#CD004454-bbs2-0059" title="DelibasIB , IngecM , YapcaOE . Does antenatal betamethasone have negative effects on fetal activities and hemodynamics in cases of preeclampsia without severe features? A prospective, placebo-controlled, randomized study. Journal of Maternal-fetal &amp; Neonatal Medicine 2016 Nov;30(22):2671-8. [CENTRAL: CN-01602216] [PMID: 27838943]">Delibas 2017</a>; <a href="./references#CD004454-bbs2-0063" title="IRCT20120918010876N3. Assessment of efficacy of antenatal betamethasone on neonatal respiratory outcome of late preterm delivery (34-37 weeks) [Assessment of efficacy of antenatal betamethasone on neonatal respiratory outcome of late preterm delivery (34-37 weeks) in singleton pregnancies]. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20120918010876N32017. [CENTRAL: CN-01898197] MirzamoradiM , HasaniNF , JamaliR , HeidarZ , BakhtiyariM . Evaluation of the effect of antenatal betamethasone on neonatal respiratory morbidities in late preterm deliveries (34-37 weeks). Journal of Maternal-fetal &amp; Neonatal Medicine2019;33(15):2533-40. [CENTRAL: CN-01787845] [EMBASE: 625854285] [PMID: 30612482]">Mirzamoradi 2019</a>; <a href="./references#CD004454-bbs2-0062" title="HantoushzadehS , JavadianP , SalmanianB , GhazanfariT , KermaniA , AbbasalizadehF , et al. Betamethasone effects on the endocervical inflammatory cytokines in preterm labor: a randomized clinical trial. International Immunopharmacology2011;11(8):1116-9. KhazardoustS , JavadianP , SalmanianB , ZandevakilF , AbbasalizadehF , AlimohamadiS , et al. A clinical randomized trial on endocervical inflammatory cytokines and Betamethasone in prime-gravid pregnant women at risk of preterm labor. Iranian Journal of Immunology2012;9(3):199-207. ">Khazardoust 2012</a>). </p> </li> </ul> </p> <p>In all cases we made every effort to contact the authors and either identified no contact details at all or the authors did not respond to our queries ‐ see <a href="./references#CD004454-bbs1-0003" title="">Studies awaiting classification</a>. </p> </section> </section> <section id="CD004454-sec-0054"> <h4 class="title">Included studies</h4> <p>Twenty‐seven studies met our inclusion criteria and were assessed as trustworthy (11,272 randomised women and 11,925 neonates). The included studies were conducted over a wide range of gestational ages, including those of extreme prematurity and late prematurity. Obstetric indications for recruitment to trials were premature rupture of membranes, spontaneous preterm labour and planned preterm delivery. Please also refer to the <a href="./references#CD004454-sec-0327" title="">Characteristics of included studies</a> tables for full details. </p> <p>Two trials were stopped early. One (<a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>; 2852 women) was stopped early for infant mortality benefits and strong evidence of a graded dose‐response effect and the other (<a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>; 32 women) was stopped due to problems with recruitment. </p> <section id="CD004454-sec-0055"> <h5 class="title">Design</h5> <p>All of the studies are randomised controlled trials (RCTs). One four‐arm trial had three intervention groups, which each received a different corticosteroid and the fourth group received placebo (<a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>). Another four‐arm trial randomised women to expectant management alone, or expectant management plus either betamethasone or ampicillin, or a combination of expectant management plus betamethasone plus ampicillin (<a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>). One three‐arm trial (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>) compared two different corticosteroids and a placebo group. One trial (<a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>), had three arms but we did not include one of the arms because it did not meet our inclusion criteria for eligible comparators. The other trials had two arms each. </p> </section> <section id="CD004454-sec-0056"> <h5 class="title">Setting</h5> <p>The included studies came from a range of healthcare systems and settings.  Ten trials (4422 randomised women) took place in lower‐ or middle‐resource settings. </p> <p>Ten of the studies were conducted in the USA (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>), two in Brazil (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>), two in Finland (<a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>), and one each in India (<a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>), Iran (<a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>), Colombia (<a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>), South Africa (<a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>), Thailand (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>), Tunisia (<a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>), Turkey (<a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>), the UK (<a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>), New Zealand (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>), Jordan (<a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>) and the Netherlands (<a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>). One study took place in the USA and Germany (<a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>), and another study took place in Bangladesh, India, Kenya, Nigeria and Pakistan (<a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </section> <section id="CD004454-sec-0057"> <h5 class="title">Participants</h5> <section id="CD004454-sec-0058"> <h6 class="title">Multiple pregnancy</h6> <p>The majority of trials recruited only women with singleton pregnancy. Twelve trials (<a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>, <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>, <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>, <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>, <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>, <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>, <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>, <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>, <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>) recruited women with singleton or multiple pregnancy. Of these, five studies (<a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>, <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>, <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>) reported some outcome data separately for included women with multiple pregnancy. In two trials recruitment was unclear but we assumed that they only included women with singleton pregnancies since the number of women was the same as the number of infants in each group (<a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>). </p> </section> <section id="CD004454-sec-0059"> <h6 class="title">Membrane status</h6> <p>Several trials specifically excluded women with premature rupture of membranes: <a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a><a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>. Eight trials reported outcome data for women with premature rupture of membranes (<a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>). The remaining included trials reported data for a mixed population or the membrane status of included women was unclear. One trial (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>) reported some outcome data separately for women with intact or ruptured membranes. </p> </section> <section id="CD004454-sec-0060"> <h6 class="title">Gestational age at trial entry</h6> <p>We have attached a table stating the gestational parameters for trials included in the review (<a href="#CD004454-tbl-0003">Table 1</a>). For the analysis of clinical subgroups for this update, we have compared trials recruiting women at gestational age of less than and including 35 weeks + 0 days with trials recruiting women 34 weeks + 0 days' gestation or greater for the review's primary outcomes. Most trials fall on either side of this division, with the exception of four studies; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>, <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>, <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>, and <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>. Data from <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a> was available for women receiving their first dose at less than 35 weeks + 0 days and from between 35 weeks + 0 days and 37 weeks + 0 days, footnotes detailing this have been added to the appropriate forest plots. The majority of women in the remaining three studies (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>) received their first dose prior to 34 weeks + 0 days, therefore we included these studies in the younger gestational age grouping for the analysis (women less than, and including, 35 weeks and 0 days), but undertook a sensitivity analysis with the studies' data removed. </p> <div class="table" id="CD004454-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Gestational age parameters for included trials</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimum</p> <p>(weeks<sup>+days</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum</p> <p>(weeks<sup>+days</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<sup>+0</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a><br/>  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a><br/>  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<sup>+6</sup><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<sup>+0</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34<sup>+0</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32<sup>+0</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33<sup>+6</sup> </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD004454-sec-0061"> <h5 class="title">Interventions</h5> <section id="CD004454-sec-0062"> <h6 class="title">Type of steroid</h6> <p>The following types of steroids were used.</p> <p> <ul id="CD004454-list-0032"> <li> <p>Dexamethasone (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </li> <li> <p>Betamethasone (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>). </p> </li> <li> <p>Methylprednisolone (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>). </p> </li> <li> <p>Hydrocortisone (<a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>). </p> </li> </ul> </p> <p>One study used either betamethasone or dexamethasone in its treatment arm (<a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>). </p> </section> <section id="CD004454-sec-0063"> <h6 class="title">Comparators</h6> <p>In most trials the control arm received placebo. In the other trials the control arm received no treatment (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>), expectant management (<a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>), and 6 mg cortisone acetate, which has 1/70th of the corticosteroid potency of the betamethasone administered to the intervention group (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>). </p> </section> <section id="CD004454-sec-0064"> <h6 class="title">Weekly repeats</h6> <p>Most trials included in this review tested a single course of corticosteroid. Eight studies allowed weekly repeat courses of study medication in their study protocols (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>).  We conducted <i>post hoc</i> analysis of primary outcomes comparing studies testing a single course of study medication with studies allowing weekly repeat courses. </p> </section> </section> <section id="CD004454-sec-0065"> <h5 class="title">Outcomes</h5> <p>The following trials reported data for the outcomes specified in our 'Summary of findings' tables. </p> <p> <ul id="CD004454-list-0033"> <li> <p>Perinatal death: 14 trials (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </li> <li> <p>Neonatal death: 22 trials (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </li> <li> <p>Respiratory distress syndrome (RDS): all trials except one (<a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>). </p> </li> <li> <p>IVH: 12 trials (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </li> <li> <p>Mean birthweight: 19 trials (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </li> <li> <p>Neurodevelopmental disability in childhood: five trials (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>). </p> </li> <li> <p>Maternal death: six trials (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </li> <li> <p>Chorioamnionitis: 15 trials (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </li> <li> <p>Endometritis: t10 trials (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </li> </ul> </p> <p>Five studies (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>) reported outcome data related to the infant in childhood. </p> <p>Only two studies (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>) reported outcome data related to the infant in adulthood. </p> </section> <section id="CD004454-sec-0066"> <h5 class="title">Dates of study</h5> <p>Eight trials were conducted during the 1970s (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>), four during the 1980s (<a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>), five during the 1990s (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>), six during the 2000s (<a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>), and four during the 2010s (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </section> <section id="CD004454-sec-0067"> <h5 class="title">Funding sources</h5> <p>Eleven trials received funding from public, educational or charitable sources (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> <p>One trial received funding from commercial sources (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>). </p> <p>Thirteen trials did not specifically report any information about funding sources (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>). </p> </section> <section id="CD004454-sec-0068"> <h5 class="title">Declarations of interest</h5> <p>In five trials the authors declared that they had no competing interests (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> <p>Twenty‐one trials did not mention authors' declarations of interest at all (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>). </p> <p>In one trial, published in languages other than English, we were unable to obtain enough translated information to know what declarations, if any, were reported (<a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>). </p> </section> </section> <section id="CD004454-sec-0069"> <h4 class="title">Excluded studies</h4> <p>We excluded 29 studies. Reasons for exclusion included the following.</p> <p> <ol id="CD004454-list-0034"> <li> <p>The study did not compare a corticosteroid with placebo or no treatment (<a href="./references#CD004454-bbs2-0028" title="AbuhamadA , GreenG , HeylP , deVecianaM . The combined use of corticosteroids and thyrotropin releasing hormone in pregnancies with preterm rupture of membranes: a randomised double blind controlled trial. American Journal of Obstetrics and Gynecology1999;180(1 Pt 2):S96. ">Abuhamad 1999</a>; <a href="./references#CD004454-bbs2-0029" title="AlthabeF , BelizanJM , MazzoniA , BerruetaM , Hemingway-FodayJ , Koso-ThomasM , et al. Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries: study protocol. Reproductive Health2012;9(1):22. AlthabeF , BelizanJM , McClureEM , Hemingway-FodayJ , BerruetaM , MazzoniA , et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. Lancet2015;385(9968):629-39. [PMID: 25458726]GoldenbergRL , ThorstenVR , AlthabeF , SaleemS , GarcesA , CarloWA , et al. The global network antenatal corticosteroids trial: impact on stillbirth. Reproductive Health2016;13(1):68. [CENTRAL: CN-01368862] [EMBASE: 610555843] [PMID: 27255082]NCT01084096. Trial of the use of antenatal corticosteroids in developing countries. https://clinicaltrials.gov/ct2/show/NCT01084096 (first received 2010). ">Althabe 2015</a>; <a href="./references#CD004454-bbs2-0032" title="DolaC , NageotteM , RumneyP , TowersC , AsratT , FreemanR , et al. The effect of antenatal treatment with betamethasone and thyrotropin releasing hormone in patients with preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S49. ">Dola 1997</a>; <a href="./references#CD004454-bbs2-0033" title="DudeC , DudeA , GilnerJ , SwamyG , GrotegutC . Predicting preterm delivery: using the MFMU BEARS trial data to optimize corticosteroid use in women at risk for preterm delivery. Reproductive Sciences (Thousand Oaks, Calif.)2016;23(Suppl 1):188A-9A. [CENTRAL: CN-02011932] ">Dude 2016</a>; <a href="./references#CD004454-bbs2-0034" title="EgermanRS , MercerB , DossJL , SibaiBM . A randomized controlled trial of oral and intramuscular dexamethasone in the prevention of neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S19. EgermanRS , MercerBM , DossJL , SibaiBM . A randomized, controlled trial of oral and intramuscular dexamethasone in the prevention of neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1998;179(5):1120-3. EgermanRS , Pierce WF 4th, AndersenRN , UmstotES , CarrTL , SibaiBM . A comparison of the bioavailability of oral and intramuscular dexamethasone in women in late pregnancy. Obstetrics &amp; Gynecology1997;89(2):276-80. EgermanRS , WalkerRA , DossJL , MercerB , SibaiBM , AndersenRN . A comparison between oral and intramuscular dexamethasone in suppressing unconjugated estriol levels during the third trimester. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S182. EgermanRS , WalkerRA , MercerBM , DossJL , SibaiBM , AndersenRA . Comparison between oral and intramuscular dexamethasone in suppressing unconjugated estriol levels during the third trimester. American Journal of Obstetrics and Gynecology1998;179(5):1234-6. ">Egerman 1998</a>; <a href="./references#CD004454-bbs2-0035" title="GariteTJ , FreemanRK , LinzeyEM , BralyPS , DorchesterWL . Prospective randomized study of corticosteroids in the management of premature rupture of the membranes and the premature gestation. American Journal of Obstetrics and Gynecology1981;141:508-15. ">Garite 1981</a>; <a href="./references#CD004454-bbs2-0038" title="IamsJD , TalbertML , BarrowsH , SachsL . Management of preterm prematurely ruptured membranes: a prospective randomized comparison of observation vs use of steroids and timed delivery. American Journal of Obstetrics and Gynecology1985;151:32-8. ">Iams 1985</a>; <a href="./references#CD004454-bbs2-0044" title="MageeLA , DawesGS , MouldenM , RedmanCW . A randomised controlled comparison of betamethasone with dexamethasone: effects on the antenatal fetal heart rate. British Journal of Obstetrics and Gynaecology1997;104(11):1233-8. ">Magee 1997</a>; <a href="./references#CD004454-bbs2-0047" title="MinouiS , VilleY , SenatM , MultonO , FernandezH , FrydmanR . Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomized study. British Journal of Obstetrics and Gynaecology1998;105:749-55. MinouiS , VilleY , SenatMV , MultonO , FernandezH , FrydmanR . Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labor a randomized study. Prenatal and Neonatal Medicine1996;1 Suppl 1:156. ">Minoui 1998</a>; <a href="./references#CD004454-bbs2-0049" title="MulderEJ , DerksJB , VisserGH . Antenatal corticosteroid therapy and fetal behaviour: a randomised evaluation of betamethasone and dexamethasone. British Journal of Obstetrics and Gynaecology1997;104(11):1239-47. ">Mulder 1997</a>; <a href="./references#CD004454-bbs2-0051" title="NCT04494529. Single Dose Antenatal Corticosteroids (SNACS) for women at risk of preterm birth [Single Dose Antenatal Corticosteroids (SNACS) pilot randomized control trial for women at risk of preterm birth]. https://clinicaltrials.gov/show/NCT04494529 (first received 2020 Jul 31). [CENTRAL: CN-02145746] ">NCT04494529 2020</a>; <a href="./references#CD004454-bbs2-0054" title="RotmenschS , LiberatiM , VishneT , CelentanoC , Ben-RafaelZ , BellatiU . The effects of betamethasone versus dexamethasone on computer-analysed fetal heart rate characteristics: a prospective randomized trial. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S185. RotmenschS , LiberatiM , VishneTH , CelentanoC , Ben-RafaelZ , BellatiU . The effect of betamethasone and dexamethasone on the fetal heart rate patterns and biophysical activities. A prospective randomized trial. Acta Obstetricia et Gynecologica Scandinavica1999;78(6):493-500. ">Rotmensch 1999</a>; <a href="./references#CD004454-bbs2-0056" title="WhittGG , BusterJE , KillamAP , ScraggWH . A comparison of two glucocorticoid regimens for acceleration of fetal lung maturation in premature labor. American Journal of Obstetrics and Gynecology1976;124:479-82. ">Whitt 1976</a>). </p> </li> <li> <p>The study was not a randomised controlled trial (<a href="./references#CD004454-bbs2-0030" title="AsnafeiN , PourrezaR , MiriSM . Pregnancy outcome in premature delivery of between 34-37 weeks and the effects of corticosteroid on it. Journal of the Gorgan University of Medical Sciences2004;6(2):57-60. ">Asnafei 2004</a>; <a href="./references#CD004454-bbs2-0036" title="GrgicG , FatusicZ , BogdanovicG . Stimulation of fetal lung maturation with dexamethasone in unexpected premature labor. Medicinski Arhiv2003;57(5-6):291-4. ">Grgic 2003</a>; <a href="./references#CD004454-bbs2-0037" title="HalacE , HalacJ , BegueEF , CasanasJM , IdiveriDR , PetitJF , et al. Prenatal and postnatal corticosteroid therapy to prevent neonatal necrotizing enterocolitis: a controlled trial. Journal of Pediatrics1990;117:132-8. ">Halac 1990</a>; <a href="./references#CD004454-bbs2-0043" title="LiuJ , WangQ , ZhaoJH , ChenYH , QinGL . The combined antenatal corticosteroids and vitamin K therapy for preventing periventricular-intraventricular hemorrhage in premature newborns less than 35 weeks gestation. Journal of Tropical Pediatrics2006;52(5):355-9. ">Liu 2006</a>; <a href="./references#CD004454-bbs2-0045" title="MaksicH , Hadzagic-CatibusicF , HeljicS , DizdarevicJ . The effects of antenatal corticosteroid treatment on IVH-PVH of premature infants. Bosnian Journal of Basic Medical Sciences2008;8(1):58-62. ">Maksic 2008</a>; <a href="./references#CD004454-bbs2-0048" title="MoralesWJ , DiebelD , LazarAJ , ZadroznyD . The effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome in preterm gestations with premature rupture of membranes. American Journal of Obstetrics and Gynecology1986;154:591-5. ">Morales 1986</a>; <a href="./references#CD004454-bbs2-0055" title="SimpsonG , HarbertG . Use of beta-methasone in management of preterm gestation with premature rupture of membranes. Obstetrics &amp; Gynecology1985;66:168-75. ">Simpson 1985</a>). </p> </li> <li> <p>Study participants were combined with a non‐randomised cohort and results were not presented separately (<a href="./references#CD004454-bbs2-0031" title="ButterfillAM , HarveyDR . Follow-up study of babies exposed to betamethasone before birth. Archives of Disease in Childhood1979;54:725. ">Butterfill 1979</a>; <a href="./references#CD004454-bbs2-0041" title="KuhnRJP , SpeirsAL , PepperellRJ , EggersTR , DoyleLW , HutchinsonA . Betamethasone, albuterol and threatened premature delivery. Obstetrics &amp; Gynecology1982;60:403-8. ">Kuhn 1982</a>). </p> </li> <li> <p>The study was withdrawn without having recruited any participants (<a href="./references#CD004454-bbs2-0050" title="NCT02351310. Effectiveness of ACS in extreme preemies [Effects of antenatal corticosteroids in patients with early (22 - 23w6d) threatened preterm birth]. Https://clinicaltrials.gov/show/NCT02351310 (first received 2015 Jan 27). [CENTRAL: CN-01551840] ">NCT02351310 2015</a>). </p> </li> <li> <p>Several studies compared repeat‐dose corticosteroids and are eligible for inclusion in the <a href="./references#CD004454-bbs2-0079" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD003935. [DOI: 10.1002/14651858.CD003935.pub4]">Crowther 2015</a> review (<a href="./references#CD004454-bbs2-0039" title="KhandelwalM , ChangE , HansenC , HunterK , MilcarekB . Betamethasone dosing interval -12 or 24 hours apart?American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S10-S11. KhandelwalM , ChangE , HansenC , HunterK , MilcarekB . Betamethasone dosing interval: 12 or 24 hours apart? A randomized, noninferiority open trial. American Journal of Obstetrics and Gynecology2012;206(3):201.e1-11. ">Khandelwal 2012</a>; <a href="./references#CD004454-bbs2-0040" title="KoivistoM , PeltoniemiOM , SaarelaT , TammelaO , JouppilaP , HallmanM . Blood glucose level in preterm infants after antenatal exposure to glucocorticoid. Acta Paediatrica2007;96(5):664-8. ">Koivisto 2007</a>; <a href="./references#CD004454-bbs2-0042" title="KurtzmanJ , GariteT , ClarkR , MaurelK , TheOCRN . Impact of a 'rescue course' of antenatal corticosteroids (ACS): a multi-center randomized placebo controlled trial. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S2. ">Kurtzman 2008</a>; <a href="./references#CD004454-bbs2-0046" title="McEvoyC , SchillingD , ClayN , SpitaleP , DurandM . Neurodevelopmental outcome and growth in infants randomized to a single rescue course of antenatal steroids. In: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting; 2011 April 30-May 3; Denver, Colorado, USA. 2011:3829.270. McEvoyC , SchillingD , PetersD , TillotsonC , SpitaleP , WallenL , et al. Respiratory compliance in preterm infants after a single rescue course of antenatal steroids: a randomized controlled trial. American Journal of Obstetrics and Gynecology2010;202(6):544.e1-9. McEvoyC , SchillingD , SegelS , SpitaleP , WallenL , BowlingS , et al. Improved respiratory compliance in preterm infants after a single rescue course of antenatal steroids: a randomized trial. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S228. McEvoyC , SchillingD , SpitaleP , GravettM , DurandM . Pulmonary function and respiratory outcomes at 12-24 months in preterm infants randomized to a single rescue course of antenatal steroids. In: Pediatric Academic Societies' 2010 Annual Meeting; 2010 May 1-4; Vancouver, Canada. 2010. McEvoyC , SchillingD , SpitaleP , WallenL , SegelS , BowlingS , et al. Improved respiratory compliance after a single rescue course of antenatal steroids: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007. McEvoyC , SchillingD , SpitaleP , WallenL , SegelS , BowlingS , et al. Improved respiratory compliance after a single rescue course of antenatal steroids: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2008 May 2-6; Honolulu, Hawaii. 2008. McEvoyC , SchillingD , SpitaleP , WallenP , SegelS , BowlingS , et al. Growth and respiratory outcomes after a single rescue course of antenatal steroids: a randomized trial. In: Pediatric Academic Societies Annual Meeting; 2009 May 2-5; Baltimore, USA. 2009. McEvoyCT , SchillingD , SegalS , SpitaleP , WallenL , BowlingS , et al. Improved respiratory compliance in preterm infants &lt;34 weeks after a single rescue course of antenatal steroids. American Journal of Respiratory and Critical Care Medicine2009;179:A4127 [Poster #423]. ">McEvoy 2010</a>; <a href="./references#CD004454-bbs2-0052" title="PapageorgiouAN , DesgrangesMF , MassonM , ColleE , ShatzR , GelfandMM . The antenatal use of betamethasone in the prevention of respiratory distress syndrome: a controlled blind study. Pediatrics1979;63:73-9. ">Papageorgiou 1979</a>; <a href="./references#CD004454-bbs2-0053" title="Romejko-WolniewiczE , OleszczukL , Zareba-SzczudlikJ , CzajkowskiK . Dosage regimen of antenatal steroids prior to preterm delivery and effects on maternal and neonatal outcomes. Journal of Maternal-Fetal and Neonatal Medicine2013;26(3):237-41. ">Romejko‐Wolniewicz 2013</a>). </p> </li> </ol> </p> <p>See the <a href="./references#CD004454-sec-0328" title="">Characteristics of excluded studies</a> table for full details. </p> <section id="CD004454-sec-0070"> <h5 class="title">Ongoing studies</h5> <p>In addition to one study that was identified in the last version of this review (<a href="./references#CD004454-bbs2-0119" title="RobertsD , BrownJ , MedleyN , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2017, Issue 3. Art. No: CD004454. [DOI: 10.1002/14651858.CD004454.pub3]">Roberts 2017</a>), and which does not yet have available results, we identified a further four ongoing studies. All of these trials are investigating the use of corticosteroids in women at the late preterm stage (34 to 36 weeks' gestation), and they aim to recruit a total of 23,500 women, mostly in low‐ and middle‐resource countries. </p> <p>See <a href="./references#CD004454-sec-0330" title="">Characteristics of ongoing studies</a> for further details. </p> </section> </section> </section> <section id="CD004454-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD004454-fig-0003">Figure 3</a> and <a href="#CD004454-fig-0004">Figure 4</a> illustrate the risks of bias which are explained in more detail below. </p> <div class="figure" id="CD004454-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD004454-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD004454-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study" data-id="CD004454-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD004454-sec-0072"> <h4 class="title">Allocation</h4> <section id="CD004454-sec-0073"> <h5 class="title">Sequence generation</h5> <p>We have summarised the methods of randomisation used in the included trials in the <a href="./references#CD004454-sec-0327" title="">Characteristics of included studies</a> table. We judged 15 trials as having low risk of bias for random sequence generation because they used techniques such as computer‐generated or random number‐generated randomisation sequences (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). The remaining 12 trials did not describe the method of sequence generation in sufficient detail so we judged them as unclear risk of bias (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>). </p> </section> <section id="CD004454-sec-0074"> <h5 class="title">Allocation concealment</h5> <p>Twelve trials described adequate allocation concealment procedures and we therefore judged them to be low risk of bias (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). We assessed one trial as having a high risk of bias due to a sealed envelope containing the identity of the contents being attached to each vial "to be opened in emergency only in case of an emergency"; the manuscripts do not state how often these were opened (<a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>). We judged the remaining trials as  unclear risk of bias due to insufficient description of the method of allocation concealment (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>). </p> </section> </section> <section id="CD004454-sec-0075"> <h4 class="title">Blinding</h4> <section id="CD004454-sec-0076"> <h5 class="title">Blinding of participants and personnel</h5> <p>Seventeen of the included trials were placebo controlled and therefore we judged them to be low risk of bias (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). The majority of these trials used normal saline, or the vehicle of the corticosteroid preparation, as the placebo. The remaining trials were judged as high risk of bias due to not blinding participants and personnel to the study intervention (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>). </p> </section> <section id="CD004454-sec-0077"> <h5 class="title">Blinding of outcome assessors</h5> <p>Blinding of outcome assessors was sufficiently reported in 10 trials which we judged as low risk of bias (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). The remaining trials did not describe whether or not outcome assessors were blinded and so were judged to be of unclear risk of bias (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>). </p> </section> </section> <section id="CD004454-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>We judged 16 trials as having low risk of attrition bias because they had low, non‐differential attrition and/or the reasons for missing data were not related to the intervention (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). Three trials were assessed as having high risk of bias. <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a> had over 20% loss to follow‐up and no intention‐to‐treat analysis.  <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a> and <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a> did not report the group allocation of the women excluded/lost to follow‐up. We assessed the remaining trials as unclear risk of bias due to lack of information or unknown impact of stated exclusions (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>). </p> </section> <section id="CD004454-sec-0079"> <h4 class="title">Selective reporting</h4> <p>We judged two trials to be high risk of bias due to selective reporting. <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a> did not provide a protocol and did not report on endometritis despite being specified in methods. <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a> did not report on hyaline membrane disease despite listing it as an outcome. </p> <p>One trial (<a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>) was judged to have unclear risk of reporting bias because of discrepancies in numbers reported for one outcome. We contacted the authors for clarification but we did not receive any response. </p> <p>The remaining trials were judged to have low risk of bias due to selective reporting because they either reported all the outcomes specified in their protocols or prospective trial registrations, or, in the case of trials published before protocols and prospective registration became commonplace, they reported all outcomes in full that were specified in their methods (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </section> <section id="CD004454-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a> as high risk of other bias because the trial was stopped early due to problems with recruitment. <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a> was assessed as high risk of bias as two of the three trial arms were discontinued after 24 months to increase group size in the other trial arm and placebo arm without explanation. We judged one trial as unclear for other potential sources of bias because it is in Persian and we are still awaiting clarification from a translator regarding risk of bias (<a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>). </p> <p>We judged the remaining trials as low risk because there was no indication of any other potential sources of bias (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> </section> </section> <section id="CD004454-sec-0081"> <h3 class="title" id="CD004454-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD004454-tbl-0001"><b>Summary of findings 1</b> Neonatal and child outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</a>; <a href="./full#CD004454-tbl-0002"><b>Summary of findings 2</b> Maternal outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</a> </p> <section id="CD004454-sec-0082"> <h4 class="title">1. Antenatal corticosteroids versus placebo or no treatment (all included studies)</h4> <section id="CD004454-sec-0083"> <h5 class="title">Primary outcomes</h5> <section id="CD004454-sec-0084"> <h6 class="title">For the fetus or neonate</h6> <section id="CD004454-sec-0085"> <p><b>Perinatal death</b></p> <p>Antenatal corticosteroids reduce the risk of perinatal death compared with placebo or no treatment (risk ratio (RR) 0.85, 95% confidence interval (CI) 0.77 to 0.93; 9833 infants; studies = 14; I<sup>2</sup> = 28%; high‐certainty evidence; <a href="./full#CD004454-tbl-0001">summary of findings Table 1</a>; <a href="./references#CD004454-fig-0017" title="">Analysis 1.1</a>). With corticosteroids there were 2.3% fewer perinatal deaths than with placebo or treatment (95% CI 1.1% fewer to 3.6% fewer). </p> <p>The shape of the funnel plot (<a href="#CD004454-fig-0005">Figure 5</a>) suggested that some evidence may be missing in areas where results would be statistically non‐significant or in the direction of a poorer outcome with corticosteroids. This may explained by lower methodological quality in smaller studies leading to spuriously inflated effects, or by non‐publication of studies because of the nature of their findings (e.g. statistical significance or direction of effect). However, we did not consider the asymmetry to be pronounced enough to downgrade the certainty of evidence. </p> <div class="figure" id="CD004454-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.4 Perinatal deaths" data-id="CD004454-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.4 Perinatal deaths </p> </div> </div> </div> <p>Sensitivity analysis removing one trial at high risk of bias for allocation concealment did not substantially change the effect estimate (RR 0.84, 95% CI 0.76 to 0.92; 9076 infants; studies = 13; I<sup>2</sup> = 31%). </p> <p>For perinatal death all trials reported data using numbers randomised as the denominator therefore there is no difference between our intention‐to‐treat (ITT) analysis and available‐case analysis. </p> </section> <section id="CD004454-sec-0086"> <p><b>Neonatal death</b></p> <p>Antenatal corticosteroids reduce the risk of neonatal death compared with placebo or no treatment (RR 0.78, 95% CI 0.70 to 0.87; 10,609 infants; studies = 22; I<sup>2</sup> = 12%; high‐certainty evidence; <a href="./full#CD004454-tbl-0001">summary of findings Table 1</a>; <a href="./references#CD004454-fig-0018" title="">Analysis 1.2</a>).  </p> <p>With corticosteroids there were 2.6% fewer neonatal deaths than with placebo or treatment (95% CI 1.5% fewer to 3.6% fewer). Sensitivity analysis comparing ITT analysis and available‐case analysis had little impact on the effect estimate (available case analysis: RR 0.78, 0.70 to 0.86; 10,189 infants). </p> <p>Sensitivity analysis removing three trials at high risk of bias for allocation concealment or incomplete outcome data did not substantially change the effect estimate (RR 0.79, 95% CI 0.71 to 0.88; 9954 infants; studies = 19; I<sup>2</sup> = 1%). </p> <p>The shape of the funnel plot (<a href="#CD004454-fig-0006">Figure 6</a>) suggested that some evidence may be missing in areas where results would be statistically non‐significant or in the direction of a poorer outcome with corticosteroids. This may explained by lower methodological quality in smaller studies leading to spuriously inflated effects, or by non‐publication of studies because of the nature of their findings (e.g. statistical significance or direction of effect). However, we did not consider the asymmetry to be pronounced enough to downgrade the certainty of evidence. </p> <div class="figure" id="CD004454-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.5 Neonatal deaths" data-id="CD004454-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.5 Neonatal deaths </p> </div> </div> </div> </section> <section id="CD004454-sec-0087"> <p><b>Fetal death</b></p> <p>Antenatal corticosteroids may have little to no effect on the risk of fetal death (RR 1.01, 95% CI 0.83 to 1.22; 9833 infants; studies = 14; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0019" title="">Analysis 1.3</a>). </p> <p>The symmetry in the funnel plot did not suggest evidence of bias due to non‐publication of results (<a href="#CD004454-fig-0007">Figure 7</a>). Sensitivity analysis removing one trial at high risk of bias for allocation concealment did not substantially change the effect estimate (RR 1.02, 95% CI 0.84 to 1.24; 9076 infants; studies = 13; I<sup>2</sup> = 0%). </p> <div class="figure" id="CD004454-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.6 Fetal deaths" data-id="CD004454-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.6 Fetal deaths </p> </div> </div> </div> <p>For fetal death all trials reported data using numbers randomised as the denominator therefore there is no difference between our ITT analysis and available case analysis. </p> </section> <section id="CD004454-sec-0088"> <p><b>Respiratory distress syndrome (RDS)</b></p> <p>Antenatal corticosteroids reduce the risk of RDS compared with placebo or no treatment (RR 0.71, 95% CI 0.65 to 0.78; 11,183 infants; studies = 26; I<sup>2</sup> = 48%; high‐certainty evidence; <a href="./full#CD004454-tbl-0001">summary of findings Table 1</a>; <a href="./references#CD004454-fig-0020" title="">Analysis 1.4</a>). With corticosteroids 4.3% fewer infants had RDS than with placebo or treatment (3.2% fewer to 5.2% fewer). </p> <p>Sensitivity analysis comparing ITT analysis and available case analysis (ACA) showed that the two effect estimates are the same (ACA RR 0.71, 95% CI 0.65 to 0.78; participants = 10,321). Sensitivity analysis removing three trials at high risk of bias for allocation concealment and incomplete outcome data did not change the effect estimate (RR 0.71, 95% CI 0.65 to 0.79; 10,203 infants; studies = 23; I<sup>2</sup> = 50%). </p> <p>The moderate heterogeneity in the analysis (I<sup>2</sup> = 48%) may be explicable by changes in neonatal care over time. Subgroup analysis based on the decade  when the trials took place (<a href="./references#CD004454-fig-0109" title="">Analysis 6.4</a>) suggested that there was a difference in effect on RDS according to the time period of the trial. However, we did not consider heterogeneity to be substantial enough to downgrade the certainty of evidence. </p> <p>The symmetry in the funnel plot did not suggest evidence of bias due to non‐publication of results (<a href="#CD004454-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD004454-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.7 Respiratory distress syndrome" data-id="CD004454-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.7 Respiratory distress syndrome </p> </div> </div> </div> </section> <section id="CD004454-sec-0089"> <p><b>Moderate to severe respiratory distress syndrome (RDS)</b></p> <p>Fewer infants had moderate to severe RDS in the groups treated with antenatal corticosteroids than in the control groups (RR 0.70, 95% CI 0.59 to 0.83; 4874 infants; studies = 7; I<sup>2</sup> = 53%; <a href="./references#CD004454-fig-0021" title="">Analysis 1.5</a>). Sensitivity analysis comparing ITT analysis and available case analysis showed no substantial difference in the effect estimate (ACA RR 0.69, 95% CI 0.59 to 0.82; 4127 infants). </p> <p>Removing one trial at high risk of attrition bias did not change the effect estimate (RR 0.69, 95% CI 0.58 to 0.82; 4031 infants; studies = 6; I<sup>2</sup> = 60%). </p> </section> <section id="CD004454-sec-0090"> <p><b>Chronic lung disease</b></p> <p>It is unclear if antenatal corticosteroids have any effect on the risk of chronic lung disease compared with placebo or no treatment (RR 0.86, 95% CI 0.41 to 1.79; 745 infants; studies = 5; I<sup>2</sup> = 65%; <a href="./references#CD004454-fig-0022" title="">Analysis 1.6</a>). Sensitivity analysis comparing ITT analysis and available case analysis showed no substantial difference in the effect estimate (ACA RR 0.86, 95% CI 0.42 to 1.79; 695 infants). Because of unexplained statistical heterogeneity we conducted random effects meta‐analysis for this outcome. </p> <p>None of the trials reporting chronic lung disease data were at high risk of bias for random sequence generation, allocation concealment or incomplete outcome data so we did not perform further sensitivity analysis. </p> </section> <section id="CD004454-sec-0091"> <p><b>Intraventricular haemorrhage (IVH)</b></p> <p>Antenatal corticosteroids probably reduce the risk of IIVH compared with placebo or no treatment (RR 0.58, 95% CI 0.45 to 0.75; 8475 infants; studies = 12; I<sup>2</sup> = 45%; moderate‐certainty evidence; <a href="./full#CD004454-tbl-0001">summary of findings Table 1</a>; <a href="./references#CD004454-fig-0023" title="">Analysis 1.7</a>). With corticosteroids 1.4% fewer infants had IVH than with placebo or treatment (95% CI 0.8% fewer to 1.8% fewer). Sensitivity analysis comparing ITT analysis and available case analysis showed no substantial difference in the effect estimate (ACA RR 0.57, 95% CI 0.45 to 0.73; 6771 infants). </p> <p>For illustrative purposes only, the analysis shows which studies reported specifically infants with grade 3‐4 IVH and which studies reported infants with any IVH. </p> <p>The moderate heterogeneity in the analysis (I<sup>2</sup> = 45%) may be partly due to differences in trial protocols, where not all trials routinely screened all infants for IVH. However, we did not consider heterogeneity to be substantial enough for a further downgrade of the certainty of evidence. </p> <p>Three studies stated which infants were screened for IVH, used ultrasound: liveborn neonates &lt; 1500 g or with signs of neonatal hypoxia (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>); neonates &lt; 1500 g by the third day (<a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>); liveborn neonates &lt; 34 weeks at birth and liveborn neonates ≥ 34 weeks at birth if indicated (<a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). The other trials reporting IVH diagnosis by ultrasound did not state which infants were screened for IVH. </p> <p>Three studies reported zero cases of IVH in both arms but they did not report a definition of how IVH was diagnosed or how many infants were screened for IVH (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a> 194 infants; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a> 200 infants; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a> 206 infants). </p> <p>The symmetry in the funnel plot did not suggest evidence of bias due to non‐publication of results (<a href="#CD004454-fig-0009">Figure 9</a>). Sensitivity analysis removing two trials where diagnosis of IVH was by postmortem only (<a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>) did not substantially change the effect estimate (RR 0.58, 95% CI 0.44 to 0.76; 6989 infants; I<sup>2</sup> = 55%). </p> <div class="figure" id="CD004454-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.7 Intraventricular haemorrhage." data-id="CD004454-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.7 Intraventricular haemorrhage. </p> </div> </div> </div> <p>None of the trials in the analysis of IVH data were at high risk of bias for random sequence generation, allocation concealment or incomplete outcome data so we did not perform further sensitivity analysis. </p> </section> <section id="CD004454-sec-0092"> <p><b>Mean birthweight</b></p> <p>Antenatal corticosteroids result in little to no difference in birthweight (mean difference (MD) ‐14.02, 95% CI ‐33.79 to 5.76; 9551 infants; studies = 19; I<sup>2</sup> = 0%; high‐certainty evidence; <a href="./full#CD004454-tbl-0001">summary of findings Table 1</a>; <a href="./references#CD004454-fig-0024" title="">Analysis 1.8</a>). </p> <p>The symmetry in the funnel plot did not suggest evidence of bias due to non‐publication of results (<a href="#CD004454-fig-0010">Figure 10</a>). Sensitivity analysis removing two trials at high risk of bias for incomplete outcome data did not substantially change the effect estimate (MD ‐12.52, 95% CI ‐32.47 to 7.43; 9328 infants; studies = 19; I<sup>2</sup> = 0%). </p> <div class="figure" id="CD004454-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.11 Mean birthweight (g)" data-id="CD004454-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-10.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.11 Mean birthweight (g) </p> </div> </div> </div> </section> </section> <section id="CD004454-sec-0093"> <h6 class="title">For the woman</h6> <section id="CD004454-sec-0094"> <p><b>Death</b></p> <p>Antenatal corticosteroids probably result in little to no difference in the risk of maternal death but the wide 95% CI includes possible benefit and possible harm (RR 1.19, 95% CI 0.36 to 3.89; 6244 women;studies = 6; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./full#CD004454-tbl-0002">summary of findings Table 2</a>; <a href="./references#CD004454-fig-0025" title="">Analysis 1.9</a>). In total six studies reported maternal death but in four of them (3174 women) there were no deaths at all (<a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>). With corticosteroids there are probably 0.0% fewer maternal deaths than with placebo or no treatment (95% CI 0.1% fewer to 0.5% more).  </p> <p>There were not enough data  to perform sensitivity analysis nor did we produce a funnel plot. </p> </section> <section id="CD004454-sec-0095"> <p><b>Chorioamnionitis</b></p> <p>Antenatal corticosteroids probably result in little to no difference in risk of chorioamnionitis (RR 0.86, 95% CI 0.69 to 1.08; 8374 women; studies = 15; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./full#CD004454-tbl-0002">summary of findings Table 2</a>; <a href="./references#CD004454-fig-0026" title="">Analysis 1.10</a>).  </p> <p>With corticosteroids 0.5% fewer women had chorioamnionitis than with placebo or no treatment (95% CI 1.1% fewer to 0.3% more). </p> <p>The symmetry in the funnel plot did not suggest evidence of bias due to non‐publication of results (<a href="#CD004454-fig-0011">Figure 11</a>). None of the trials in the analysis of chorioamnionitis data were at high risk of bias for random sequence generation, allocation concealment or incomplete outcome data so we did not perform sensitivity analysis. </p> <div class="figure" id="CD004454-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.2 Chorioamnionitis" data-id="CD004454-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-11.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.2 Chorioamnionitis </p> </div> </div> </div> </section> <section id="CD004454-sec-0096"> <p><b>Endometritis</b></p> <p>Antenatal corticosteroids probably result in little to no difference in the risk of endometritis but wide 95% CI includes possible benefit and possible harm (RR 1.14, 95% CI 0.82 to 1.58; 6764 women; studies = 10; I<sup>2</sup> = 20%; moderate‐certainty evidence; <a href="./full#CD004454-tbl-0002">summary of findings Table 2</a>; <a href="./references#CD004454-fig-0027" title="">Analysis 1.11</a>). </p> <p>The symmetry in the funnel plot did not suggest evidence of bias due to non‐publication of results (<a href="#CD004454-fig-0012">Figure 12</a>). None of the trials in the analysis of endometritis data were at high risk of bias for random sequence generation, allocation concealment or incomplete outcome data so we did not perform sensitivity analysis. </p> <div class="figure" id="CD004454-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.11 Endometritis." data-id="CD004454-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-12.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.11 Endometritis. </p> </div> </div> </div> </section> </section> <section id="CD004454-sec-0097"> <h6 class="title">For the child</h6> <section id="CD004454-sec-0098"> <p><b>Death</b></p> <p>It is uncertain if antenatal corticosteroids have any effect on the risk of death in childhood (RR 0.68, 95% CI 0.36 to 1.27; 1010 children; studies = 4; I<sup>2</sup> = 21%; <a href="./references#CD004454-fig-0028" title="">Analysis 1.12</a>). Removing a trial at high risk of bias for allocation concealment did not substantially change the effect estimate (RR 0.52, 95% CI 0.24 to 1.11; 593 children; studies = 3; I<sup>2</sup> = 25%). </p> </section> <section id="CD004454-sec-0099"> <p><b>Neurodevelopmental disability or developmental delay</b></p> <p>Antenatal corticosteroids probably lead to a reduction in developmental delay in childhood (RR 0.51, 95% CI 0.27 to 0.97; 600 children; studies = 3; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./full#CD004454-tbl-0001">summary of findings Table 1</a>; <a href="./references#CD004454-fig-0029" title="">Analysis 1.13</a>). Age at follow‐up was between two and 12 years. </p> <p>We did not identify any data that could be pooled for our composite outcome of neurodevelopment disability but we have presented data that we found relating to the separate aspects neurodevelopment disability. It is uncertain if corticosteroids have any effect on intellectual impairment (RR 0.86, 95% CI 0.44 to 1.69; 778 children; studies = 3; I<sup>2</sup> = 0%), visual impairment (RR 0.55, 95% CI 0.24 to 1.23; 166 children; studies = 2; I<sup>2</sup> = 0%) or hearing impairment (RR 0.64, 95% CI 0.04 to 9.87; 166 children; studies = 2) (<a href="./references#CD004454-fig-0029" title="">Analysis 1.13</a>).  </p> <p>With so few trials contributing to this outcome, and due to the different ways it is measured, we did not perform sensitivity analysis, nor did we produce a funnel plot. </p> </section> </section> <section id="CD004454-sec-0100"> <h6 class="title">For the child as adult</h6> <section id="CD004454-sec-0101"> <p><b>Death</b></p> <p>It is uncertain if antenatal corticosteroids have any effect on death in adulthood (RR 1.00, 95% CI 0.56 to 1.81; 988 participants; studies = 1; <a href="./references#CD004454-fig-0030" title="">Analysis 1.14</a>). </p> </section> <section id="CD004454-sec-0102"> <p><b>Neurodevelopmental disability</b></p> <p>It is uncertain if antenatal corticosteroids have any effect on visual impairment in adulthood (RR 0.91, 95% CI 0.53 to 1.55; 192 participants; studies = 1), hearing impairment in adulthood (RR 0.24, 95% CI 0.03 to 2.03; 192 participants; studies = 1) or intellectual impairment in adulthood (RR 0.24, 95% CI 0.01 to 4.95; 273 participants; studies = 2) (<a href="./references#CD004454-fig-0031" title="">Analysis 1.15</a>).  </p> </section> </section> </section> <section id="CD004454-sec-0103"> <h5 class="title">Secondary outcomes</h5> <section id="CD004454-sec-0104"> <h6 class="title">For the woman</h6> <section id="CD004454-sec-0105"> <p><b>Fever after trial entry requiring the use of antibiotics</b></p> <p>It is uncertain if corticosteroids have any effect on a woman's risk of fever requiring antibiotics (RR 0.66, 95% CI 0.36 to 1.21; studies = 3; 363 women; I² = 0%; <a href="./references#CD004454-fig-0032" title="">Analysis 1.16</a>). </p> </section> <section id="CD004454-sec-0106"> <p><b>Intrapartum fever requiring the use of antibiotics</b></p> <p>It is uncertain if corticosteroids have any effect on a woman's risk of intrapartum fever (RR 0.60, 95% CI 0.15 to 2.49; 319 women; studies = 2; I<sup>2</sup> = 36%; <a href="./references#CD004454-fig-0033" title="">Analysis 1.17</a>). </p> </section> <section id="CD004454-sec-0107"> <p><b>Postnatal fever</b></p> <p>Corticosteroids may make little to no difference to a woman's risk of postnatal fever (RR 0.92, 95% CI 0.64 to 1.33; 1323 women; studies = 5; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0034" title="">Analysis 1.18</a>). </p> </section> <section id="CD004454-sec-0108"> <p><b>Admission to intensive care unit</b></p> <p>It is uncertain if corticosteroids have any effect on a woman's risk of being admitted to intensive care (RR 0.74, 95% CI 0.26 to 2.05; 319 women; studies = 2; <a href="./references#CD004454-fig-0035" title="">Analysis 1.19</a>).  </p> </section> <section id="CD004454-sec-0109"> <p><b>Side effects of therapy</b></p> <p>Seven trials reported no side effects for women in any arm (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>; 1182 women). Two other trials reported a range of different side effects in women: any side effects at first dose (RR 0.69, 95% CI 0.59 to 0.82; 2825 women; studies = 1); dyspnoea (RR 0.33, 95% CI 0.01 to 8.15; 2828 women; studies = 1); gastrointestinal upset (RR 2.99, 95% CI 0.12 to 73.37; 2828 women; studies = 1); hyperglycaemia (RR 0.33, 95% CI 0.01 to 8.15; 2828 women; studies = 1); leucocytosis (RR 0.33, 95% CI 0.01 to 8.15; 2828 women; studies = 1); migraine (RR 1.00, 95% CI 0.06 to 15.93; 2828 women; studies = 1) (<a href="./references#CD004454-fig-0036" title="">Analysis 1.20</a>). </p> </section> <section id="CD004454-sec-0110"> <p><b>Glucose intolerance</b></p> <p>One small study (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>), reported that women in the corticosteroid arm were more likely to have glucose intolerance than in the control arm (RR 2.71, 95% CI 1.14 to 6.46; participants = 123; studies = 1; <a href="./references#CD004454-fig-0037" title="">Analysis 1.21</a>). This study used a treatment regimen that included weekly repeat doses of corticosteroids if the infant remained undelivered. </p> </section> <section id="CD004454-sec-0111"> <p><b>Hypertension</b></p> <p>It is uncertain if corticosteroids have any effect on a woman's risk of hypertension (RR 1.03, 95% CI 0.59 to 1.79; 288 women; studies = 2; I<sup>2</sup> = 0%) (<a href="./references#CD004454-fig-0038" title="">Analysis 1.22</a>). </p> </section> </section> <section id="CD004454-sec-0112"> <h6 class="title">For the fetus or neonate</h6> <section id="CD004454-sec-0113"> <p><b>Apgar score less than seven at five minutes</b></p> <p>Fewer infants exposed to antenatal corticosteroids had an Apgar score less than seven at five minutes of age (RR 0.88, 95% CI 0.78 to 0.98; 5727 infants; studies = 12; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0039" title="">Analysis 1.23</a>). Sensitivity analysis comparing ITT analysis and available case analysis showed no substantial difference in effect estimate (ACA RR 0.89, 95% CI 0.79 to 0.99; 5243 infants). </p> <p>Exploration of asymmetry in the funnel plot suggests that the effect estimate may be influenced by smaller trials at higher risk of bias therefore it is possible that the true direction and size of effect are different (<a href="#CD004454-fig-0013">Figure 13</a>). </p> <div class="figure" id="CD004454-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.30 Apgar &lt; 7 at 5 minutes" data-id="CD004454-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-13.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.30 Apgar &lt; 7 at 5 minutes </p> </div> </div> </div> </section> <section id="CD004454-sec-0114"> <p><b>Interval between trial entry and birth</b></p> <p>Corticosteroids may have little to no effect on the interval between trial entry and birth (MD 0.23 days, 95% CI ‐1.86 to 2.32 days; 1513 infants; studies = 3; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0040" title="">Analysis 1.24</a>). </p> </section> <section id="CD004454-sec-0115"> <p><b>Mean length at birth (height) [cm]</b></p> <p>Corticosteroids may have little to no effect on babies' length (height) at birth (MD 0.00 cm, 95% CI ‐0.37 to 0.37 cm; 2766 infants; studies = 1; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0041" title="">Analysis 1.25</a>). </p> </section> <section id="CD004454-sec-0116"> <p><b>Mean head circumference at birth</b></p> <p>Corticosteroids may have little to no effect on babies' head circumference at birth (MD 0.00 cm, 95% CI ‐0.22 to 0.22 cm; 2766 infants; studies = 1; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0042" title="">Analysis 1.26</a>). </p> </section> <section id="CD004454-sec-0117"> <p><b>Mean skin fold thickness at birth</b></p> <p>Not reported.</p> </section> <section id="CD004454-sec-0118"> <p><b>Small‐for‐gestational age</b></p> <p>It is uncertain if antenatal corticosteroids have any effect on incidence of small‐for‐gestational‐age infants (RR 1.11, 95% CI 0.96 to 1.28; 3478 infants; studies = 5; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0043" title="">Analysis 1.27</a>). </p> </section> <section id="CD004454-sec-0119"> <p><b>Mean placental weight</b></p> <p>Not reported.</p> </section> <section id="CD004454-sec-0120"> <p><b>Neonatal blood pressure</b></p> <p>Not reported.</p> </section> <section id="CD004454-sec-0121"> <p><b>Admission to neonatal intensive care unit (NICU)</b></p> <p>Corticosteroids may slightly reduce the risk of being admitted to a NICU (RR 0.96, 95% CI 0.91 to 1.00; 6667 infants; studies = 9; I<sup>2</sup> = 34%; <a href="./references#CD004454-fig-0044" title="">Analysis 1.28</a>). </p> </section> <section id="CD004454-sec-0122"> <p><b>Need for inotropic support</b></p> <p>Not reported.</p> </section> <section id="CD004454-sec-0123"> <p><b>Mean duration of inotropic support</b></p> <p>Not reported.</p> </section> <section id="CD004454-sec-0124"> <p><b>Need for mechanical ventilation/continuous positive airways pressure (CPAP)</b></p> <p>Treatment with antenatal corticosteroids may lead to less need for ventilation/CPAP (RR 0.75, 95% CI 0.66 to 0.84; 4519 infants; studies = 11; I<sup>2</sup> = 4%; <a href="./references#CD004454-fig-0045" title="">Analysis 1.29</a>). The symmetry of the funnel plot did not suggest evidence of bias due to non‐publication of results (<a href="#CD004454-fig-0014">Figure 14</a>). </p> <div class="figure" id="CD004454-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.25 Need for mechanical ventilation/CPAP" data-id="CD004454-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-14.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.25 Need for mechanical ventilation/CPAP </p> </div> </div> </div> </section> <section id="CD004454-sec-0125"> <p><b>Mean duration of mechanical ventilation/continuous positive airways pressure (CPAP)</b></p> <p>It is uncertain if corticosteroids have any effect on the duration of mechanical ventilation/CPAP (MD ‐1.91 days, 95% CI ‐4.59 to 0.76 days; 471 infants; studies = 3; I<sup>2</sup> = 77%; <a href="./references#CD004454-fig-0046" title="">Analysis 1.30</a>). </p> <p>One study (<a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>) reported median duration of mechanical ventilation (<a href="./references#CD004454-fig-0047" title="">Analysis 1.31</a>) and median duration of CPAP (<a href="./references#CD004454-fig-0048" title="">Analysis 1.32</a>). There was little difference between the two groups. </p> </section> <section id="CD004454-sec-0126"> <p><b>Air leak syndrome</b></p> <p>It is uncertain if corticosteroids have any effect on the risk of air leak syndrome (RR 0.76, 95% CI 0.32 to 1.80; 2965 infants; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0049" title="">Analysis 1.33</a>). </p> </section> <section id="CD004454-sec-0127"> <p><b>Duration of oxygen supplementation (days)</b></p> <p>In one study, infants receiving corticosteroids required less oxygen supplementation (MD ‐2.86 days, 95% CI ‐5.51 to ‐0.21 days; 73 infants; <a href="./references#CD004454-fig-0050" title="">Analysis 1.34</a>). One study (<a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>) reported median duration of oxygen supplementation (<a href="./references#CD004454-fig-0051" title="">Analysis 1.35</a>). The median duration in the corticosteroids group was 36 hours (interquartile range (IQR) 18 to 96; 726 infants)) compared with 48 hours (IQR 12 to 93; 756 infants) in the placebo group. </p> </section> <section id="CD004454-sec-0128"> <p><b>Surfactant use</b></p> <p>Corticosteroids may reduce the need to use surfactant (RR 0.65, 95% CI 0.50 to 0.85; 6104 infants; studies = 6; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0052" title="">Analysis 1.36</a>). </p> </section> <section id="CD004454-sec-0129"> <p><b>Systemic infection in first 48 hours of life</b></p> <p>Treatment with antenatal corticosteroids may lead to fewer infants having systemic infection in the first 48 hours after birth (RR 0.60, 95% CI 0.41 to 0.88; 1708 infants; studies = 7; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0053" title="">Analysis 1.37</a>). </p> </section> <section id="CD004454-sec-0130"> <p><b>Proven infection while in the neonatal intensive care unit (NICU)</b></p> <p>Treatment with antenatal corticosteroids may reduce the risk of infection while in the NICU (RR 0.79, 95% CI 0.64 to 0.98; 5521 infants; studies = 10; I<sup>2</sup> = 29%; <a href="./references#CD004454-fig-0054" title="">Analysis 1.38</a>). The symmetry of the funnel plot did not suggest evidence of bias due to non‐publication of results (<a href="#CD004454-fig-0015">Figure 15</a>). </p> <div class="figure" id="CD004454-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.38 Proven infection while in the neonatal intensive care unit." data-id="CD004454-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-15.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.38 Proven infection while in the neonatal intensive care unit. </p> </div> </div> </div> </section> <section id="CD004454-sec-0131"> <p><b>Necrotising enterocolitis</b></p> <p>Corticosteroids may reduce the risk of necrotising enterocolitis (RR 0.50, 95% CI 0.32 to 0.78; 4702 infants; studies = 10; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0055" title="">Analysis 1.39</a>). The symmetry of the funnel plot did not suggest evidence of bias due to non‐publication of results (<a href="#CD004454-fig-0016">Figure 16</a>). </p> <div class="figure" id="CD004454-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.39 Necrotising enterocolitis." data-id="CD004454-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-16.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.39 Necrotising enterocolitis. </p> </div> </div> </div> </section> <section id="CD004454-sec-0132"> <p><b>Hypothalamo‐pituitary‐adrenal (HPA) axis function</b></p> <p>It is uncertain if corticosteroids have any effect on HPA axis function (cortisol MD 3.94 log units, 95% CI ‐3.12 to 11.00 log units; 27 infants; studies = 1; <a href="./references#CD004454-fig-0056" title="">Analysis 1.40</a>). </p> </section> </section> <section id="CD004454-sec-0133"> <h6 class="title">For the child</h6> <section id="CD004454-sec-0134"> <p><b>Mean weight</b></p> <p>It is uncertain if corticosteroids have any effect on childhood weight (MD 0.30 kg, 95% CI ‐0.39 to 1.00 kg; 333 children; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0057" title="">Analysis 1.41</a>) (age at follow‐up was six to 12 years). </p> </section> <section id="CD004454-sec-0135"> <p><b>Mean head circumference</b></p> <p>It is uncertain if corticosteroids have any effect on childhood on head circumference (MD 0.27 cm, 95% CI ‐0.08 to 0.63 cm; 328 children; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0058" title="">Analysis 1.42</a>) (age at follow‐up was six to 12 years). </p> </section> <section id="CD004454-sec-0136"> <p><b>Mean height</b></p> <p>It is uncertain if corticosteroids have any effect on childhood height (MD 1.02 cm, 95% CI ‐0.26 to 2.29 cm; 334 children; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0059" title="">Analysis 1.43</a>) (age at follow‐up was six to 12 years). </p> </section> <section id="CD004454-sec-0137"> <p><b>Mean skin fold thickness</b></p> <p>Not reported.</p> </section> <section id="CD004454-sec-0138"> <p><b>Abnormal lung function</b></p> <p>Not reported.</p> </section> <section id="CD004454-sec-0139"> <p><b>Mean blood pressure</b></p> <p>It is uncertain if corticosteroids have any effect on childhood systolic blood pressure (MD ‐1.60 mmHg, 95% CI ‐4.06 to 0.86 mmHg; 223 children; studies = 1; <a href="./references#CD004454-fig-0060" title="">Analysis 1.44</a>) (age at follow‐up was six to 12 years). </p> </section> <section id="CD004454-sec-0140"> <p><b>Glucose intolerance</b></p> <p>Not reported.</p> </section> <section id="CD004454-sec-0141"> <p><b>Hypothalamo‐pituitary‐adrenal H(PA) axis function</b></p> <p>Not reported.</p> </section> <section id="CD004454-sec-0142"> <p><b>Dyslipidaemia</b></p> <p>Not reported.</p> </section> <section id="CD004454-sec-0143"> <p><b>Cerebral palsy</b></p> <p>Antenatal corticosteroids may reduce a child's risk of cerebral palsy but the evidence is uncertain because the confidence interval is wide and includes possible harm (RR 0.60, 95% CI 0.34 to 1.03; 904 children; studies = 5; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0061" title="">Analysis 1.45</a>) (age at follow‐up was two to 12 years). </p> </section> <section id="CD004454-sec-0144"> <p><b>Behavioural/learning difficulties</b></p> <p>It is uncertain if corticosteroids have any effect on a child's risk of behavioural/learning difficulties (RR 0.86, 95% CI 0.35 to 2.09; participants = 90; studies = 1; <a href="./references#CD004454-fig-0062" title="">Analysis 1.46</a>). </p> </section> </section> <section id="CD004454-sec-0145"> <h6 class="title">For the child as adult</h6> <section id="CD004454-sec-0146"> <p><b>Mean weight</b></p> <p>It is uncertain if corticosteroids have any effect on weight in adulthood (MD ‐0.83 kg, 95% CI ‐6.41 to 4.76 kg; 538 participants; studies = 2; I<sup>2</sup> = 60%; <a href="./references#CD004454-fig-0063" title="">Analysis 1.47</a>). </p> </section> <section id="CD004454-sec-0147"> <p><b>Mean head circumference</b></p> <p>It is uncertain if corticosteroids have any effect on head circumference in adulthood (MD 0.03 cm, 95% CI ‐0.33 to 0.38 cm; 537 participants; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0064" title="">Analysis 1.48</a>). </p> </section> <section id="CD004454-sec-0148"> <p><b>Mean height</b></p> <p>It is uncertain if corticosteroids have any effect on height in adulthood (MD 0.91 cm, 95% CI ‐0.28 to 2.10 cm; 537 participants; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0065" title="">Analysis 1.49</a>). </p> </section> <section id="CD004454-sec-0149"> <p><b>Mean skin fold thickness</b></p> <p>It is uncertain if corticosteroids have any effect on skin fold thickness in adulthood (triceps MD ‐0.02 log units, 95% CI ‐0.11 to 0.07 log units;456 participants; studies = 1; biceps MD ‐0.01 log units, 95% CI ‐0.11 to 0.09 log units; 456 participants; studies = 1; subscapular MD 0.01 log units, 95% CI ‐0.08 to 0.10 log units;441 participants; studies = 1 suprailiac MD ‐0.01 log units, 95% CI ‐0.12 to 0.10 log units; 452 participants; studies = 1; <a href="./references#CD004454-fig-0066" title="">Analysis 1.50</a>). </p> </section> <section id="CD004454-sec-0150"> <p><b>Abnormal lung function</b></p> <p>It is uncertain if antenatal corticosteroids has any effect on lung function (forced vital capacity) at age 30 years (forced vital capacity MD ‐0.70, 95% CI ‐3.16 to 1.76; 383 participants; studies = 1; <a href="./references#CD004454-fig-0067" title="">Analysis 1.51</a>). </p> </section> <section id="CD004454-sec-0151"> <p><b>Mean blood pressure</b></p> <p>It is uncertain if corticosteroids have any effect on systolic blood pressure in adulthood (MD ‐0.87 mmHg, 95% CI ‐2.81 to 1.07 mmHg; 545 participants; studies = 2; I<sup>2</sup> = 47%; <a href="./references#CD004454-fig-0068" title="">Analysis 1.52</a>). </p> </section> <section id="CD004454-sec-0152"> <p><b>Glucose intolerance</b></p> <p>Long‐term follow‐up in one study (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>) showed increased insulin release 30 minutes following a fasting 75 g oral glucose tolerance test (MD 0.16 log insulin units, 95% CI 0.04 to 0.28 log insulin units; 412 participants; studies = 1; <a href="./references#CD004454-fig-0069" title="">Analysis 1.53</a>) in 30‐year‐olds who had been exposed to antenatal corticosteroid. Results were inconclusive for fasting glucose concentrations (MD 0.01 mmol/L, 95% CI ‐0.09 to 0.11 mmol/L; 432 participants; studies = 1), or 30 minutes following a 75 g oral glucose tolerance test (MD 0.21 mmol/L, 95% CI ‐0.12 to 0.54 mmol/L; participants = 413; studies = 1). At 120 minutes following a 75 g oral glucose tolerance test, exposure to antenatal corticosteroids was associated with a reduction in glucose concentration (MD ‐0.27 mmol/L; 95% CI ‐0.52 to ‐0.02 mmol/L; 410 participants; studies = 1) (<a href="./references#CD004454-fig-0070" title="">Analysis 1.54</a>). However, the study reported no difference between those exposed to antenatal corticosteroids and those not exposed in the prevalence of diabetes. </p> </section> <section id="CD004454-sec-0153"> <p><b>Hypothalamo‐pituitary‐adrenal (HPA) axis function</b></p> <p>It is uncertain if corticosteroids have any effect on HPA axis function in adulthood (cortisol MD 0.06 log units, 95% CI ‐0.02 to 0.14 log units; 444 participants; studies = 1; <a href="./references#CD004454-fig-0071" title="">Analysis 1.55</a>). </p> </section> <section id="CD004454-sec-0154"> <p><b>Dyslipidaemia</b></p> <p>Not reported.</p> </section> <section id="CD004454-sec-0155"> <p><b>Mean age at puberty</b></p> <p>It is uncertain if corticosteroids have any effect on mean age at puberty (MD for girls 0 years, 95% CI ‐0.94 to 0.94 years; 38 girls; studies = 1; <a href="./references#CD004454-fig-0072" title="">Analysis 1.56</a>) (data not available for boys). </p> </section> <section id="CD004454-sec-0156"> <p><b>Bone density</b></p> <p>One study reported that there was no difference between those exposed to antenatal corticosteroids and those not exposed for bone density at age 30 years in a subset of participants (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>). </p> </section> <section id="CD004454-sec-0157"> <p><b>Educational achievement</b></p> <p>It is uncertain if corticosteroids have any effect on educational achievement defined as attending university or polytechnic education (RR 0.94, 95% CI 0.80 to 1.10; 534 participants; studies = 1; <a href="./references#CD004454-fig-0073" title="">Analysis 1.57</a>). </p> </section> </section> <section id="CD004454-sec-0158"> <h6 class="title">For health services</h6> <section id="CD004454-sec-0159"> <p><b>Mean length of antenatal hospitalisation for women</b></p> <p>It is uncertain if corticosteroids have any effect on length of antenatal hospitalisation (MD ‐0.00 days, 95% CI ‐0.23 to 0.22 days; 412 women; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0074" title="">Analysis 1.58</a>). </p> <p>Four other studies reported data relating to overall length of maternal hospital stay (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). In all of the trials there was little to no difference between the groups (<a href="./references#CD004454-fig-0075" title="">Analysis 1.59</a>). </p> </section> <section id="CD004454-sec-0160"> <p><b>Mean length of postnatal hospitalisation for women</b></p> <p>It is uncertain if corticosteroids have any effect on length of postnatal hospitalisation for women (MD 0.00 days, 95% CI ‐1.72 to 1.72 days; 218 women; studies = 1; <a href="./references#CD004454-fig-0076" title="">Analysis 1.60</a>). </p> </section> <section id="CD004454-sec-0161"> <p><b>Mean length of neonatal hospitalisation</b></p> <p>It is uncertain if corticosteroids have any effect on length of neonatal hospitalisation (MD 0.18 days, 95% CI ‐0.51 to 0.87 days; 788 infants; studies = 5; I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0077" title="">Analysis 1.61</a>). </p> <p>Two studies (<a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>) reported median neonatal hospitalisation and found very little difference between the two groups (<a href="./references#CD004454-fig-0078" title="">Analysis 1.62</a>). </p> </section> <section id="CD004454-sec-0162"> <p><b>Cost of maternal care</b></p> <p>not reported</p> </section> <section id="CD004454-sec-0163"> <p><b>Cost of neonatal care</b></p> <p>not reported.</p> </section> </section> </section> </section> <section id="CD004454-sec-0164"> <h4 class="title">Clinical subgroups</h4> <p>We have analysed the results for prespecified clinical subgroups (covariates) in comparisons 2, 3, 4 and 5, and added further <i>post hoc</i> analyses to explore the possible impact of change in practice over time (comparison 6), protocols with weekly steroid administration (comparison 7), and gestational age at randomisation (comparison 8). Where there was a sufficient number of trials reporting data for meaningful analyses, we have explored the evidence for the review's primary outcomes. These analyses are hypothesis‐generating only and should not be interpreted as conclusive. </p> </section> <section id="CD004454-sec-0165"> <h4 class="title">2. Antenatal corticosteroids versus placebo or no treatment (singleton and women with multiple pregnancies) </h4> <p>Discrete outcome data for those women delivering multiple pregnancies were available from only five studies (<a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>), with the remainder of the studies including only singleton pregnancies, or reporting data from combined singleton and multiple pregnancies. We have been unable to confirm whether the <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a> trial included only singleton pregnancy, but this is suggested by the equal numbers of women and infants reported. We have included data from this study in the singleton subgroup. </p> <section id="CD004454-sec-0166"> <h5 class="title">For the fetus or neonate</h5> <section id="CD004454-sec-0167"> <h6 class="title">Perinatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on perinatal death between singleton pregnancies, multiple pregnancies and trials with a combination of singleton and multiple pregnancies (P = 0.77, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0079" title="">Analysis 2.1</a>). </p> </section> <section id="CD004454-sec-0168"> <h6 class="title">Neonatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on neonatal death between singleton pregnancies, multiple pregnancies and trials with a combination of singleton and multiple pregnancies (P = 0.52, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0080" title="">Analysis 2.2</a>). </p> </section> <section id="CD004454-sec-0169"> <h6 class="title">Fetal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on fetal death between singleton pregnancies, multiple pregnancies and trials with a combination of singleton and multiple pregnancies (P = 0.42, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0081" title="">Analysis 2.3</a>). </p> </section> <section id="CD004454-sec-0170"> <h6 class="title">Respiratory distress syndrome (RDS)</h6> <p>The test for subgroup differences did not suggest a difference in effect on RDS in multiple pregnancies compared with singleton pregnancies and trials with a combination of singleton and multiple pregnancies (P = 0.08, I<sup>2</sup> = 60%; <a href="./references#CD004454-fig-0082" title="">Analysis 2.4</a>). </p> </section> <section id="CD004454-sec-0171"> <h6 class="title">Moderate/severe respiratory distress syndrome (RDS)</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0172"> <h6 class="title">Chronic lung disease</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0173"> <h6 class="title">Intraventricular haemorrhage (IVH)</h6> <p>The test for subgroup differences did not suggest a difference in effect on IVH in multiple pregnancies compared with singleton pregnancies and trials with a combination of singleton and multiple pregnancies (P = 0.56, I<sup>2</sup> = 0%; <a href="./references#CD004454-fig-0083" title="">Analysis 2.5</a>). </p> </section> <section id="CD004454-sec-0174"> <h6 class="title">Mean birthweight</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> </section> <section id="CD004454-sec-0175"> <h5 class="title">For the woman</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the woman. </p> </section> <section id="CD004454-sec-0176"> <h5 class="title">For the child</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child. </p> </section> <section id="CD004454-sec-0177"> <h5 class="title">For the child as adult</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child as adult. </p> </section> </section> <section id="CD004454-sec-0178"> <h4 class="title">3. Antenatal corticosteroids versus placebo or no treatment (by presence or absence of ruptured membranes at first dose of corticosteroids) </h4> <p>Discrete outcome data from women with intact membranes at the first dose of study medication were available from eight studies (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>), discrete outcome data from women with ruptured membranes at the first dose of study medication were available from ten studies (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>), with the remainder of the studies not reporting rupture of membrane status or reporting combined data from women with intact and ruptured membranes. </p> <p>Relevant subgroups compared below are: 1. pregnant women with intact membranes, 2. pregnant women with ruptured membranes, and 3. pregnant women for whom membrane status was not reported separately or mixed populations. Analyses with small amounts of data missing are the following: 3.1 Perinatal death (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>); 3.2 Neonatal death (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>); 3.3 Fetal death (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>); 3.4 RDS (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a>; <a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a>); 3.5 IVH (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>); 3.6 Birthweight (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>); and 3.7 Chorioamnionitis (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>). Overall totals for these outcomes will not match our main analyses in Comparison 1 due to small amounts of missing data where ruptured membrane status was missing for some women. </p> <section id="CD004454-sec-0179"> <h5 class="title">For the fetus or neonate</h5> <section id="CD004454-sec-0180"> <h6 class="title">Perinatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on perinatal death between babies born from pregnancies with intact membranes, pregnancies with ruptured membranes and trials with a combination of pregnancies with intact and rupture membranes (P = 0.08, I<sup>2</sup> = 60%, overlapping confidence intervals; <a href="./references#CD004454-fig-0084" title="">Analysis 3.1</a>). </p> </section> <section id="CD004454-sec-0181"> <h6 class="title">Neonatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on neonatal death between babies born from pregnancies with intact membranes, pregnancies with ruptured membranes and trials with a combination of pregnancies with intact and rupture membranes (P = 0.29, I<sup>2</sup> = 20%, overlapping confidence intervals; <a href="./references#CD004454-fig-0085" title="">Analysis 3.2</a>). </p> </section> <section id="CD004454-sec-0182"> <h6 class="title">Fetal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on fetal death between babies born from pregnancies with intact membranes, pregnancies with ruptured membranes and trials with a combination of pregnancies with intact and rupture membranes (P = 0.81, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0086" title="">Analysis 3.3</a>). </p> </section> <section id="CD004454-sec-0183"> <h6 class="title">Respiratory distress syndrome (RDS)</h6> <p>The test for subgroup differences did not suggest a difference in effect on RDS between babies born from pregnancies with intact membranes, pregnancies with ruptured membranes and trials with a combination of pregnancies with intact and ruptured membranes (P = 0.08, I<sup>2</sup> = 60%, overlapping confidence intervals; <a href="./references#CD004454-fig-0087" title="">Analysis 3.4</a>). </p> </section> <section id="CD004454-sec-0184"> <h6 class="title">Moderate/severe respiratory distress syndrome (RDS)</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0185"> <h6 class="title">Chronic lung disease</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0186"> <h6 class="title">Intraventricular haemorrhage (IVH)</h6> <p>The test for subgroup differences suggested a difference in effect on IVH between babies born from pregnancies with intact membranes, pregnancies with ruptured membranes and trials with a combination of pregnancies with intact and ruptured membranes (P = 0.02, I<sup>2</sup> = 76%, overlapping confidence intervals; <a href="./references#CD004454-fig-0088" title="">Analysis 3.5</a>). However, the effect estimates of the intact membranes group and the ruptured membranes group are close to each other, while the difference detected by the statistical test is likely to be caused by the mixed population group. Furthermore, we cannot be certain that the variability in effect estimates is due to genuine subgroup differences rather than chance. </p> </section> <section id="CD004454-sec-0187"> <h6 class="title">Mean birthweight</h6> <p>The test for subgroup differences suggests there may be a difference in effect on birthweight between babies born from pregnancies with intact membranes, pregnancies with ruptured membranes and trials with a combination of pregnancies with intact and rupture membranes (P = 0.46, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0089" title="">Analysis 3.6</a>). </p> </section> </section> <section id="CD004454-sec-0188"> <h5 class="title">For the woman</h5> <section id="CD004454-sec-0189"> <h6 class="title">Maternal death</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0190"> <h6 class="title">Chorioamnionitis</h6> <p>The test for subgroup differences did not suggest a difference in effect on chorioamnionitis between women with intact membranes, women with ruptured membranes and trials with a combination of women with intact and rupture membranes (P = 0.51, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0090" title="">Analysis 3.7</a>). </p> </section> <section id="CD004454-sec-0191"> <h6 class="title">Endometritis</h6> <p>The test for subgroup differences did not suggest a difference in effect on endometritis between babies born from pregnancies with intact membranes, pregnancies with ruptured membranes and trials with a combination of pregnancies with intact and rupture membranes (P = 0.99, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0091" title="">Analysis 3.8</a>). </p> </section> </section> <section id="CD004454-sec-0192"> <h5 class="title">For the child</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child. </p> </section> <section id="CD004454-sec-0193"> <h5 class="title">For the child as adult</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child as adult. </p> </section> </section> <section id="CD004454-sec-0194"> <h4 class="title">4. Antenatal corticosteroids versus placebo or no treatment (for women with hypertension syndrome) </h4> <p>Meaningful analysis was not possible for several primary outcomes due to the small number of trials reporting results by presence or absence of hypertension syndromes. </p> <section id="CD004454-sec-0195"> <h5 class="title">For the fetus or neonate</h5> <section id="CD004454-sec-0196"> <h6 class="title">Perinatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on perinatal death between babies whose mothers had hypertension syndrome, mothers without hypertension syndrome and trials where hypertension was not reported separately (P = 0.99, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0092" title="">Analysis 4.1</a>). </p> </section> <section id="CD004454-sec-0197"> <h6 class="title">Neonatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on perinatal death between babies whose mothers had hypertension syndrome, mothers without hypertension syndrome and trials where hypertension was not reported separately (P = 0.16, I<sup>2</sup> = 46%, overlapping confidence intervals; <a href="./references#CD004454-fig-0093" title="">Analysis 4.2</a>). </p> </section> <section id="CD004454-sec-0198"> <h6 class="title">Fetal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on fetal death between babies whose mothers had hypertension syndrome and babies whose mothers did not have hypertension syndrome or babies in trials where hypertension was not reported separately (P = 0.09, I<sup>2</sup> = 59%, overlapping confidence intervals; <a href="./references#CD004454-fig-0094" title="">Analysis 4.3</a>). </p> </section> <section id="CD004454-sec-0199"> <h6 class="title">Respiratory distress syndrome (RDS)</h6> <p>The test for subgroup differences suggests there may be a difference in effect on RDS death between babies whose mothers had hypertension syndrome and babies whose mothers did not have hypertension syndrome or babies in trials where hypertension was not reported separately (P = 0.007, I<sup>2</sup> = 80%; <a href="./references#CD004454-fig-0095" title="">Analysis 4.4</a>). An examination of the effect estimates and their overlapping confidence intervals suggests that the variability detected by the test for subgroup differences may be related to size of effect but not to direction of effect, whereby the size of effect is larger in the group of women with hypertension than in the other two groups. It should also be noted that the difference in effect size between the trials with women with hypertension and the trials in women without hypertension is small, the cause of the subgroup difference may be due to the group of trials with mixed populations having a difference effect size from the other two groups. Furthermore, we cannot be certain that the variability in effect estimates is due to genuine subgroup differences rather than chance. </p> </section> <section id="CD004454-sec-0200"> <h6 class="title">Moderate/severe respiratory distress syndrome (RDS)</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0201"> <h6 class="title">Chronic lung disease</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0202"> <h6 class="title">Intraventricular haemorrhage (IVH)</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0203"> <h6 class="title">Mean birthweight</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> </section> <section id="CD004454-sec-0204"> <h5 class="title">For the woman</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the woman. </p> </section> <section id="CD004454-sec-0205"> <h5 class="title">For the child</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child. </p> </section> <section id="CD004454-sec-0206"> <h5 class="title">For the child as adult</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child as adult. </p> </section> </section> <section id="CD004454-sec-0207"> <h4 class="title">5. Antenatal corticosteroids versus placebo or no treatment (by type of corticosteroid)</h4> <section id="CD004454-sec-0208"> <h5 class="title">For the fetus or neonate</h5> <section id="CD004454-sec-0209"> <h6 class="title">Perinatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on perinatal death between different types of corticosteroid (P = 0.62, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0096" title="">Analysis 5.1</a>). </p> </section> <section id="CD004454-sec-0210"> <h6 class="title">Neonatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on neonatal death between different types of corticosteroid (P = 0.62, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0097" title="">Analysis 5.2</a>). </p> </section> <section id="CD004454-sec-0211"> <h6 class="title">Fetal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on fetal death between different types of corticosteroid (P = 0.90, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0098" title="">Analysis 5.3</a>). </p> </section> <section id="CD004454-sec-0212"> <h6 class="title">Respiratory distress syndrome (RDS)</h6> <p>The test for subgroup differences suggests there may be a difference in effect on RDS between different types of corticosteroid (P = 0.04, I<sup>2</sup> = 63%, overlapping confidence intervals; <a href="./references#CD004454-fig-0099" title="">Analysis 5.4</a>). The difference seems to be attributable to the groups using dexamethasone and betamethasone. However given the overlapping confidence intervals of the two effect estimates, we cannot be certain that the variability in effect estimates is due to genuine subgroup differences rather than chance. </p> </section> <section id="CD004454-sec-0213"> <h6 class="title">Moderate/severe respiratory distress syndrome (RDS)</h6> <p>The test for subgroup differences suggests there may be a difference in effect on moderate/severe RDS between different types of corticosteroid (P = 0.03, I<sup>2</sup> = 65.8%, overlapping confidence intervals; <a href="./references#CD004454-fig-0100" title="">Analysis 5.5</a>). The difference seems to be attributable to the groups using dexamethasone and betamethasone. However given the overlapping confidence intervals of the two effect estimates, we cannot be certain that the variability in effect estimates is due to genuine subgroup differences rather than chance. </p> </section> <section id="CD004454-sec-0214"> <h6 class="title">Chronic lung disease</h6> <p>The test for subgroup differences did not suggest a difference in effect on chronic lung disease between different types of corticosteroid (P = 0.17, I<sup>2</sup> = 47%, overlapping confidence intervals; <a href="./references#CD004454-fig-0101" title="">Analysis 5.6</a>). </p> </section> <section id="CD004454-sec-0215"> <h6 class="title">Intraventricular haemorrhage (IVH)</h6> <p>The test for subgroup differences did not suggest a difference in effect on IVH between different types of corticosteroid (P = 0.06, I<sup>2</sup> = 71%, overlapping confidence intervals; <a href="./references#CD004454-fig-0102" title="">Analysis 5.7</a>). </p> </section> <section id="CD004454-sec-0216"> <h6 class="title">Mean birthweight</h6> <p>The test for subgroup differences did not suggest a difference in effect on mean birthweight between different types of corticosteroid (P = 0.38, I<sup>2</sup> = 2%, overlapping confidence intervals; <a href="./references#CD004454-fig-0103" title="">Analysis 5.8</a>). </p> </section> </section> <section id="CD004454-sec-0217"> <h5 class="title">For the woman</h5> <section id="CD004454-sec-0218"> <h6 class="title">Maternal death</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0219"> <h6 class="title">Chorioamnionitis</h6> <p>The test for subgroup differences suggests there may be a difference in effect on chorioamnionitis between different types of corticosteroid (P = 0.02, I<sup>2</sup> = 82%; <a href="./references#CD004454-fig-0104" title="">Analysis 5.9</a>). Betamethasone may reduce the risk of chorioamnionitis compared to control treatments, while the effect estimate of dexamethasone compared to control treatments is inconclusive. Taking into consideration the overlapping confidence intervals of the two effect estimates, we cannot be certain that the variability in effect estimates is due to genuine subgroup differences rather than chance. </p> </section> <section id="CD004454-sec-0220"> <h6 class="title">Endometritis</h6> <p>The test for subgroup differences did not suggest a difference in effect on endometritis between different types of corticosteroid (P = 0.13, I<sup>2</sup> = 57%, overlapping confidence intervals; <a href="./references#CD004454-fig-0105" title="">Analysis 5.10</a>). </p> </section> </section> <section id="CD004454-sec-0221"> <h5 class="title">For the child</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child. </p> </section> <section id="CD004454-sec-0222"> <h5 class="title">For the child as adult</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child as adult. </p> </section> </section> <section id="CD004454-sec-0223"> <h4 class="title">6. Antenatal corticosteroids versus placebo or no treatment (by decade of trial)</h4> <p>The subgroup tests in RevMan 5 are not ideal to test whether or not there were trends across decades; the test can only indicate if at least one decade differs from another, and not if there is a trend over time. We advise caution when interpreting the findings below, especially regarding survival across decades. </p> <section id="CD004454-sec-0224"> <h5 class="title">For the fetus or neonate</h5> <section id="CD004454-sec-0225"> <h6 class="title">Perinatal death</h6> <p>The test for subgroup differences suggests there may be a difference in effect on perinatal death according to the decade when the trial took place (P = 0.02, I<sup>2</sup> = 65%; <a href="./references#CD004454-fig-0106" title="">Analysis 6.1</a>), whereby there appears to be a difference between trials conducted in the 1970s ‐ 1980s (CIs cross the line of no effect) and later trials (clearly favouring corticosteroids). Reasons for the differences are uncertain and may be due to variation in standard of care across decades or because of trial locations. Furthermore, we cannot be certain that it is due to genuine subgroup differences rather than due to chance. </p> </section> <section id="CD004454-sec-0226"> <h6 class="title">Neonatal death</h6> <p>The test for subgroup differences suggests there may be a difference in effect on neonatal death according to the decade when the trial took place (P = 0.03, I<sup>2</sup> = 64%; <a href="./references#CD004454-fig-0107" title="">Analysis 6.2</a>), whereby there appears to be a greater effect size in trials conducted in the 2000s compared with 2010s. Reasons for the differences are uncertain and may be due to variation in standard of care across decades or because of trial locations. Furthermore, we cannot be certain that the difference is due to genuine subgroup differences rather than due to chance. </p> </section> <section id="CD004454-sec-0227"> <h6 class="title">Fetal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on fetal death according to the decade when the trial took place (P = 0.86, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0108" title="">Analysis 6.3</a>). </p> </section> <section id="CD004454-sec-0228"> <h6 class="title">Respiratory distress syndrome (RDS)</h6> <p>The test for subgroup differences suggests there may be a difference in effect on RDS according to the decade when the trial took place (P = 0.01, I<sup>2</sup> = 69%; <a href="./references#CD004454-fig-0109" title="">Analysis 6.4</a>). In all decades the effect estimates are in the same direction and favour corticosteroid treatment reducing RDS. Their overlapping confidence intervals means that we cannot be certain that the result is due to genuine subgroup differences rather than due to chance. </p> </section> <section id="CD004454-sec-0229"> <h6 class="title">Moderate/severe respiratory distress syndrome (RDS)</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0230"> <h6 class="title">Chronic lung disease</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0231"> <h6 class="title">Intraventricular haemorrhage (IVH)</h6> <p>The test for subgroup differences did not suggest a difference in effect on IVH according to the decade when the trial took place (P = 0.10, I<sup>2</sup> = 49%, overlapping confidence intervals; <a href="./references#CD004454-fig-0110" title="">Analysis 6.5</a>). </p> </section> <section id="CD004454-sec-0232"> <h6 class="title">Mean birthweight</h6> <p>The test for subgroup differences did not suggest a difference in effect on birthweight according to the decade when the trial took place (P = 0.81, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0111" title="">Analysis 6.6</a>). </p> </section> </section> <section id="CD004454-sec-0233"> <h5 class="title">For the woman</h5> <section id="CD004454-sec-0234"> <h6 class="title">Maternal death</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0235"> <h6 class="title">Chorioamnionitis</h6> <p>The test for subgroup differences did not suggest a difference in effect on chorioamnionitis according to the decade when the trial took place (P = 0.07, I<sup>2</sup> = 55%, overlapping confidence intervals; <a href="./references#CD004454-fig-0112" title="">Analysis 6.7</a>). </p> </section> <section id="CD004454-sec-0236"> <h6 class="title">Endometritis</h6> <p>The test for subgroup differences did not suggest a difference in effect on endometritis according to the decade when the trial took place (P = 0.36, I<sup>2</sup> = 7%, overlapping confidence intervals; <a href="./references#CD004454-fig-0113" title="">Analysis 6.8</a>). </p> </section> </section> <section id="CD004454-sec-0237"> <h5 class="title">For the child</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child. </p> </section> <section id="CD004454-sec-0238"> <h5 class="title">For the child as adult</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child as adult. </p> </section> </section> <section id="CD004454-sec-0239"> <h4 class="title">7. Antenatal corticosteroids versus placebo or no treatment (by presence or absence in protocol of weekly repeat doses of corticosteroid) </h4> <p>Seven of the included studies allowed weekly repeat courses of study medication in their study protocols (<a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a>; <a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a>; <a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a>; <a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>). </p> <section id="CD004454-sec-0240"> <h5 class="title">For the fetus or neonate</h5> <section id="CD004454-sec-0241"> <h6 class="title">Perinatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on perinatal death between protocols with a single course and those including weekly repeats (P = 0.63, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0114" title="">Analysis 7.1</a>). </p> </section> <section id="CD004454-sec-0242"> <h6 class="title">Neonatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on neonatal death between protocols with a single course and those including weekly repeats (P = 0.43, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0115" title="">Analysis 7.2</a>). </p> </section> <section id="CD004454-sec-0243"> <h6 class="title">Fetal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on fetal death between protocols with a single course and those including weekly repeats (P = 0.68, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0116" title="">Analysis 7.3</a>). </p> </section> <section id="CD004454-sec-0244"> <h6 class="title">Respiratory distress syndrome (RDS)</h6> <p>The test for subgroup differences did not suggest a difference in effect on RDS between protocols with a single course and those including weekly repeats (P = 0.55, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0117" title="">Analysis 7.4</a>). </p> </section> <section id="CD004454-sec-0245"> <h6 class="title">Moderate/severe respiratory distress syndrome (RDS)</h6> <p>The test for subgroup differences did not suggest a difference in effect on moderate/severe RDS between protocols with a single course and those including weekly repeats (P = 0.53, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0118" title="">Analysis 7.5</a>). </p> </section> <section id="CD004454-sec-0246"> <h6 class="title">Chronic lung disease</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0247"> <h6 class="title">Intraventricular haemorrhage (IVH)</h6> <p>The test for subgroup differences did not suggest a difference in effect on IVH between protocols with a single course and those including weekly repeats (P = 0.99, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0119" title="">Analysis 7.6</a>). </p> </section> <section id="CD004454-sec-0248"> <h6 class="title">Mean birthweight</h6> <p>The test for subgroup differences did not suggest a difference in effect on birthweight between protocols with a single course and those including weekly repeats (P = 0.29, I<sup>2</sup> = 12%, overlapping confidence intervals; <a href="./references#CD004454-fig-0120" title="">Analysis 7.7</a>). </p> </section> </section> <section id="CD004454-sec-0249"> <h5 class="title">For the woman</h5> <section id="CD004454-sec-0250"> <h6 class="title">Maternal death</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0251"> <h6 class="title">Chorioamnionitis</h6> <p>The test for subgroup differences did not suggest a difference in effect on chorioamnionitis between protocols with a single course and those including weekly repeats (P = 0.68, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0121" title="">Analysis 7.8</a>). </p> </section> <section id="CD004454-sec-0252"> <h6 class="title">Endometritis</h6> <p>The test for subgroup differences did not suggest a difference in effect on endometritis between protocols with a single course and those including weekly repeats (P = 0.11, I<sup>2</sup> = 61%, overlapping confidence intervals; <a href="./references#CD004454-fig-0122" title="">Analysis 7.9</a>). </p> </section> </section> <section id="CD004454-sec-0253"> <h5 class="title">For the child</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child. </p> </section> <section id="CD004454-sec-0254"> <h5 class="title">For the child as adult</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child as adult. </p> </section> </section> <section id="CD004454-sec-0255"> <h4 class="title">8. Gestational age at trial entry (less than or equal to 35 weeks + 0 days; greater than or equal to 34 weeks + 0 days) </h4> <p>We have split studies according to the gestational age at which pregnant women entered trials to receive their first dose of corticosteroids and have considered two, slightly overlapping subgroups: 1) women less than, and including, 35 weeks and 0 days and 2) women greater than, and including, 34 weeks and 0 days. Four studies could be analysed in either group (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>). We addressed these issues as follows: data from <a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a> were available for women entering the trial at less than 35 weeks + 0 days and from between 35 weeks + 0 days and 37 weeks + 0 days. The majority of women in the remaining three studies (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>) were of less than 34 weeks + 0 days gestation, therefore we included these studies in the younger gestational age grouping for the analysis (women less than and including 35 weeks and 0 days), but we undertook a sensitivity analysis with the studies' data removed. </p> <section id="CD004454-sec-0256"> <h5 class="title">For the fetus or neonate</h5> <section id="CD004454-sec-0257"> <h6 class="title">Perinatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on perinatal death between women with pregnancy gestations at less than or equal to 35 weeks and those at 34 weeks or greater (P = 0.13, I<sup>2</sup> = 56%, overlapping confidence intervals; <a href="./references#CD004454-fig-0123" title="">Analysis 8.1</a>). </p> <p>Sensitivity analysis removing two studies (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>) did not substantially change the test for subgroup difference (P = 0.12, I<sup>2</sup> = 58%). </p> </section> <section id="CD004454-sec-0258"> <h6 class="title">Neonatal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on neonatal death between women with pregnancy gestations at less than or equal to 35 weeks and those at 34 weeks or greater (P = 0.24, I<sup>2</sup> = 28%, overlapping confidence intervals; <a href="./references#CD004454-fig-0124" title="">Analysis 8.2</a>). </p> <p>Sensitivity analysis removing two studies (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>) did not substantially change the test for subgroup difference (P = 0.23, I<sup>2</sup> = 32%). </p> </section> <section id="CD004454-sec-0259"> <h6 class="title">Fetal death</h6> <p>The test for subgroup differences did not suggest a difference in effect on fetal death between women with pregnancy gestations at less than or equal to 35 weeks and those at 34 weeks or greater (P = 0.40, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0125" title="">Analysis 8.3</a>). </p> <p>Sensitivity analysis removing two studies (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>) did not change the test for subgroup difference (P = 0.40, I<sup>2</sup> = 0%). </p> </section> <section id="CD004454-sec-0260"> <h6 class="title">Respiratory distress syndrome (RDS)</h6> <p>The test for subgroup differences did not suggest a difference in effect on RDS between women with pregnancy gestations at less than or equal to 35 weeks and those at 34 weeks or greater (P = 0.60, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0126" title="">Analysis 8.4</a>). </p> <p>Sensitivity analysis removing three studies (<a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a>; <a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a>; <a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a>) did not substantially change the test for subgroup difference (P = 0.58, I<sup>2</sup> = 0%). </p> </section> <section id="CD004454-sec-0261"> <h6 class="title">Moderate/severe respiratory distress syndrome (RDS)</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0262"> <h6 class="title">Chronic lung disease</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0263"> <h6 class="title">Intraventricular haemorrhage (IVH)</h6> <p>The test for subgroup differences did not suggest a difference in effect on IVH between women with pregnancy gestations at less than or equal to 35 weeks and those at 34 weeks or greater (P = 0.16, I<sup>2</sup> = 49%, overlapping confidence intervals; <a href="./references#CD004454-fig-0127" title="">Analysis 8.5</a>). </p> </section> <section id="CD004454-sec-0264"> <h6 class="title">Mean birthweight</h6> <p>The test for subgroup differences did not suggest a difference in effect on birthweight between women with pregnancy gestations at less than or equal to 35 weeks and those at 34 weeks or greater (P = 0.77, I<sup>2</sup> = 0%, overlapping confidence intervals; <a href="./references#CD004454-fig-0128" title="">Analysis 8.6</a>). </p> <p>The effect estimate in this analysis is slightly different from the main analysis (<a href="./references#CD004454-fig-0024" title="">Analysis 1.8</a>) because the data from one study (<a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a>) have been analysed in six different gestational age groups, whereas in the main analysis we have presented the mean for the overall trial population. </p> </section> </section> <section id="CD004454-sec-0265"> <h5 class="title">For the woman</h5> <section id="CD004454-sec-0266"> <h6 class="title">Maternal death</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> <section id="CD004454-sec-0267"> <h6 class="title">Chorioamnionitis</h6> <p>The test for subgroup differences did not suggest a difference in effect on chorioamnionitis between women with pregnancy gestations at less than or equal to 35 weeks and those at 34 weeks or greater (P = 0.11, I<sup>2</sup> = 61%, overlapping confidence intervals; <a href="./references#CD004454-fig-0129" title="">Analysis 8.7</a>). </p> </section> <section id="CD004454-sec-0268"> <h6 class="title">Endometritis</h6> <p>Insufficient data to perform subgroup analysis.</p> </section> </section> <section id="CD004454-sec-0269"> <h5 class="title">For the child</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child. </p> </section> <section id="CD004454-sec-0270"> <h5 class="title">For the child as adult</h5> <p>There were insufficient data to perform subgroup analysis for any of the primary outcomes related to the child as adult. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004454-sec-0271" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004454-sec-0271"></div> <section id="CD004454-sec-0272"> <h3 class="title" id="CD004454-sec-0272">Summary of main results</h3> <p>In this updated review includes 27 studies involving 11,272 women and 11,925 infants. Our results support the conclusion of the previous review (<a href="./references#CD004454-bbs2-0119" title="RobertsD , BrownJ , MedleyN , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2017, Issue 3. Art. No: CD004454. [DOI: 10.1002/14651858.CD004454.pub3]">Roberts 2017</a>), that treatment with antenatal corticosteroids reduces perinatal death, neonatal death, respiratory distress syndrome (RDS), and intraventricular haemorrhage (IVH) in preterm infants. </p> <p>High‐certainty evidence suggests that antenatal corticosteroids reduce the risk of perinatal death, neonatal death and RDS, and have little to no effect on birthweight (high‐certainty evidence; <a href="./full#CD004454-tbl-0001">summary of findings Table 1</a>). Antenatal corticosteroids probably reduce the risk of IVH (moderate‐certainty evidence; <a href="./full#CD004454-tbl-0001">summary of findings Table 1</a>). Antenatal corticosteroids probably reduce the risk of developmental delay in later childhood (moderate‐certainty evidence; <a href="./full#CD004454-tbl-0001">summary of findings Table 1</a>). Further, the evidence suggests that antenatal corticosteroids reduce the risk of moderate and severe RDS. The evidence is uncertain if antenatal corticosteroids have any effect on the risk of death (in childhood or adulthood), or on neurodevelopmental disability in later adulthood. </p> <p>Moderate‐certainty evidence suggests that antenatal corticosteroids probably result in little to no difference in the risk of maternal death or endometritis but the wide 95% CIs include possible benefit and possible harm (<a href="./full#CD004454-tbl-0002">summary of findings Table 2</a>). Antenatal corticosteroids probably result in little to no difference in the risk of chorioamnionitis (moderate‐certainty evidence; <a href="./full#CD004454-tbl-0002">summary of findings Table 2</a>). </p> <p>In addition to the benefit of antenatal corticosteroids reducing the risk for a number of our primary outcomes for the fetus or neonate (perinatal death, neonatal death, RDS, moderate and severe RDS, IVH), we found evidence of potential benefit of antenatal corticosteroids reducing the risk for a number of our secondary outcomes for the fetus or neonate: Apgar score &lt; 7 at five minutes, admission to the neonatal intensive care unit (NICU), need for mechanical ventilation/continuous positive airways pressure (CPAP), duration of oxygen supplementation, surfactant use, systemic infection in the first 48 hours of life, proven infection while in the NICU, and necrotising enterocolitis. However, antenatal corticosteroids may have little to no effect on the risk of fetal death. For the remainder of the secondary outcomes for the fetus or neonate, we are uncertain of the overall effect of antenatal corticosteroids. </p> <p>For the woman, child, and adult we generally found no evidence of harm from antenatal corticosteroids apart from increased glucose tolerance in women and increased insulin resistance in adults; in fact we found some evidence suggesting potentially decreased side effects in women receiving corticosteroids, although for a number of the outcomes investigated there were no or insufficient data. </p> <p>Overall, the complete body of evidence of antenatal corticosteroids for women at risk of preterm birth strongly favours important clinical benefit for the fetus and neonate, including reducing risk of death and major neonatal morbidity, without evidence of major clinical harm to either the women, the fetus, neonate, child or adult. </p> </section> <section id="CD004454-sec-0273"> <h3 class="title" id="CD004454-sec-0273">Overall completeness and applicability of evidence</h3> <p>We have attempted to identify all available published and unpublished randomised trial data for the use of antenatal corticosteroids for women at risk of preterm birth. Additional data have been obtained and included where possible. We believe that the data are comprehensive and relevant to all women at risk of preterm birth. Comparisons of repeat antenatal corticosteroid regimens, of different antenatal corticosteroids and of the use of antenatal corticosteroids at term before elective birth are described in other Cochrane Reviews (<a href="./references#CD004454-bbs2-0074" title="BrownfootFC , GagliardiDI , BainE , MiddletonP , CrowtherCA . Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD006764. [DOI: 10.1002/14651858.CD006764.pub3]">Brownfoot 2013</a>; <a href="./references#CD004454-bbs2-0079" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD003935. [DOI: 10.1002/14651858.CD003935.pub4]">Crowther 2015</a>; <a href="./references#CD004454-bbs2-0107" title="SotiriadisA , MakrydimasG , PapatheodorouS , IoannidisJP , McGoldrickE . Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD006614. [DOI: 10.1002/14651858.CD006614.pub3]">Sotiriadis 2018</a>). </p> <p>Since the last update of this review (<a href="./references#CD004454-bbs2-0119" title="RobertsD , BrownJ , MedleyN , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2017, Issue 3. Art. No: CD004454. [DOI: 10.1002/14651858.CD004454.pub3]">Roberts 2017</a>), we have been able to add substantial evidence from low‐ and middle‐resource settings for most of our primary outcomes. The evidence supplied by these studies is consistent with that of the previous review, and the incorporation of these data into the current review should reassure clinicians who work in these settings that the evidence presented is applicable to the population they serve. This is important, as preterm birth is the leading cause of death in children younger than five years worldwide, with greater burden in low‐ and middle‐resource settings (<a href="./references#CD004454-bbs2-0076" title="ChawanpaiboonS , VogelJP , MollerA , LumbiganonP , PetzoldM , HoganD , et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Global Health2019;7:e37–e46.">Chawanpaiboon 2019</a>). </p> <p>In subgroup analyses we examined the effect of antenatal corticosteroids in women with singleton versus women with multiple pregnancies, in women with intact membranes versus ruptured membranes at first dose, and in women with pregnancy‐induced hypertension syndromes. The test for subgroup differences did not find substantial differences between subgroups to suggest that the applicability of the evidence should be different to one subgroup versus another; in other words the evidence remains applicable to all clinical subgroups examined. However, for a number of the subgroups, the number of studies, and participants within studies, contributing data are limited and thus the subgroup analyses do need to be interpreted with caution. </p> <p>Whether antenatal corticosteroids are beneficial in the current era of advanced neonatal practice has been questioned on the basis that previous conclusions concerning their benefits drew on data from the 1970s. In this update, we have included 10 studies published since 2000 (<a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a>; <a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a>; <a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a>; <a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a>; <a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a>; <a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a>; <a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a>; <a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a>; <a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a>; <a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a>), as well as analyses for the previous decades. These more recent studies contributed over 60% of the overall data to the review. Overall, the results show consistent benefits of steroid use, without any strong evidence that antenatal corticosteroids are not beneficial in the current era of advanced neonatal practice. </p> <p>The gestational age range at which antenatal corticosteroids provide benefit has been subject to debate. Four studies enrolled infants between 24 weeks and 0 days and 26 weeks and 0 days, with another three studies not reporting the lower gestational age limit with which they enrolled (<a href="#CD004454-tbl-0003">Table 1</a>). Ideally, this question should be investigated with individual patient data analysis using <i>a priori</i> agreed gestational age cut‐offs. We examined outcomes based on gestational age divisions of up to, and including, 35 weeks + 0 days and greater than, and including, 34 weeks + 0 days at trial entry. We included data from over 4000 women and infants from trials that enrolled from 34 weeks + 0 days. The test for subgroup differences did not find differences between subgroups for the outcomes of perinatal death, neonatal death, fetal death, RDS, IVH, birthweight or chorioamnionitis. This large body of evidence supports the use of antenatal corticosteroids in women at risk of late preterm birth, although there are currently insufficient data to comment on long‐term effects for the child and adult. </p> <p>In our subgroup analyses of different corticosteroids we found little evidence of a difference in efficacy between the two types of corticosteroids, apart from a possible difference with less maternal chorioamnionitis occurring with betamethasone. However the confidence intervals overlapped and our analysis is subject to bias as allocation to one type of corticosteroid or the other was not subject to randomisation. Further, our overall results in this subgroup analysis are consistent with another review (<a href="./references#CD004454-bbs2-0074" title="BrownfootFC , GagliardiDI , BainE , MiddletonP , CrowtherCA . Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD006764. [DOI: 10.1002/14651858.CD006764.pub3]">Brownfoot 2013</a>; 10 studies; 1089 women and 1161 infants), which compared different corticosteroid regimens and found insufficient evidence to support the use of one corticosteroid over the other. </p> <p>In our analysis the test for subgroup differences between trials administering a single course of steroids and trial protocols allowing weekly repeats, should the infant remain undelivered, did not suggest a difference in effect. However, this finding should not be interpreted as evidence in support of weekly repeats which is the subject of another Cochrane Review (<a href="./references#CD004454-bbs2-0079" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD003935. [DOI: 10.1002/14651858.CD003935.pub4]">Crowther 2015</a>) </p> </section> <section id="CD004454-sec-0274"> <h3 class="title" id="CD004454-sec-0274">Quality of the evidence</h3> <p>The evidence described in this review is based on 27 randomised controlled trials comparing antenatal corticosteroids with no antenatal corticosteroids. Overall, the evidence is consistent. There are some limitations in several trials where there was no placebo treatment used in the control group, and therefore the participants and caregivers were not blinded, and there was insufficient information in several trials to enable us to make judgements on the processes of randomisation or allocation concealment. The lack of information is most likely due to the era in which the trials were conducted, when this information was not a requirement for publication. We did not downgrade for risk of bias because our sensitivity analyses did not indicate that the effect estimates would be substantially different with those trials removed from the analysis. </p> <p>We assessed the evidence for perinatal death, neonatal death, RDS and birthweight as high certainty, which means that future trials are unlikely to change these findings. We assessed the evidence for IVH as moderate certainty because of the complexity involved in diagnosing IVH; earlier studies only reported this outcome at post mortem (consistent with lack of investigative techniques at the time), while latter studies utilised diagnosis by ultrasound, universally (but consistent with clinical practice) not all infants were screened for this outcome and so we cannot be certain that the effect estimate in our analysis is a true reflection of the risk in the whole trial population. </p> <p>For pregnant women, we assessed the evidence as moderate certainty for three outcomes: maternal death, chorioamnionitis and endometritis. Downgrading in each case was for imprecision due to wide confidence intervals crossing the line of no effect. There were very few data for maternal death. </p> <p>For the first time, we have considered the identified studies in terms of their trustworthiness in addition to using GRADE and the Cochrane 'Risk of bias' tool. We believe that the steps we have taken to evaluate studies' trustworthiness, and to remove studies whose trustworthiness could not be ascertained, adds to the value of the review and enhances its reliability. Studies were removed from the analysis and put into 'awaiting classification' because of concerns around randomisation processes, lack of evidence of ethics approval and/or prospective trial registration (for studies published after 2010) and, in the case of studies published only as abstracts, lack of confirmation that the available data were from the final analysis. Arguments for including data from studies published only in abstract form centre largely around publication bias in favour of studies with positive results and for studies conducted in environments where English is the primary language. However, subsequent publication of scientific meeting abstracts as full manuscripts is associated with better quality of the studies (<a href="./references#CD004454-bbs2-0103" title="SchererRW , MeerpohlJJ , PfeiferN , SchmuckerC , SchwarzerG , vonElmE . Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: MR000005. [DOI: 10.1002/14651858.MR000005.pub4]">Scherer 2018</a>). Furthermore, the inclusion of the four trials with abstract only data available would have added only an additional 179 participants to the RDS analysis, the single primary outcome where all four of these studies contributed data to the previous review (<a href="./references#CD004454-bbs2-0119" title="RobertsD , BrownJ , MedleyN , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2017, Issue 3. Art. No: CD004454. [DOI: 10.1002/14651858.CD004454.pub3]">Roberts 2017</a>). </p> <p>Assessing selective or incomplete reporting of results of randomised controlled trials is notoriously difficult when only published trial reports are available. These concerns led to the call for prospective trial registration (<a href="./references#CD004454-bbs2-0106" title="SimesRJ . Publication bias: the case for an international registry of clinical trials. Journal of Clinical Oncology1986;4:1529-41.">Simes 1986</a>), which was subsequently adopted by the International Committee of Medical Journal Editors in 2004 (<a href="./references#CD004454-bbs2-0080" title="De AngelisC , DrazenJM , FrizelleFA , et al. Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors. New England Journal of Medicine2004;351:1250-1.">De Angelis 2004</a>). In this review, although none of the early trials had been registered the two largest and most recent trials were prospectively registered and reported their pre‐specified outcomes in full. </p> <p>The need for prospective ethics has been recognised by the Declaration of Helsinki for many decades (<a href="./references#CD004454-bbs2-0109" title="The World Medical Association. Declaration of Helsinki. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/2013;Version 8.">The World Medical Association 2013</a>). Our exclusion of three trials published since 2010 due to lack of evidence of ethics approval and/or prospective trial registration appears fair and in keeping with these important principles of high‐quality randomised controlled trial conduct. We have attempted to contact study authors and we acknowledge that further trustworthy evidence may come to light from some studies. We welcome contact from study authors should they wish to engage with us. </p> </section> <section id="CD004454-sec-0275"> <h3 class="title" id="CD004454-sec-0275">Potential biases in the review process</h3> <p>Through our comprehensive search strategy we have attempted to identify all relevant trials regardless of publication status or language. Two or more review authors independently appraised the trials, extracted the data, assessed risk of bias and applied the GRADE method to assess the certainty of evidence. Where data were missing, we have contacted the original trialists and some additional data have been provided that enhances the content of this review. </p> <p>We are aware of potential bias in our assumption that trials where the number of women is the same is the same as the number of infants included only singleton pregnancies. </p> <p>A common situation in trials of pregnant women is that some outcomes do not apply to all randomised participants; specifically neonatal mortality and morbidity outcomes can only apply to those fetuses that survive to birth. While the number of 'eligible' participants can be used as a denominator in analysis of neonatal mortality and morbidity outcomes, this approach risks introducing bias as the comparison is not between the randomised groups, particularly if there is a difference in survival to birth between intervention groups. Consistent with this approach we have used the number of fetuses randomised for our primary neonatal mortality and morbidity outcomes (neonatal death, RDS, moderate/severe RDS, chronic lung disease, and IVH). Fourteen studies (9883 infants) provided data for fetal death, with the outcome reported in 399 (6%). While we could have undertaken a sensitivity analysis of our primary neonatal mortality and morbidity outcomes using 'eligible' infants (i.e. removing fetal deaths) as the denominator, this was not deemed necessary as the two groups where very well balanced in terms of fetal deaths (RR 1.01, 95% CI 0.83 to 1.22), and the neonatal mortality and morbidity outcomes analysed had tight confidence levels. </p> <p>While we applied our trustworthiness screening tool using objectively‐defined criteria we acknowledge that there may be some subjective interpretation in its application. Similarly, there may be an element of subjectivity in the application of  'Risk of bias' assessment and GRADE rating of evidence certainty. To minimise the potential for introducing bias with respect to 'Risk of bias' assessment, GRADE rating and trustworthiness screening we ensured each of these stages was carried out independently by two review authors with agreement reached by consensus through consultation with a third review author where necessary. </p> </section> <section id="CD004454-sec-0276"> <h3 class="title" id="CD004454-sec-0276">Agreements and disagreements with other studies or reviews</h3> <p>Current international recommendations, including those of the World Health Organization, have used earlier versions of this review on which to base their recommendations (<a href="./references#CD004454-bbs2-0114" title="WHO. WHO recommendations on interventions to improve preterm birth outcomes: evidence base. https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/preterm-birth-guideline/en/2015.">WHO 2015</a>). </p> <p>A systematic review conducted for a bi‐national clinical practice guideline for Australia and New Zealand in 2015 reported on the same maternal and neonatal benefits as the primary outcomes of this systematic review (<a href="./references#CD004454-bbs2-0071" title="Antenatal Corticosteroids Clinical Practice Guidelines Panel. Antenatal corticosteroids given to women prior to birth to improve fetal, infant, child and adult health: Clinical Practice Guidelines. Liggins Institute, The University of Auckland, Auckland, New Zealand2015.">Antenatal Corticosteroid CPG Panel 2015</a>), and had agreement with respect to the principle findings of this review </p> <p>As mentioned above, additional Cochrane Reviews consider evidence for repeat antenatal corticosteroid regimens (<a href="./references#CD004454-bbs2-0079" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD003935. [DOI: 10.1002/14651858.CD003935.pub4]">Crowther 2015</a>), different types of antenatal corticosteroids (<a href="./references#CD004454-bbs2-0074" title="BrownfootFC , GagliardiDI , BainE , MiddletonP , CrowtherCA . Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD006764. [DOI: 10.1002/14651858.CD006764.pub3]">Brownfoot 2013</a>), use of antenatal corticosteroids at term before elective birth (<a href="./references#CD004454-bbs2-0107" title="SotiriadisA , MakrydimasG , PapatheodorouS , IoannidisJP , McGoldrickE . Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD006614. [DOI: 10.1002/14651858.CD006614.pub3]">Sotiriadis 2018</a>), maternal versus direct fetal administration of corticosteroids (<a href="./references#CD004454-bbs2-0111" title="UtamaDP , Crowther. Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD008981. [DOI: 10.1002/14651858.CD008981.pub3]">Utama 2018</a>), and strategies for optimising antenatal corticosteroid administration (<a href="./references#CD004454-bbs2-0102" title="RohwerAC , OladapoOT , HofmeyrGJ . Strategies for optimising antenatal corticosteroid administration for women with anticipated preterm birth. Cochrane Database of Systematic Reviews2020, Issue 5. Art. No: CD013633. [DOI: 10.1002/14651858.CD013633]">Rohwer 2020</a>). Ten studies contributing data to the review of repeat antenatal corticosteroids (4733 women and 5700 neonates) found that repeat corticosteroids reduce the risk of neonates experiencing RDS and serious outcomes, but at the expense of lower birthweight (although this was not associated with lower birthweight adjusted for gestational age), without evidence of harm at early childhood follow‐up (<a href="./references#CD004454-bbs2-0079" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD003935. [DOI: 10.1002/14651858.CD003935.pub4]">Crowther 2015</a>). Four studies contributing data to the review of antenatal corticosteroids at term before elective birth (3856 women and 3893 neonates) found low‐certainty evidence that corticosteroids reduce the risk of RDS, transient tachypnoea, and admission into neonatal special care for the neonate, but not a reduction in need for mechanical ventilation (<a href="./references#CD004454-bbs2-0107" title="SotiriadisA , MakrydimasG , PapatheodorouS , IoannidisJP , McGoldrickE . Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD006614. [DOI: 10.1002/14651858.CD006614.pub3]">Sotiriadis 2018</a>). Twelve studies contributing data to the review of different types of antenatal corticosteroids (1557 women and 1661 neonates) found evidence that dexamethasone may reduced the risk of IVH compared to betamethasone, although the authors concluded that more trials are urgently needed (<a href="./references#CD004454-bbs2-0074" title="BrownfootFC , GagliardiDI , BainE , MiddletonP , CrowtherCA . Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD006764. [DOI: 10.1002/14651858.CD006764.pub3]">Brownfoot 2013</a>). No studies were identified comparing maternal versus direct fetal routes of corticosteroids (<a href="./references#CD004454-bbs2-0111" title="UtamaDP , Crowther. Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD008981. [DOI: 10.1002/14651858.CD008981.pub3]">Utama 2018</a>). Three cluster‐randomised controlled trials contributing data to the review of strategies for antenatal corticosteroid administration were unable to be pooled in meta‐analysis. In two trials, promoting the use of antenatal corticosteroids resulted in increased use of antenatal corticosteroids, whereas one trial did not find a difference in the rate of antenatal corticosteroid administration compared to usual care. The authors found in low‐resource settings that a strategy of actively promoting the use of antenatal corticosteroid in women at risk of preterm birth may increase antenatal corticosteroid use in the target population, but may also carry a substantial risk of unnecessary exposure of antenatal corticosteroids in women in whom antenatal corticosteroid is not indicated. At the population level, these effects were probably associated with increased risks of fetal death, perinatal death, neonatal death, and maternal infection (<a href="./references#CD004454-bbs2-0102" title="RohwerAC , OladapoOT , HofmeyrGJ . Strategies for optimising antenatal corticosteroid administration for women with anticipated preterm birth. Cochrane Database of Systematic Reviews2020, Issue 5. Art. No: CD013633. [DOI: 10.1002/14651858.CD013633]">Rohwer 2020</a>). Thus the inclusion of important data from low‐ and medium‐resource settings in the current review provides direct randomised controlled trial evidence that antenatal corticosteroids are effective in women at risk of preterm birth in these settings. However as demonstrated in the <a href="./references#CD004454-bbs2-0102" title="RohwerAC , OladapoOT , HofmeyrGJ . Strategies for optimising antenatal corticosteroid administration for women with anticipated preterm birth. Cochrane Database of Systematic Reviews2020, Issue 5. Art. No: CD013633. [DOI: 10.1002/14651858.CD013633]">Rohwer 2020</a> review clinicians need to ensure that appropriate women in such settings are targeted. </p> <p>A number of recent systematic reviews have analysed observational data with respect to the use of antenatal corticosteroids in women at risk of preterm birth before 24 and 25 weeks (<a href="./references#CD004454-bbs2-0099" title="ParkCK , IsayamaT , McDonaldSD . Antenatal corticosteroid therapy before 24 weeks of gestation: a systematic review and meta-analysis. Obstetrics and Gynecology2016;127(4):715-25.">Park 2016</a>; 17 studies, 3626 participants; <a href="./references#CD004454-bbs2-0082" title="DeshmukhM , PatoleS . Antenatal corticosteroids for neonates born before 25 Weeks-A systematic review and meta-analysis. PLOS One2017;12(9):e0176090.">Deshmukh 2017</a>; eight studies, 10,109 participants; <a href="./references#CD004454-bbs2-0083" title="DeshmukhM , PatoleS . Antenatal corticosteroids in impending preterm deliveries before 25 weeks' gestation. Archives of Disease in Childhood. Fetal and Neonatal Edition2018;103(2):F173-F176.">Deshmukh 2018</a> nine studies, 13,443 participants). Authors found moderate‐certainty evidence that antenatal corticosteroids reduced neonatal mortality (<a href="./references#CD004454-bbs2-0082" title="DeshmukhM , PatoleS . Antenatal corticosteroids for neonates born before 25 Weeks-A systematic review and meta-analysis. PLOS One2017;12(9):e0176090.">Deshmukh 2017</a>; <a href="./references#CD004454-bbs2-0083" title="DeshmukhM , PatoleS . Antenatal corticosteroids in impending preterm deliveries before 25 weeks' gestation. Archives of Disease in Childhood. Fetal and Neonatal Edition2018;103(2):F173-F176.">Deshmukh 2018</a>; <a href="./references#CD004454-bbs2-0099" title="ParkCK , IsayamaT , McDonaldSD . Antenatal corticosteroid therapy before 24 weeks of gestation: a systematic review and meta-analysis. Obstetrics and Gynecology2016;127(4):715-25.">Park 2016</a>) and IVH (<a href="./references#CD004454-bbs2-0082" title="DeshmukhM , PatoleS . Antenatal corticosteroids for neonates born before 25 Weeks-A systematic review and meta-analysis. PLOS One2017;12(9):e0176090.">Deshmukh 2017</a>; <a href="./references#CD004454-bbs2-0083" title="DeshmukhM , PatoleS . Antenatal corticosteroids in impending preterm deliveries before 25 weeks' gestation. Archives of Disease in Childhood. Fetal and Neonatal Edition2018;103(2):F173-F176.">Deshmukh 2018</a>), which is consistent with our findings from randomised controlled trials. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004454-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Applying the trustworthiness screening tool criteria" data-id="CD004454-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Applying the trustworthiness screening tool criteria</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004454-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD004454-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-04" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study" data-id="CD004454-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.4 Perinatal deaths" data-id="CD004454-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.4 Perinatal deaths </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.5 Neonatal deaths" data-id="CD004454-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.5 Neonatal deaths </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.6 Fetal deaths" data-id="CD004454-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.6 Fetal deaths </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.7 Respiratory distress syndrome" data-id="CD004454-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.7 Respiratory distress syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.7 Intraventricular haemorrhage." data-id="CD004454-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.7 Intraventricular haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.11 Mean birthweight (g)" data-id="CD004454-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.11 Mean birthweight (g) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.2 Chorioamnionitis" data-id="CD004454-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.2 Chorioamnionitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.11 Endometritis." data-id="CD004454-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.11 Endometritis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-13" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.30 Apgar &lt; 7 at 5 minutes" data-id="CD004454-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.30 Apgar &lt; 7 at 5 minutes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-14" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.25 Need for mechanical ventilation/CPAP" data-id="CD004454-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.25 Need for mechanical ventilation/CPAP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-15" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.38 Proven infection while in the neonatal intensive care unit." data-id="CD004454-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.38 Proven infection while in the neonatal intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-FIG-16" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.39 Necrotising enterocolitis." data-id="CD004454-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-FIG-16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.39 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-FIG-16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 1: Perinatal death" data-id="CD004454-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 1: Perinatal death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 2: Neonatal death" data-id="CD004454-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 2: Neonatal death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 3: Fetal death" data-id="CD004454-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 3: Fetal death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 4: Respiratory distress syndrome" data-id="CD004454-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 4: Respiratory distress syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 5: Moderate/severe respiratory distress syndrome" data-id="CD004454-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 5: Moderate/severe respiratory distress syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 6: Chronic lung disease" data-id="CD004454-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 6: Chronic lung disease </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 7: Intraventricular haemorrhage" data-id="CD004454-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 7: Intraventricular haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 8: Mean birthweight (g)" data-id="CD004454-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 8: Mean birthweight (g) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 9: Maternal death" data-id="CD004454-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 9: Maternal death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 10: Chorioamnionitis" data-id="CD004454-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 10: Chorioamnionitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 11: Endometritis" data-id="CD004454-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 11: Endometritis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 12: Death in childhood" data-id="CD004454-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 12: Death in childhood </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 13: Neurodevelopmental disability in childhood" data-id="CD004454-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 13: Neurodevelopmental disability in childhood </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 14: Death into adulthood" data-id="CD004454-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 14: Death into adulthood </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 15: Neurodevelopmental disability in adulthood" data-id="CD004454-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 15: Neurodevelopmental disability in adulthood </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 16: Fever in women after trial entry requiring the use of antibiotics" data-id="CD004454-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 16: Fever in women after trial entry requiring the use of antibiotics </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 17: Intrapartum fever in woman requiring the use of antibiotics" data-id="CD004454-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 17: Intrapartum fever in woman requiring the use of antibiotics </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 18: Postnatal fever in woman" data-id="CD004454-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 18: Postnatal fever in woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 19: Admission into adult intensive care unit" data-id="CD004454-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 19: Admission into adult intensive care unit </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 20: Side effects of therapy in women" data-id="CD004454-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 20: Side effects of therapy in women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 21: Glucose intolerance" data-id="CD004454-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 21: Glucose intolerance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 22: Hypertension" data-id="CD004454-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 22: Hypertension</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 23: Apgar &lt; 7 at 5 minutes" data-id="CD004454-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 23: Apgar &lt; 7 at 5 minutes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 24: Mean interval between trial entry and birth (days)" data-id="CD004454-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 24: Mean interval between trial entry and birth (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 25: Mean length at birth (cm)" data-id="CD004454-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 25: Mean length at birth (cm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 26: Mean head circumference at birth (cm)" data-id="CD004454-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 26: Mean head circumference at birth (cm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 27: Small‐for‐gestational age" data-id="CD004454-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 27: Small‐for‐gestational age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 28: Admission to neonatal intensive care unit" data-id="CD004454-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 28: Admission to neonatal intensive care unit </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 29: Need for mechanical ventilation/CPAP" data-id="CD004454-fig-0045" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 29: Need for mechanical ventilation/CPAP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 30: Mean duration of mechanical ventilation/CPAP (days)" data-id="CD004454-fig-0046" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 30: Mean duration of mechanical ventilation/CPAP (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0047"> <p> <div class="table" id="CD004454-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Median (IQR) duration of mechanical ventilation (hours)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>WHO 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 hours (12‐48)</p> <p>83 infants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 hours (12‐60)</p> <p>103 infants</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 31: Median (IQR) duration of mechanical ventilation (hours) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0047">Navigate to figure in review</a></div> </div> <div class="figure" id="CD004454-fig-0048"> <p> <div class="table" id="CD004454-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Median (IQR) duration of CPAP (hours)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>WHO 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 hours (24‐96)</p> <p>265 infants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 hours (24‐84)</p> <p>337 infants</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 32: Median (IQR) duration of CPAP (hours) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0048">Navigate to figure in review</a></div> </div> <div class="figure" id="CD004454-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 33: Air leak syndrome" data-id="CD004454-fig-0049" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 33: Air leak syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 34: Mean duration of oxygen supplementation (hours)" data-id="CD004454-fig-0050" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 34: Mean duration of oxygen supplementation (hours) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0051"> <p> <div class="table" id="CD004454-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Median (IQR) duration of oxygen supplementation (hours)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>WHO 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (18‐96)</p> <p>726 infants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (12‐93)</p> <p>756 infants</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 35: Median (IQR) duration of oxygen supplementation (hours) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0051">Navigate to figure in review</a></div> </div> <div class="figure" id="CD004454-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 36: Surfactant use" data-id="CD004454-fig-0052" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 36: Surfactant use </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 37: Systemic infection in the first 48 hours of life" data-id="CD004454-fig-0053" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 37: Systemic infection in the first 48 hours of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.38" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 38: Proven infection while in the neonatal intensive care unit" data-id="CD004454-fig-0054" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.38.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.38.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 38: Proven infection while in the neonatal intensive care unit </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.38.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.39" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 39: Necrotising enterocolitis" data-id="CD004454-fig-0055" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.39.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 39: Necrotising enterocolitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.39.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.40" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 40: Mean infant HPA axis function (cortisol)" data-id="CD004454-fig-0056" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.40.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.40.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 40: Mean infant HPA axis function (cortisol) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.40.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.41" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 41: Mean childhood weight (kg)" data-id="CD004454-fig-0057" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.41.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.41.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 41: Mean childhood weight (kg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.41.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.42" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 42: Mean childhood head circumference (cm)" data-id="CD004454-fig-0058" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.42.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.42.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 42: Mean childhood head circumference (cm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.42.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.43" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 43: Mean childhood height (cm)" data-id="CD004454-fig-0059" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.43.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.43.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 43: Mean childhood height (cm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.43.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.44" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 44: Mean childhood systolic blood pressure (mmHg)" data-id="CD004454-fig-0060" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.44.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.44.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 44: Mean childhood systolic blood pressure (mmHg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.44.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.45" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 45: Cerebral palsy in childhood" data-id="CD004454-fig-0061" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.45.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.45.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 45: Cerebral palsy in childhood </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.45.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.46" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 46: Behavioural/learning difficulties in childhood" data-id="CD004454-fig-0062" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.46.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.46.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 46: Behavioural/learning difficulties in childhood </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.46.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.47" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 47: Mean adult weight (kg)" data-id="CD004454-fig-0063" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.47.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.47.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 47: Mean adult weight (kg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.47.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.48" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 48: Mean adult head circumference (cm)" data-id="CD004454-fig-0064" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.48.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.48.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 48: Mean adult head circumference (cm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.48.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.49" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 49: Mean adult height (cm)" data-id="CD004454-fig-0065" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.49.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.49.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.49</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 49: Mean adult height (cm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.49.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.50" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 50: Mean adult skinfold thickness (log values)" data-id="CD004454-fig-0066" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.50.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.50.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.50</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 50: Mean adult skinfold thickness (log values) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.50.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.51" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 51: Abnormal lung function measured as forced vital capacity (adult)" data-id="CD004454-fig-0067" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.51.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.51.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.51</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 51: Abnormal lung function measured as forced vital capacity (adult) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.51.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.52" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 52: Mean adult systolic blood pressure (mmHg)" data-id="CD004454-fig-0068" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.52.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.52.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.52</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 52: Mean adult systolic blood pressure (mmHg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.52.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.53" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 53: Mean adult insulin (log values)" data-id="CD004454-fig-0069" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.53.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.53.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.53</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 53: Mean adult insulin (log values) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.53.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.54" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 54: Mean adult glucose" data-id="CD004454-fig-0070" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.54.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.54.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.54</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 54: Mean adult glucose </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.54.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.55" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 55: Mean adult HPA axis function (mean log fasting cortisol)" data-id="CD004454-fig-0071" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.55.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.55.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.55</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 55: Mean adult HPA axis function (mean log fasting cortisol) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.55.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.56" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 56: Mean age at puberty (years)" data-id="CD004454-fig-0072" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.56.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.56.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.56</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 56: Mean age at puberty (years) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.56.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.57" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 57: Educational achievement by adulthood (university or polytechnic education)" data-id="CD004454-fig-0073" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.57.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.57.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.57</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 57: Educational achievement by adulthood (university or polytechnic education) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.57.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.58" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 58: Mean length of antenatal hospitalisation (days)" data-id="CD004454-fig-0074" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.58.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.58.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.58</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 58: Mean length of antenatal hospitalisation (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.58.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0075"> <p> <div class="table" id="CD004454-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Length of maternal hospital stay</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Measure</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Attawattanakul 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall length of maternal hospital stay (days) (mean (SD))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.57 (0.87)</p> <p>96 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.58 (0.75)</p> <p>98 women</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Gyamfi‐Bannerman 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall length of maternal hospital stay (days) (median (IQR))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (3 to 5)</p> <p>1427 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (3 to 5)</p> <p>1400 women</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mansouri 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of women requiring a hospital stay of more than three days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/100</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>WHO 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall length of maternal hospital stay (days) (median (IQR))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (4 to 20)</p> <p>1323 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (4 to19)</p> <p>1322 women</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.59</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 59: Length of maternal hospital stay </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0075">Navigate to figure in review</a></div> </div> <div class="figure" id="CD004454-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.60" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 60: Mean length of postnatal hospitalisation (days)" data-id="CD004454-fig-0076" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.60.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.60.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.60</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 60: Mean length of postnatal hospitalisation (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.60.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-001.61" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 61: Mean length of neonatal hospitalisation (days)" data-id="CD004454-fig-0077" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.61.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-001.61.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.61</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 61: Mean length of neonatal hospitalisation (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-001.61.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0078"> <p> <div class="table" id="CD004454-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Length of neonatal hospitalisation</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Measure</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Gyamfi‐Bannerman 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall length of neonatal hospital stay (days) (median (IQR))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (4 to 12)</p> <p>1427 infants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (4 to 13)</p> <p>1400 infants</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>WHO 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall length of neonatal hospital stay (days) (median (IQR))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (3 to17)</p> <p>1320 infants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (3 to 17)</p> <p>1301 infants</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.62</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus placebo or no treatment, Outcome 62: Length of neonatal hospitalisation </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0078">Navigate to figure in review</a></div> </div> <div class="figure" id="CD004454-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy, Outcome 1: Perinatal death ‐ single or multiple pregnancy" data-id="CD004454-fig-0079" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy, Outcome 1: Perinatal death ‐ single or multiple pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy, Outcome 2: Neonatal death ‐ single or multiple pregnancy" data-id="CD004454-fig-0080" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy, Outcome 2: Neonatal death ‐ single or multiple pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy, Outcome 3: Fetal death ‐ single or multiple pregnancy" data-id="CD004454-fig-0081" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy, Outcome 3: Fetal death ‐ single or multiple pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy, Outcome 4: Respiratory distress syndrome ‐ single or multiple pregnancy" data-id="CD004454-fig-0082" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy, Outcome 4: Respiratory distress syndrome ‐ single or multiple pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy, Outcome 5: Intraventricular haemorrhage ‐ single or multiple pregnancy" data-id="CD004454-fig-0083" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy, Outcome 5: Intraventricular haemorrhage ‐ single or multiple pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 1: Perinatal death ‐ intact or ruptured membranes" data-id="CD004454-fig-0084" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 1: Perinatal death ‐ intact or ruptured membranes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 2: Neonatal deaths ‐ intact or ruptured membranes" data-id="CD004454-fig-0085" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 2: Neonatal deaths ‐ intact or ruptured membranes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 3: Fetal death ‐ intact or ruptured membranes" data-id="CD004454-fig-0086" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 3: Fetal death ‐ intact or ruptured membranes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 4: RDS ‐ intact or ruptured membranes" data-id="CD004454-fig-0087" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 4: RDS ‐ intact or ruptured membranes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 5: IVH ‐ intact or ruptured membranes" data-id="CD004454-fig-0088" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 5: IVH ‐ intact or ruptured membranes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 6: Birthweight ‐ intact or ruptured membranes" data-id="CD004454-fig-0089" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 6: Birthweight ‐ intact or ruptured membranes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 7: Chorioamnionitis ‐ intact or ruptured membranes" data-id="CD004454-fig-0090" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 7: Chorioamnionitis ‐ intact or ruptured membranes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 8: Endometritis ‐ intact or ruptured membranes" data-id="CD004454-fig-0091" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose, Outcome 8: Endometritis ‐ intact or ruptured membranes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Corticosteroids versus placebo or no treatment ‐ hypertension syndrome versus all other trials, Outcome 1: Perinatal deaths ‐ hypertension syndrome vs other trials" data-id="CD004454-fig-0092" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Corticosteroids versus placebo or no treatment ‐ hypertension syndrome versus all other trials, Outcome 1: Perinatal deaths ‐ hypertension syndrome vs other trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Corticosteroids versus placebo or no treatment ‐ hypertension syndrome versus all other trials, Outcome 2: Neonatal deaths ‐ hypertension syndrome vs other trials" data-id="CD004454-fig-0093" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Corticosteroids versus placebo or no treatment ‐ hypertension syndrome versus all other trials, Outcome 2: Neonatal deaths ‐ hypertension syndrome vs other trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Corticosteroids versus placebo or no treatment ‐ hypertension syndrome versus all other trials, Outcome 3: Fetal deaths ‐ hypertension syndrome vs other trials" data-id="CD004454-fig-0094" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Corticosteroids versus placebo or no treatment ‐ hypertension syndrome versus all other trials, Outcome 3: Fetal deaths ‐ hypertension syndrome vs other trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Corticosteroids versus placebo or no treatment ‐ hypertension syndrome versus all other trials, Outcome 4: Respiratory distress syndrome ‐ hypertension syndrome vs other trials" data-id="CD004454-fig-0095" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Corticosteroids versus placebo or no treatment ‐ hypertension syndrome versus all other trials, Outcome 4: Respiratory distress syndrome ‐ hypertension syndrome vs other trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 1: Perinatal death ‐ type of steroid" data-id="CD004454-fig-0096" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 1: Perinatal death ‐ type of steroid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 2: Neonatal death ‐ type of steroid" data-id="CD004454-fig-0097" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 2: Neonatal death ‐ type of steroid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 3: Fetal death ‐ type of steroid" data-id="CD004454-fig-0098" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 3: Fetal death ‐ type of steroid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 4: Respiratory distress syndrome ‐ type of steroid" data-id="CD004454-fig-0099" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 4: Respiratory distress syndrome ‐ type of steroid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 5: Moderate/severe respiratory distress syndrome ‐ type of steroid" data-id="CD004454-fig-0100" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 5: Moderate/severe respiratory distress syndrome ‐ type of steroid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 6: Chronic lung disease ‐ type of steroid" data-id="CD004454-fig-0101" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 6: Chronic lung disease ‐ type of steroid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 7: IVH ‐ type of steroid" data-id="CD004454-fig-0102" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 7: IVH ‐ type of steroid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 8: Birthweight ‐ type of steroid" data-id="CD004454-fig-0103" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 8: Birthweight ‐ type of steroid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 9: Chorioamnionitis ‐ type of steroid" data-id="CD004454-fig-0104" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 9: Chorioamnionitis ‐ type of steroid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 10: Endometritis ‐ type of steroid" data-id="CD004454-fig-0105" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroids versus placebo or no treatment ‐ type of steroid, Outcome 10: Endometritis ‐ type of steroid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 1: Perinatal death ‐ decade of trial" data-id="CD004454-fig-0106" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 1: Perinatal death ‐ decade of trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 2: Neonatal death ‐ decade of trial" data-id="CD004454-fig-0107" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 2: Neonatal death ‐ decade of trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 3: Fetal death ‐ decade of trial" data-id="CD004454-fig-0108" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 3: Fetal death ‐ decade of trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 4: Respiratory distress syndrome ‐ decade of trial" data-id="CD004454-fig-0109" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 4: Respiratory distress syndrome ‐ decade of trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 5: IVH ‐ decade of trial" data-id="CD004454-fig-0110" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 5: IVH ‐ decade of trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 6: Birthweight ‐ decade of trial" data-id="CD004454-fig-0111" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 6: Birthweight ‐ decade of trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 7: Chorioamnionitis ‐ decade of trial" data-id="CD004454-fig-0112" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 7: Chorioamnionitis ‐ decade of trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 8: Endometritis ‐ decade of trial" data-id="CD004454-fig-0113" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Corticosteroids versus placebo or no treatment ‐ decade of trial, Outcome 8: Endometritis ‐ decade of trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 1: Perinatal death ‐ protocol with weekly repeats" data-id="CD004454-fig-0114" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 1: Perinatal death ‐ protocol with weekly repeats </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 2: Neonatal death ‐ protocol with weekly repeats" data-id="CD004454-fig-0115" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 2: Neonatal death ‐ protocol with weekly repeats </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 3: Fetal death ‐ protocol with weekly repeats" data-id="CD004454-fig-0116" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 3: Fetal death ‐ protocol with weekly repeats </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 4: Respiratory distress syndrome ‐ protocol with weekly repeats" data-id="CD004454-fig-0117" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 4: Respiratory distress syndrome ‐ protocol with weekly repeats </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 5: Moderate/severe respiratory distress syndrome" data-id="CD004454-fig-0118" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 5: Moderate/severe respiratory distress syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 6: IVH ‐ protocol with weekly repeats" data-id="CD004454-fig-0119" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 6: IVH ‐ protocol with weekly repeats </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 7: Birthweight ‐ protocol with weekly repeats" data-id="CD004454-fig-0120" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 7: Birthweight ‐ protocol with weekly repeats </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 8: Chorioamnionitis ‐ protocol with weekly repeats" data-id="CD004454-fig-0121" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 8: Chorioamnionitis ‐ protocol with weekly repeats </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-007.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 9: Endometritis ‐ protocol with weekly repeats" data-id="CD004454-fig-0122" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-007.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroids versus placebo or no treatment ‐ weekly repeats, Outcome 9: Endometritis ‐ protocol with weekly repeats </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-007.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 1: Perinatal death ‐ gestational age at trial entry" data-id="CD004454-fig-0123" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 1: Perinatal death ‐ gestational age at trial entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 2: Neonatal death ‐ gestational age at trial entry" data-id="CD004454-fig-0124" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 2: Neonatal death ‐ gestational age at trial entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 3: Fetal death ‐ gestational age at trial entry" data-id="CD004454-fig-0125" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 3: Fetal death ‐ gestational age at trial entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 4: Respiratory distress syndrome ‐ gestational age at trial entry" data-id="CD004454-fig-0126" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 4: Respiratory distress syndrome ‐ gestational age at trial entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 5: IVH ‐ gestational age at trial entry" data-id="CD004454-fig-0127" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 5: IVH ‐ gestational age at trial entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 6: Birthweight ‐ gestational age at trial entry" data-id="CD004454-fig-0128" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 6: Birthweight ‐ gestational age at trial entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004454-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/urn:x-wiley:14651858:media:CD004454:CD004454-CMP-008.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 7: Chorioamnionitis ‐ gestational age at trial entry" data-id="CD004454-fig-0129" src="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_t/tCD004454-CMP-008.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8: Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry, Outcome 7: Chorioamnionitis ‐ gestational age at trial entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/media/CDSR/CD004454/image_n/nCD004454-CMP-008.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004454-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Neonatal and child outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Neonatal and child outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants born of women at risk of preterm birth<br/><b>Setting:</b> hospitals settings in low‐, middle‐ and high‐resource countries<br/><b>Intervention:</b> corticosteroids<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Without Corticosteroids</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With Corticosteroids</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perinatal death (composite of fetal death (<i>in utero</i> death) and neonatal death)<br/>№ of participants: 9833<br/>(14 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.77 to 0.93) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids reduce perinatal death compared with placebo or no treatment.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3%<br/>(12 to 14.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3% fewer<br/>(3.6 fewer to 1.1 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neonatal death (infants born with signs of life who die within the first 28 days)<br/>№ of participants: 10,609<br/>(22 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/>(0.70 to 0.87) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids reduce neonatal death compared with placebo or no treatment.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3%<br/>(8.3 to 10.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6% fewer<br/>(3.6 fewer to 1.5 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Respiratory distress syndrome<br/>№ of participants: 11,183<br/>(26 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/>(0.65 to 0.78) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids reduce respiratory distress syndrome compared with placebo or no treatment.</p> <p>We did not downgrade for risk of bias (two trials) at high risk of bias due to lack of placebo in control) because sensitivity analysis removing those trials made very little difference to the effect estimate. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5%<br/>(9.6 to 11.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3% fewer<br/>(5.2 fewer to 3.2 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intraventricular haemorrhage (IVH)<br/>№ of participants: 8475<br/>(12 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.58<br/>(0.45 to 0.75) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably reduce intraventricular haemorrhage compared with placebo or no treatment. </p> <p>We did not downgrade for risk of bias (four trials infants) at high risk of bias due to lack of placebo in control groups) because sensitivity analysis removing those trials made very little difference to the effect estimate. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9%<br/>(1.5 to 2.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4% fewer<br/>(1.8 fewer to 0.8 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean birthweight (g)<br/>№ of participants: 9551<br/>(19 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean birthweight in the control group ranged from 941 g to 2654 g</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 14.02 lower<br/>(33.79 lower to 5.76 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids result in little to no difference in mean birthweight compared with placebo or no treatment. </p> <p>We did not downgrade for risk of bias (two trials at high risk of bias due to incomplete outcome data) because sensitivity analysis removing those trials made very little difference to the effect estimate. </p> <p>We did not downgrade for imprecision because the confidence interval showed a difference at most on average of 33 g in weight, which is less than 10% of the lightest mean weight in any trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developmental delay in childhood<br/>№ of participants: 600 (3 RCTs). </p> <p>Age at follow‐up: 2 to 12 years.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>RR 0.51 (0.27 to 0.97)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.0%</p> <p>(2.1 to 7.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8% fewer</p> <p>(5.7 fewer to 0.2 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corticosteroids probably lead to a slight reduction in developmental delay in childhood compared with placebo or no treatment. </p> <p>Additionally, in three studies (778 children) it was uncertain if corticosteroids had any effect on intellectual impairment (RR 0.86, 95% CI 0.44 to 1.69). In two studies (166 children) it was uncertain if corticosteroids had any effect on the risk of visual impairment (RR 0.55, 95% CI 0.24 to 1.23) and in one study (82 children) it was uncertain if corticosteroids have any effect on hearing impairment (RR 0.64, 95% CI 0.04 to 9.87). Another study reported no children with hearing impairment in either group (84 children). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for indirectness: in some trials only a subset of infants were screened for IVH; some trials diagnosed IVH at postmortem only. </p> <p><sup>2</sup> Downgraded one level for risk of bias: unclear randomisation, allocation concealment, incomplete outcome data and selective reporting </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Neonatal and child outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004454-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Maternal outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Maternal outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women at risk of preterm birth<br/><b>Setting:</b> hospitals settings in low‐, middle‐ and high‐resource countries<br/><b>Intervention:</b> corticosteroids<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Without Corticosteroids</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With Corticosteroids</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maternal death<br/>follow up: 90 days<br/>№ of participants: 6244<br/>(6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.19<br/>(0.36 to 3.89) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably result in little to no difference in maternal death, but the wide 95% CI includes possible benefit and possible harm, compared to placebo or no treatment. </p> <p>Four studies (3174 women) reported zero deaths in either arm.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2%<br/>(0.1 to 0.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer (0.1 fewer to 0.5 more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chorioamnionitis<br/>№ of participants: 8374<br/>(15 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.69 to 1.08) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably make little to no difference to the risk of chorioamnionitis but the wide 95% CI includes possible benefit and possible harm, compared to placebo/no treatment. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0%<br/>(2.4 to 3.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% fewer<br/>(1.1 fewer to 0.3 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometritis<br/>№ of participants: 6764<br/>(10 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(0.82 to 1.58) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corticosteroids probably make little to no difference to the risk of endometritis but the wide 95% CI includes possible benefit and possible harm, compared to placebo/no treatment. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1%<br/>(1.5 to 2.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3% more<br/>(0.3 fewer to 1.1 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio, </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for imprecision: few events and wide 95% CI that includes possible benefit and possible harm </p> <p><sup>2</sup> Downgraded one level for imprecision: wide 95% CI that includes possible benefit and possible harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Maternal outcomes: corticosteroids compared to placebo or no treatment for accelerating fetal lung maturation for women at risk of preterm birth</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004454-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Gestational age parameters for included trials</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimum</p> <p>(weeks<sup>+days</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum</p> <p>(weeks<sup>+days</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0001" title="AmorimMM , SantosLC , FaundesA . Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology1999;180(5):1283-8. ">Amorim 1999</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0002" title="AttawattanakulN , TansupswatdikulP . Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2015;23:25-33. ">Attawattanakul 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0003" title="BalciO , OzdemirS , MahmoudAS , AcarA , ColakogluMC . The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecologic and Obstetric Investigation2010;70(2):95-9. ">Balci 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0004" title="BlockMF , KlingOR , CrosbyWM . Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstetrics &amp; Gynecology1977;50:186-90. ">Block 1977</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0005" title="BauerCR , MorrisonJC , PooleWK , KoronesSB , BoehmJJ , RigattoH , et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics1984;73:682-8. BurkettG , BauerCR , MorrisonJC , CuretLB . Effect of prenatal dexamethasone administration on the prevention of respiratory distress syndrome in twin pregnancies. Journal of Perinatology1986;6:304-8. Collaborative Group on Antenatal Steroid Therapy. Amniotic fluid phospholipids after maternal administration of dexamethasone. American Journal of Obstetrics and Gynecology1983;145:484-90. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration in the infant: long term follow-up. Journal of Pediatrics1984;105:259-67. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology1981;141:276-87. CuretLB , RaoAV , ZachmanRD , MorrisonJ , BurkettG , PooleK , et al. Maternal smoking and respiratory distress syndrome. American Journal of Obstetrics and Gynecology1983;147:446-50. HaningRV , CuretLB , PooleK , BoehnleinLM , KuzmaDL , MeierSM . Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol, and estriol. American Journal of Obstetrics and Gynecology1989;161:1549-53. WiebickeW , PoynterA , ChernickV . Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome. Pediatric Pulmonology1988;5:27-30. ZachmanRD , BauerCR , BoehmJ , KoronesSB , RigattoH , RaoAV . Effect of antenatal dexamethasone on neonatal leukocyte count. Journal of Perinatology1988;8:111-3. ZachmanRD . The NIH multicenter study and miscellaneous clinical trials of antenatal corticosteroid administration. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives. Vol. II. London &amp; New York: Academic Press, 1982:275-96. ">Collaborative 1981</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<sup>+0</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0006" title="PattinsonRC , FunkM , MakinJD , FickiH . The effect of dexamethasone on the immune system of women with preterm premature rupture of membranes: a randomised controlled trial. In: 15th Conference on Priorities in Perinatal Care in Southern Africa; 1996 March 5-8; Goudini Spa, South Africa. 1996. PattinsonRC , MakinJD , FunkM , DelportSD , MacdonaldAP , NormanK . The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre double blind, placebo controlled randomised trial. South African Medical Journal1999;89(8):865-70. PattinsonRC . A meta-analysis of the use of corticosteroids in pregnancies complicated by preterm premature rupture of membranes. South African Medical Journal1999;89(8):870-3. The DEXIPROM Study Group. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre placebo controlled randomised controlled trial. In: 16th Conference on Priorities in Perinatal Care; 1997; South Africa. 1997:32-4. ">Dexiprom 1999</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0007" title="FekihM , ChaiebA , SbouiH , DenguezliW , HidarS , KhairiH . Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study [Apport de la corticotherapie antenatale dans la prevention de la maladie des membranes hyalines chez le premature. Etude prospective randomisee]. Tunisie Medicale2002;80(5):260-5. ">Fekih 2002</a><br/>  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0008" title="DonnaiP . UK multicentre trial of betamethasone for the prevention of respiratory distress syndrome. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 81. GamsuHR , MullingerBM , DonnaiP , DashCH . Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British Journal of Obstetrics and Gynaecology1989;96:401-10. ">Gamsu 1989</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0009" title="GariteTJ , RumneyPJ , BriggsGG , HardingJA , NageotteMP , TowersCV , et al. A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. American Journal of Obstetrics and Gynecology1992;166:646-51. GariteTJ , RumneyPJ , BriggsGG . A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-28 weeks gestation. Surgery, Gynecology and Obstetrics1993;176:37. ">Garite 1992</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0010" title="Battarbee AshleyN . 41: fetal metabolic biomarkers after late preterm betamethasone and their association with neonatal hypoglycemia. American Journal of Obstetrics and Gynecology2020;222(1):S35-S36. [CENTRAL: CN-02074433] [EMBASE: 2004455290]BicoccaMJ , Chen H-Y, BlackwellS , SibaiB , MfmuN . 457: does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity?American Journal of Obstetrics and Gynecology2019;220(1):S306-S307. [CENTRAL: CN-01758135] [EMBASE: 2001405365]CarpenterJ , JablonskiK , KoncinskyJ , VarnerM , Joss-MooreL . Antenatal steroids do not affect splicing or DNA methylation of the glucocorticoid receptor gene in cord blood T-cells. Reproductive Sciences (Thousand Oaks, Calif.)2017;24(Suppl 1):258A. [CENTRAL: CN-01363475] [EMBASE: 615322896]DotyMS , Chen H-Y, ChauhanSP , SibaiBM . 464: time interval from betamethasone to delivery among women at risk for late preterm delivery. American Journal of Obstetrics and Gynecology2019;220(1):S310-1. [CENTRAL: CN-01710941] [EMBASE: 2001405276]Gyamfi-BannermanC , ThomEA , BlackwellSC , TitaAT , ReddyUM , SaadeGR , et al. Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine2016;374(14):1311-20. Gyamfi-BannermanC , ZupancicJA , SandovalG , GrobmanWA , BlackwellSC , TitaAT , et al. Cost-effectiveness of antenatal corticosteroid therapy vs no therapy in women at risk of late preterm delivery: a secondary analysis of a randomized clinical trial. JAMA Pediatrics2019;173(5):462-8. [CENTRAL: CN-01916423] [EMBASE: 626717642] [PMID: 30855640]Gyamfi-BannermanC . Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. American Journal of Obstetrics and Gynecology2016;214(1 Suppl):S2. Gyamfi-BannermanC . Respiratory morbidity after betamethasone (BMZ) treatment in infants of women at risk for late preterm delivery (LPD). American Journal of Obstetrics and Gynecology2018;218(1 Suppl 1):S353. [CENTRAL: CN-01450832] [EMBASE: 620309716]Gyamfi-BannermanC . Respiratory morbidity in pregnancies at risk for late preterm delivery in relation to cord blood concentrations of betamethasone and cortisol. Reproductive Sciences (thousand Oaks, Calif.)2016;23(Suppl 1):274A. [EMBASE: 72226697]NCT01222247. Antenatal late preterm steroids (ALPS): a randomized placebo-controlled trial. clinicaltrials.gov/ct2/show/NCT01222247 (Date first received: 14 October 2010). PurischS , Handal-OreficeR , AnanthCV , Gyamfi-BannermanC . Effect of BMI on neonatal respiratory outcomes in women at risk for late preterm birth. American Journal of Obstetrics and Gynecology. Conference: 38th Annual Meeting of the Society for Maternal-fetal Medicine: the Pregnancy Meeting. United States2018;218(1 Suppl 1):S393-S394. [CENTRAL: CN-01450813] [EMBASE: 620309949]ViteriOA , DotyMS , AlraisMA , SibaiBM . 471: intended administration of antenatal late preterm steroids: is a single dose enough?American Journal of Obstetrics and Gynecology2019;220(1):S315. [CENTRAL: CN-01710606] [EMBASE: 2001405752]WernerEF , RomanoME , RouseDJ , SandovalG , Gyamfi-BannermanC , BlackwellSC , et al. Association of gestational diabetes mellitus with neonatal respiratory morbidity. Obstetrics and Gynecology2019;133(2):349-53. [CENTRAL: CN-01788495] [EMBASE: 626098249] [PMID: 30633135]">Gyamfi‐Bannerman 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0011" title="EronenM , KariA , PesonenE , HallmanM . The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus: a randomised double-blind study. American Journal of Diseases of Children1993;147:187-92. KariMA , AkinoT , HallmanM . Prenatal dexamethasone (DEX) treatment before preterm delivery and rescue therapy of exogenous surfactant- surfactant components and surface activity in airway specimens (AS). In: Proceedings of the 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 486. KariMA , HallmanM , EronenM , TeramoK , VirtanenM , KoivistoM , et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomised placebo-controlled multicenter study. Pediatrics1994;93:730-6. SalokorpiT , SajaniemiN , HallbackH , KariA , RitaH , vonWendtL . Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatrica1997;86:294-8. ">Kari 1994</a><br/>  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<sup>+6</sup><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0012" title="LewisD , BrodyK , EdwardsM , BrouilletteRM , BurlisonS , LondonSN . Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Obstetrics &amp; Gynecology1996;88(5):801-5. ">Lewis 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0013" title="DalzielSR , FenwickS , CundyT , ParagV , BeckTJ , RodgersA , et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. Journal of Bone &amp; Mineral Research2006;21(8):1175-86. DalzielSR , LiangA , ParagV , RodgersA , HardingJE . Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics2004;114:e373-e377. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ2005;331:665. DalzielSR , LimVK , LambertA , McCarthyD , ParagV , RodgersA , et al. Psychological functioning and health-related quality of life in adulthood after preterm birth. Developmental Medicine and Child Neurology2007;49(8):597-602. DalzielSR , ParagV , HardingJE . Blood pressure at 6 years of age following exposure to antenatal betamethasone. In: 7th Annual Congress of the Perinatal Society of Australia and New Zealand; 2003 March 9-12; Tasmania, Australia. 2003:P13. DalzielSR , ReaHH , WalkerNK , ParagV , MantellC , RodgersA , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax2006;61(8):678-83. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Cardiovascular risk factors after exposure to antenatal betamethasone: 30-year follow-up of a randomised controlled trial. Lancet2005;365:1856-62. DalzielSR , WalkerNK , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomised controlled trial [abstract]. Pediatric Research2004;55 Suppl:101. DalzielSR , WalkerNR , ParagV , MantellC , ReaHH , RodgersA , et al. Long-term effects of antenatal exposure to betamethasone: thirty year follow-up of a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2004 May 1-4; San Francisco, USA. 2004. HardingJE , PangJ , KnightDB , LigginsGC . Do antenatal corticosteroids help in the setting of preterm rupture of membranes?American Journal of Obstetrics and Gynecology2001;184:131-9. HowieRN , LigginsGC . Clinical trial of antepartum betamethasone therapy for prevention of respiratory distress in pre-term infants. In: AndersonAB , BeardRW , BrudenellJM , DunnPM , editors(s). Pre-term Labour. London: RCOG, 1977:281-9. HowieRN , LigginsGC . Prevention of respiratory distress syndrome in premature infants by antepartum glucocorticoid treatment. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1973:369-80. HowieRN , LigginsGC . The New Zealand study of antepartum glucocorticoid treatment. In: FarrellPM , editors(s). Lung Development: Biological and Clinical Perspectives, II. Academic Press: London &amp; New York, 1982:255-65. HowieRN . Pharmacological acceleration of lung maturation. In: VilleeCA , VilleeDB , ZuckermanJ , editors(s). Respiratory Distress Syndrome. London &amp; New York: Academic Press, 1986:385-96. LigginsGC , HowieRN . A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972;50:515-25. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by antepartum corticosteroid therapy. In: Proceedings of Sir Joseph Barcroft Centenary Symposium, Fetal and Neonatal Physiology; 1972; UK. Cambridge University Press: UK, 1973:613-7. LigginsGC , HowieRN . Prevention of respiratory distress syndrome by maternal steroid therapy. In: GluckL , editors(s). Modern Perinatal Medicine. Chicago: Yearbook Publishers, 1974:415-24. LigginsGC . Prenatal glucocorticoid treatment: prevention of respiratory distress syndrome. In: MooreTD , editors(s). Lung maturation and the prevention of hyaline membrane disease, report of 70th Ross Conference on Paediatric Research. Ross Labs, 1976:97-103. MacArthurB , HowieRN , DeZoeteA , ElkinsJ , LiangAY . Long term follow up of children exposed to betamethasone in utero. In: TejaniN , editors(s). Obstetrical Events and Developmental Sequelae. CRC Press, 1989:81-9. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1981;68:638-43. MacArthurB , HowieRN , DeZoeteA , ElkinsJ . School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics1982;70:99-105. ">Liggins 1972b</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0014" title="LopezAL , RojasRL , RodriguezMV , SanchezAJ . Use of corticoids in preterm pregnancy with premature rupture of membranes [Uso de los corticoides en embarazo pretermino con ruptura prematura de membranas]. Revista Colombiana de Obstetricia y Ginecologia1989;40:147-51. ">Lopez 1989</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<sup>+0</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0015" title="IRCT138901193666N1. Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. www.irct.ir (Date first received: 17 May 2010). MansouriM , SeyedolshohadaeiF , CompanyF , SetareS , MazhariS . Effect of antenatal betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences2010;12(3):18-23. ">Mansouri 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0016" title="MoralesWJ , AngelJL , O'BrienWF , KnuppelRA . Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics &amp; Gynecology1989;73:721-6. ">Morales 1989</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004454-bbs2-0017" title="MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Obstetrics &amp; Gynecology1980;56:583-90. MorrisonJC , SchneiderJM , WhybrewWD , BucovazET . Effect of corticosteroids and fetomaternal disorders on the L:S ratio. Surgery, Gynecology and Obstetrics1981;153:464. MorrisonJC , WhybrewWD , BucovazET , ScheinerJM . Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. American Journal of Obstetrics and Gynecology1978;131:358-66. ">Morrison 1978</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34<sup>+0</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0018" title="NelsonLH , MeisPJ , HatjisCG , ErnestJM , DillardR , ScheyHM . Premature rupture of membranes: a prospective randomized evaluation of steroids, latent phase and expectant management. Obstetrics &amp; Gynecology1985;66:55-8. ">Nelson 1985</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004454-bbs2-0019" title="CTRI/2016/12/007570. Effct of antenatal corticosteroids on respiratory morbidity in late preterm newborns - a randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/12/0075702016. [CENTRAL: CN-01807588] DorairajanG , OntelaV , VishnuB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm new-borns: a randomized controlled trial. https://epostersonline.com/rcog2018/node/58?view=true (accessed 4 September 2020). DorairajanG , OntellaV , BhatV , ChinnakaliP . Effect of antenatal dexamethasone on respiratory morbidity of late preterm newborns: a randomized controlled trial. BJOG: an international journal of obstetrics and gynaecology2018;125(Suppl 1):67-8. [CENTRAL: CN-01571886] [EMBASE: 621569896]OntelaV , DorairajanG , BhatVB , ChinnakaliP . Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. Journal of Tropical Pediatrics2018;64(6):531-8. [CENTRAL: CN-01991657] [EMBASE: 626300500] [PMID: 29365196]">Ontela 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0020" title="PortoAM , CoutinhoIC , CorreiaJB , AmorimMM . Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ2011;342:d1696. ">Porto 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0021" title="QublanH , MalkawiH , HiasatM , HindawiIM , Al-TaaniMI , Abu-KhaitSA , et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical &amp; Experimental Obstetrics &amp; Gynecology2001;28(3):183-6. ">Qublan 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0023" title="DessensAB , HaasHS , KoppeJG . Twenty year follow up of antenatal corticosteroid treatment. Pediatrics2000;105(6):1325. DessensAB , Smolders-de HaasH , KoppeJG . Twenty year follow up in antenatally corticosteroid-treated subjects. Prenatal and Neonatal Medicine1998;3 Suppl 1:32. SchmandB , NeuvelJ , Smolder-de HaasH , HoeksJ , TreffersPE , KoppeJG . Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics1990;86:58-64. SchutteMF , KoppeJG , TreffersPE , BreurW . The influence of 'treatment' in premature delivery on incidence of RDS. In: Proceedings of the 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1; Vienna, Austria. 1978:Abstract no: 80. SchutteMF , TreffersPE , KoppeJG , BreurW , Filedt KokJC . The clinical use of corticosteroids for the acceleration of fetal lung maturity [Klinische toepassing van corticosteroiden ter bevordering van de foetale long-rijpheid]. Nederlands Tijdschrift voor Geneeskunde1979;123(11):420-7. SchutteMF , TreffersPE , KoppeJG , BreurW . The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British Journal of Obstetrics and Gynaecology1980;87:127-31. Smolders-de HaasH , NeuvelJ , SchmandB , TreffersPE , KoppeJG , HoeksJ . Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12- year follow up. Pediatrics1990;86(1):65-70. ">Schutte 1980</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004454-bbs2-0022" title="SchmidtPL , SimsME , StrassnerHT , PaulRH , MuellerE , McCartD . Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. American Journal of Obstetrics and Gynecology1984;148:178-86. ">Schmidt 1984</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32<sup>+0</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0024" title="ShanksA , GrossG , ShimT , AllsworthJ , MogaC , SadovskyY , et al. Antenatal steroids for enhancement of fetal lung maturity after 34 weeks: lung maturity and antenatal steroids (LUMAS) study. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S58. ShanksA , GrossG , ShimT , AllsworthJ , SadovskyY , BildiriciI . Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology2010;203(1):47.e1-47.e5. ">Shanks 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0025" title="SilverRK , VyskocilCR , SolomonSL , FarrellEE , MacGregorSN , NeerhofMG . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. American Journal of Obstetrics and Gynecology1995;172:254. SilverRK , VyskocilCR , SolomonSL , RaginA , NeerhofMG , FarrellEE . Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered prior to 30 weeks of gestation. Obstetrics &amp; Gynecology1996;87:683-91. ">Silver 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004454-bbs2-0026" title="TeramoK , HallmanM , RaivioKO . Maternal glucocorticoid in unplanned premature labor. Pediatric Research1980;14:326-9. ">Teramo 1980</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<sup>+6</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004454-bbs2-0027" title="ACTRN12617000476336. The WHO ACTION-I (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12617000476336 (first received 2017)2017. [CENTRAL: CN-01812305] WHO ACTION Trials Collaborators. Antenatal dexamethasone for early preterm birth in low-resource countries. New England Journal of Medicine2020;October 23:DOI: 10.1056/NEJMoa2022398. WHO ACTION Trials Collaborators. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials2019;20(1):507. [CENTRAL: CN-02010986] [EMBASE: 628924308] [PMID: 31420064]">WHO 2020</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26<sup>+0</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33<sup>+6</sup> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Gestational age parameters for included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/full#CD004454-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004454-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Corticosteroids versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.83, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.65, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Moderate/severe respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.59, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Chronic lung disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.41, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Intraventricular haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.45, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Any IVH grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.45, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 IVH Grade 3‐4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.27, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 IVH diagnosed at postmortem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.34, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Mean birthweight (g) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.02 [‐33.79, 5.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Maternal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.36, 3.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Chorioamnionitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.69, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Endometritis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.82, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Death in childhood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.36, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Neurodevelopmental disability in childhood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Developmental delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.27, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Intellectual impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.44, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 Hearing impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.04, 9.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.4 Visual impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.24, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Death into adulthood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.56, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Neurodevelopmental disability in adulthood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Visual impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.53, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Hearing impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 Intellectual impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.01, 4.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Fever in women after trial entry requiring the use of antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.36, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Intrapartum fever in woman requiring the use of antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.15, 2.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Postnatal fever in woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.64, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Admission into adult intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.26, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Side effects of therapy in women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Any side effects at first dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.59, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.3 Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.99 [0.12, 73.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.4 Hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.5 Leucocytosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.6 Migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 15.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Glucose intolerance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [1.14, 6.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.59, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Apgar &lt; 7 at 5 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.78, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Mean interval between trial entry and birth (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐1.86, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Mean length at birth (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.37, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Mean head circumference at birth (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.22, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Small‐for‐gestational age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.96, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Need for mechanical ventilation/CPAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.66, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Mean duration of mechanical ventilation/CPAP (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.91 [‐4.59, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Median (IQR) duration of mechanical ventilation (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Median (IQR) duration of CPAP (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 Air leak syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.32, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 Mean duration of oxygen supplementation (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.86 [‐5.51, ‐0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.35 Median (IQR) duration of oxygen supplementation (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.36 Surfactant use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.50, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.37 Systemic infection in the first 48 hours of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.41, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.38 Proven infection while in the neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.64, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.39 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.32, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.40 Mean infant HPA axis function (cortisol) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.94 [‐3.12, 11.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.1 In babies born &lt; 24 hours after 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [‐11.93, 29.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.2 In babies born 24‐48 hours after 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐8.68, 8.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.3 In babies born &gt; 48 hours after 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.00 [‐1.90, 27.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.41 Mean childhood weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.39, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.1 Liggins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.32, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.2 Schutte (females)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐6.55, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.3 Schutte (males)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐3.88, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.42 Mean childhood head circumference (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐0.08, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.1 Liggins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.11, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.2 Schutte (females)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐1.05, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.3 Schutte (males)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐0.51, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.43 Mean childhood height (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [‐0.26, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.43.1 Liggins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐0.39, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.43.2 Schutte (females)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐3.08, 6.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.43.3 Schutte (males)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐3.79, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.44 Mean childhood systolic blood pressure (mmHg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐4.06, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.45 Cerebral palsy in childhood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.34, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.46 Behavioural/learning difficulties in childhood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.35, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.47 Mean adult weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.83 [‐6.41, 4.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.47.1 Schutte (females)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.00 [‐12.93, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.47.2 Schutte (males)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐9.91, 7.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.47.3 Liggins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [‐0.72, 5.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.48 Mean adult head circumference (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.33, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.1 Schutte (females)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐1.03, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.2 Schutte (males)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.37, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.3 Liggins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.34, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.49 Mean adult height (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [‐0.28, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.49.1 Schutte (females)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐5.37, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.49.2 Schutte (males)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [‐2.30, 8.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.49.3 Liggins (females)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [‐0.65, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.49.4 Liggins (males)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [‐1.03, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.50 Mean adult skinfold thickness (log values) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.50.1 Triceps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.11, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.50.2 Biceps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.11, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.50.3 Subscapular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.08, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.50.4 Suprailiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.12, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.51 Abnormal lung function measured as forced vital capacity (adult) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐3.16, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.52 Mean adult systolic blood pressure (mmHg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.87 [‐2.81, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.52.1 Schutte (females)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐9.12, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.52.2 Schutte (males)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐7.17, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.52.3 Liggins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [‐1.88, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.53 Mean adult insulin (log values) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.53.1 Fasting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.03, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.53.2 30 minutes fasting following a 75 g oral glucose tolerance test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.04, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.53.3 120 minutes following a 75 g oral glucose tolerance test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.27, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.54 Mean adult glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.54.1 Fasting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.09, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.54.2 30 minutes fasting following a 75 g oral glucose tolerance test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.12, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.54.3 120 minutes following a 75 g oral glucose tolerance test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.52, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.55 Mean adult HPA axis function (mean log fasting cortisol) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.02, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.56 Mean age at puberty (years) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.56.1 Schutte (females)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.94, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.57 Educational achievement by adulthood (university or polytechnic education) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.80, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.58 Mean length of antenatal hospitalisation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.23, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.59 Length of maternal hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.60 Mean length of postnatal hospitalisation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐1.72, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.61 Mean length of neonatal hospitalisation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.51, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.62 Length of neonatal hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Corticosteroids versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004454-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Perinatal death ‐ single or multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 In babies born from singleton pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.70, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 In babies born from multiple pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.41, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.77, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Neonatal death ‐ single or multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 In babies born from singleton pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.71, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 In babies born from multiple pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.57, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.50, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Fetal death ‐ single or multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.83, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 In babies born from singleton pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.76, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 In babies born from multiple pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.20, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.80, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Respiratory distress syndrome ‐ single or multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.65, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 In babies born from singleton pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.57, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 In babies born from multiple pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.61, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.68, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Intraventricular haemorrhage ‐ single or multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.45, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 In babies born from singleton pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.35, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 In babies born from multiple pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.08, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 Mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.48, 0.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ single or multiple pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004454-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Perinatal death ‐ intact or ruptured membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 In babies born from pregnancies with intact membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.71, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 In babies born from pregnancies with ruptured membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.47, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Not reported or mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.78, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Neonatal deaths ‐ intact or ruptured membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 In babies born from pregnancies with intact membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.60, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 In babies born from pregnancies with ruptured membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.46, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Not reported or mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.71, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Fetal death ‐ intact or ruptured membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.83, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 In babies born from pregnancies with intact membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.73, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 In babies born from pregnancies with ruptured membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.46, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 Not reported or mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.80, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 RDS ‐ intact or ruptured membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.64, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 In babies born from pregnancies with intact membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1924</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.50, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 In babies born from pregnancies with ruptured membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.60, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 Not reported or mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.67, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 IVH ‐ intact or ruptured membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.45, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 In babies born from pregnancies with intact membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.28, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 In babies born from pregnancies with ruptured membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.28, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 Not reported or mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.64, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Birthweight ‐ intact or ruptured membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.86 [‐34.59, 4.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 In babies born from pregnancies with intact membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐30.27 [‐100.43, 39.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 In babies born from pregnancies with ruptured membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐49.72 [‐113.91, 14.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 Not reported or mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.40 [‐31.10, 12.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Chorioamnionitis ‐ intact or ruptured membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 In women with intact membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.50, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 In women with ruptured membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.72, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 Not reported or mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.54, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Endometritis ‐ intact or ruptured membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.82, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 In women with intact membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.61, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 In women with ruptured membranes at 1st dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.55, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.3 Not reported or mixed population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.73, 1.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ intact membranes versus ruptured membranes at first dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004454-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ hypertension syndrome versus all other trials</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Perinatal deaths ‐ hypertension syndrome vs other trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Hypertension syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.57, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 No hypertension syndrome or hypertension syndromes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 Hypertension not reported separately</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.76, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Neonatal deaths ‐ hypertension syndrome vs other trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Hypertension syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.28, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 No hypertension syndrome or hypertension syndromes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.65, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 Hypertension not reported separately</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Fetal deaths ‐ hypertension syndrome vs other trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.83, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Women with hypertension syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.91, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 No hypertension syndrome or hypertension syndromes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.49, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Hypertension not reported separately</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.83, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Respiratory distress syndrome ‐ hypertension syndrome vs other trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.65, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Hypertension syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.34, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 No hypertension syndrome or hypertension syndromes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.48, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Hypertension not reported separately</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ hypertension syndrome versus all other trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004454-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ type of steroid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Perinatal death ‐ type of steroid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.69, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.43, 5.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Neonatal death ‐ type of steroid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.71, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.59, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.20, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.4 Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.42, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Fetal death ‐ type of steroid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.78, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.74, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.08, 47.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Respiratory distress syndrome ‐ type of steroid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.65, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.70, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.55, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.3 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.36, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.4 Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.56, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Moderate/severe respiratory distress syndrome ‐ type of steroid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.59, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.67, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 Betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.37, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.3 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.32, 6.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.4 Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.26, 5.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Chronic lung disease ‐ type of steroid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.41, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.41, 9.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.21, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 IVH ‐ type of steroid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.45, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.54, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.2 Betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.34, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Birthweight ‐ type of steroid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.02 [‐33.79, 5.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.84 [‐31.09, 38.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.2 Betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.40 [‐44.61, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.3 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐146.68 [‐371.30, 77.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.4 Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐121.00 [‐430.59, 188.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Chorioamnionitis ‐ type of steroid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.69, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.84, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.2 Betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.51, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Endometritis ‐ type of steroid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.82, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.92, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10.2 Betamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.63, 1.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ type of steroid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004454-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ decade of trial</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Perinatal death ‐ decade of trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Trials conducted in 1970s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 Trials conducted in 1980s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.59, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 Trials conducted in 1990s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.46, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.4 Trials conducted in 2000s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.31, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.5 Trials conducted in 2010s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.79, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Neonatal death ‐ decade of trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Trials conducted in 1970s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.67, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Trials conducted in 1980s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.55, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.3 Trials conducted in 1990s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.40, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.4 Trials conducted in 2000s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.31, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.5 Trials conducted in 2010s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Fetal death ‐ decade of trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.83, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 Trials conducted in 1970s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.69, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 Trials conducted in 1980s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.42 [0.37, 31.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.3 Trials conducted in 1990s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.49, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.4 Trials conducted in 2000s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.19, 4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.5 Trials conducted in 2010s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.79, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Respiratory distress syndrome ‐ decade of trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.65, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 Trials conducted in 1970s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.54, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 Trials conducted in 1980s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.55, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.3 Trials conducted in 1990s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.65, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.4 Trials conducted in 2000s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.26, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.5 Trials conducted in 2010s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.69, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 IVH ‐ decade of trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.45, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 Trials conducted in 1970s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.33, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.2 Trials conducted in 1980s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.26, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.3 Trials conducted in 1990s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.44, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.4 Trials conducted in 2000s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.15, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.5 Trials conducted in 2010s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [0.69, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Birthweight ‐ decade of trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.02 [‐33.79, 5.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 Trials conducted in 1970s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐41.39 [‐110.05, 27.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.2 Trials conducted in 1980s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.60 [‐108.55, 69.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.3 Trials conducted in 1990s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐33.13 [‐102.39, 36.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.4 Trials conducted in 2000s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.77 [‐61.95, 20.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.5 Trials conducted in 2010s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.82 [‐30.36, 22.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Chorioamnionitis ‐ decade of trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.69, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.1 Trials conducted in 1970s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.46, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.2 Trials conducted in 1980s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.25, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.3 Trials conducted in 1990s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.85, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.4 Trials conducted in 2000s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.59, 6.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.5 Trials conducted in 2010s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.48, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Endometritis ‐ decade of trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.82, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8.1 Trials conducted in 1970s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.07, 15.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8.2 Trials conducted in 1980s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [0.88, 6.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8.3 Trials conducted in 1990s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.53, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8.4 Trials conducted in 2000s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.75, 2.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ decade of trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004454-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ weekly repeats</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Perinatal death ‐ protocol with weekly repeats <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Single course only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Courses including weekly repeats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.75, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Neonatal death ‐ protocol with weekly repeats <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Single course only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.68, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Courses including weekly repeats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.67, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Fetal death ‐ protocol with weekly repeats <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.83, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 Single course only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.70, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 Courses including weekly repeats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.82, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Respiratory distress syndrome ‐ protocol with weekly repeats <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.65, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 Single course only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.64, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.2 Courses including weekly repeats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.60, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Moderate/severe respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.59, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 Single course only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.47, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.2 Courses including weekly repeats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.59, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 IVH ‐ protocol with weekly repeats <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.45, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.1 Single course only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.37, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.2 Courses including weekly repeats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.43, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Birthweight ‐ protocol with weekly repeats <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.02 [‐33.79, 5.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.1 Single course only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.90 [‐44.39, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.2 Courses including weekly repeats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.72 [‐33.92, 39.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Chorioamnionitis ‐ protocol with weekly repeats <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.69, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.1 Single courses only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.61, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.2 Courses including weekly repeats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.65, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.9 Endometritis ‐ protocol with weekly repeats <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.82, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.1 Single courses only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.49, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.2 Courses including weekly repeats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.94, 2.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ weekly repeats</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004454-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Perinatal death ‐ gestational age at trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.77, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Less than or equal to 35 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.76, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Greater than or equal to 34 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.68, 4.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Neonatal death ‐ gestational age at trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Less than or equal to 35 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.69, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Greater than or equal to 34 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.49, 4.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Fetal death ‐ gestational age at trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 Less than or equal to 35 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.81, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 Greater than or equal to 34 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.42, 8.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Respiratory distress syndrome ‐ gestational age at trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.65, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 Less than or equal to 35 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.63, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.2 Greater than or equal to 34 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.60, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 IVH ‐ gestational age at trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.45, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.1 Less than or equal to 35 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.44, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.2 Greater than or equal to 34 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.91 [0.24, 102.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Birthweight ‐ gestational age at trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.36 [‐32.99, 6.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.1 Less than or equal to 35 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.78 [‐40.81, 21.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.2 Greater than or equal to 34 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.75 [‐41.09, 9.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.7 Chorioamnionitis ‐ gestational age at trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7.1 Less than or equal to 35 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.73, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7.2 Greater than or equal to 34 weeks + 0 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.34, 0.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Corticosteroids versus placebo or no treatment ‐ gestational age at trial entry</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004454.pub4/references#CD004454-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004454.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD004454-note-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD004454-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004454-note-0025">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004454-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD004454-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD004454-note-0024">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD004454-note-0014">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD004454-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD004454-note-0026">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD004454-note-0013">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD004454-note-0012">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD004454-note-0023">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004454-note-0021">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004454-note-0022">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004454\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004454\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004454\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004454\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004454\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004454.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004454.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004454.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004454.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004454.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715978570"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004454.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715978575"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004454.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9444cff49368',t:'MTc0MDcxNTk3OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 